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Abstract 
E26 transformation specific (Ets) proteins are a versatile class of 
transcription factors. They act both up and downstream of signal 
transduction cascades, are causative in cancer generation and are 
able to control the expression of other transcription factors. Thus 
they play an important role in cellular growth, proliferation and 
differentiation. The ets gene family is characterised by an 85 amino 
acid DNA binding domain and currently consists of around 30 
members. They have been shown to be proto-oncogenes and it is 
this featur~ that has elicited much research into their regulation 
and function in both normal and neoplasic tissue. The high level of 
conservation within the ETS domain of the family identifies all Ets 
proteins as sequence-specific DNA-binding proteins. Many have 
been identified as having a role in the regulation of gene 
expression. The retention of many ets genes throughout evolution 
implies there would be few redundant genes (Thomas, 1993) and 
therefore each gene would have a unique biological role. Because of 
the common DNA binding domain, the regulation of the ets genes 
must be complex to provide specificity of action throughout the 
family (Laudet et al., 1999). 
A cDNA sequence was isolated from mammary gland tissue and 
characterised as belonging to the Ets family of transcription 
factors. The gene was designated BrETS for Breast ETS. Recent 
publications have described the gene as Elf-5 (Zhou et al., 1998) 
and ESE-2 (Oettgen et al., 1999). BrEts showed a restricted pattern 
of spatial expression, being strongly expressed in the mammary 
gland. Its expression in the mammary gland also exhibits a tightly 
controlled temporal pattern, which implicates it in mammary 
processes such as development and differentiation. As BrETS is 
highly expressed m the mammary gland (where intense 
extracellular remodelling occurs), and has been localised to the 
epithelial tissue, it may play a role in the regulation of matrix 
metalloproteinases or their inhibitors. 
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Genomic DNA spanning the BrETS locus was isolated in this study. 
It was found to encompass approximately 3kb of upstream 
sequence, the first two exons and intron 1. Multiple transcription 
start sites have been identified, indicative of a TATA-less, tissue-
specific gene. Deletion constructs of the proximal promoter (850bp) 
were examined in cell culture. The mammary gland derived cell 
lines HCl 1 and CommalD were used, in conjunction with a 
chloramphenicol acetyltransferase reporter system. A region of 
sequence between -70 and -200bp was identified as having up-
regulated transcriptional activity above an empty expression vector 
in cell culture. Analysis of more distal promoter constructs 
resulted in decreased activity, to a level representative of basal 
activity. The first intron (6kb) was also examined in vitro as a 
complete construct and as smaller fragments. Low levels of 
reporter activity were seen with these constructs in cell culture. 
DNasel hypersensitive analysis on the immediate promoter region 
revealed the presence of a hypersensitive site within the first 
intron. This implies a regulatory element of potential importance is 
located here, though further research is required to determine the 
element(s) and significance. 
The identification of regulatory regions may allow for the 
determination of tissue-specific elements and regions that control 
the expression of the gene. This information may be later 
extrapolated and manipulated in vivo as a means of controlling the 
expression of the BrETS gene. 
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Chapter 1. Introduction and literature 
• review 
1.0 Background 
This investigation characterises some features of the Ese-2/ Elf-5 
gene promoter. The gene will be referred to as Ese-2 throughout 
this manuscript, as it is more closely related to members of the Ese 
subfamily than the Elf subfamily, despite the locus link 
classification. 
Ese-2 is a member of the Ets family of transcription factors, which 
are characterised by an 85 amino acid DNA binding domain. Both 
the human and mouse Ese-2 genes were described by Zhou et al., 
in 1998 (named ELF-5) and subsequently in 1999 by Oettgen et al. 
ESE-2 was characterised as an epithelium specific factor closely 
related to ESE-1, though functionally distinct (Oettgen et al., 
1999). 
Zhou et al., ( 1998) and Oettgen et al., ( 1999) have shown that Ese-
2 expression is restricted to cells of epithelial origin, including 
mammary gland, salivary gland, kidney, lung, prostate, colon, 
ovary, pancreas, liver, placenta, and the gastrointestinal tract. 
The starting point for the present investigation was a cDNA 
sequence that was isolated from mammary gland tissue and 
characterised as belonging to the Ets family of transcription 
factors. The gene was designated BrETS for Breast ETS. 
This chapter discusses the previous research and information 
known regarding the ets transcription factor family, including 
physical characteristics, binding properties and regulation with 
respect to the specificity required to meet a high level of control. As 
BrETS is highly expressed in the mammary gland (where intense 
extracellular remodelling occurs), and has been localised to the 
epithelial tissue, it may well play a role in the regulation of matrix 
metalloproteinases or their inhibitors. Some background on Ets 
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factors acting in the context of the extracellular matrix is given. In 
the later section of this chapter, a brief overview of the aims and 
content of the study are given, together with the previous research 
already completed in the area. 
1.1 The Ets family of transcription factors 
Transcription factors are proteins that bind to specific sequence 
motifs on the DNA and influence the rate of initiation of 
transcription as well as the amount of transcription that occurs 
from that gene. 
The ets family of transcription factors was named after the first 
member was described in 1983 (Leprince et al., 1983; Nunn et al., 
1983). v-ets (E26 !ransformation .§.pecific or E-!wenty six .§.pecific) 
was discovered to be a cellular sequence that was transduced by 
the avian retrovirus E26. E26 is a fusion hybrid consisting of the 5' 
region of the retroviral gag gene, mybE and the ets sequence. The 
cellular counterpart of v-ets (c-ets) is transcribed under normal 
conditions in chicken cells as a major 7.5kb polyadenylated RNA 
and the sequence is conserved through evolution (Leprince et al., 
1983; Nunn et al., 1983). 
Following the discovery of v-ets, many other ets genes were 
identified from phylogenetically divergent species and the family 
now comprises upward of 30 members. These genes are listed in 
Table 1.1. 
The oncogenic nature of the family was confirmed with experiments 
in vitro and in vivo using the Ets-2 gene. c-Ets-2 was shown to be 
oncogenic and mitogenic when expressed in NIH3T3 cells. Its over-
expression results in stimulated cell proliferation and abolishment 
of a serum requirement. Cells transfected with c-ets-2 form 
colonies in a semi-solid medium and induce tumours in nude mice 
(Seth et al., 1989). 
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1.1.1 The ETS domain 
The conserved region that identifies the family is known as the 
ETS-domain and is responsible for the DNA binding of this group 
of proteins. Through a comparison of the DNA binding properties of 
the murine ets-1 proto-oncogene, murine PU. 1 and Drosophila 
E7 4, Karim et al. discovered a sequence specific region of 85 amino 
acids which was highly conserved. This was termed the ETS 
domain (Karim et al., 1990). At the same time a role for the ETS 
protein domain was discovered as it was found to bind DNA in a 
sequence specific manner (Gunther et al., 1990; Klemsz et al., 
1990; Urness and Thummel, 1990). Fragments of the conserved 
domain from PU .1 and Ets-1 proteins retained the DNA binding 
capability (Gunther et al., 1990; Klemsz et al., 1990). 
For many years, the ETS domain was believed to be a novel DNA 
binding motif due to its lack of sequence homology to any other 
well characterised motif (Johnson and McKnight, 1989; Mitchell 
and Tijan, 1989). It contains no cysteines or histidines positioned 
for stabilising a zinc finger structure, neither are the a helical 
regions spaced appropriately for a helix-turn-helix configuration 
(Murre et al., 1989). Basic amino acids are found in the C-terminus 
of the ETS domain but have no similarity with leucine zipper /basic 
region proteins (Landschulz et al., 1989) or helix-loop-helix 
proteins (Murre et al., 1989). However, the ETS domain does 
contain a region of three highly conserved tryptophans separated 
by 17-20 amino acids and a basic region (Janknecht and 
Nordheim, 1993). This spacing resembles a region found in the 
myb proteins, which function in DNA binding (Anton and 
Frampton, 1988). PU .1 is an exception to the three-tryptophan 
pattern having one replaced by a tyrosine residue. The tryptophan 
side chain was thought to intercalate into the DNA of Ets-1 and 
rotate 180° in relation to the ETS site. However, more recent 
evidence suggests that there is no tryptophan intercalation (Graves 
and Gillespie, 1996). In fact, it was the elucidation of the 30 
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structure of Fli-1 (Liang, 1994a), Ets-1 (Donaldson et al., 1994; 
Werner et al., 1995) and PU.l/Spi-1 (Kodandapani, 1996) that 
demonstrated the ETS domain belonged to the superfamily of helix-
turn-helix proteins. Analysis of the binding domain whilst targets 
are either bound or un-bound has shown the domain has 3 a-
helices and a 4 stranded antiparallel P-sheet (Sharrocks et al., 
1997). Major groove contacts with the DNA binding site GGAA/T 
are made by a loop formed between the P3-P4 turn and between a-
helices 2 and 3 (Kodandapani, 1996). The ETS domain is so highly 
conserved throughout the family that this mode of binding is likely 
to be identical in all the family proteins. The ETS domain is found 
to be in one of three locations within the protein. Near the carboxyl 
terminus, the amino terminus or centrally located, though it is not 
known if its position is of biological significance. 
1.1.2 Phylogeny of the Ets transcription factor family 
Ets genes are widely dispersed throughout metazoans ranging from 
chordates, arthropods and higher mammals to sponges, 
ctenophores and flatworms. So far, no examples have been found 
in plant, fungi or protozoans and none in the genome of the 
budding yeast, Saccharomyces cerevisiae. The origin of ets genes 
may pre-date the diversification of metazoans, as indicated by the 
discovery of ets members in sponges and coelenterates (Degnan et 
al., 1993). Previous phylogenetic studies hypothesise a period of 
gene duplication in early metazoan evolution and an extended 
period of conservation within the family implicated by a relatively 
small number of genes (Lautenberger et al., 1992; Laudet et al., 
1993; Shenk and Steele, 1993; Graves and Petersen, 1998; Laudet 
et al., 1999). 
The strong conservation of the ETS domain which spans 84-90 
amino acids is the defining feature of the ets family members, and 
is important both structurally and functionally (Donaldson et al., 
1994; Liang et al., 1994b; Werner et al., 1995; Donaldson et al., 
Chapter 1. Introduction and literature review 
5 
1996; Kodandapani, 1996). The discovery of the ETS domain 
winged-helix-turn-helix (WHTH) structure with the resolution of 
the 30 structure presents a possible evolutionary grouping in this 
superfamily of transcriptional regulators. This structure retains 
high similarity to the helix-turn-helix (HTH) of the E.coli catabolite 
gene activator protein, the HNF3/fork head family and the heat 
shock factor family (Donaldson et al., 1994; Liang, 1994a; 
Donaldson et al., 1996; Kodandapani, 1996). 
A highly conserved N-terminal region is found in some Ets family 
members, referred to as the Pointed domain (Klambt, 1993). This 
domain is conserved in Ets-1, Ets-2, GABPa., Erg, Fli-1, Tel, Yan 
and Ese members and it is proposed to play a role in protein-
protein interactions and specifically for Tel in its self-association 
(Carroll et al., 1996; Golub et al., 1996; McLean et al., 1996; 
Jousset et al., 1997). 
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Table 1.1 List of ets genes. 
Ets gene name(s) Subfamily 
ERG ERG 
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In support of the protein-protein interaction, the more conserved 
core of Pointed has been aligned with sequences in other non-Ets 
proteins including a region in the Polycomb protein family and in 
cytoplasmic proteins involved in yeast sexual differentiation 
(Alkema et al., 1996; Gunster et al., 1997; Graves and Petersen, 
1998). The conserved domain is called SEP, for yeast sterility, Ets-
related, polycomb proteins. 
Several recent phylogenetic analyses have been performed, mostly 
resulting in a consensus alignment and grouping of the ets genes 
(Laudet et al., 1999; Kas et al., 2000). Laudet et al. used several 
methods to align amino acid sequences, and a distance tree was 
constructed with the neighbour-joining method and tested by 
'bootstrap' replications. This tree displays high similarity to all 
other attempts at phylogenetic relationships and includes 13 
subgroups within the family (ETS, ER71, GABP, PEA3, ERG, ERF, 
ELK, DETS4, ELF, ESE, TEL, YAN, SP-1). The phylogenetic tree 
derived by Kas et al. (2000) reveals the same 13 subgroups, though 
with some variation in nearest neighbours, likely to be due to the 
different methods used to construct the trees. This was generated 
by alignment using the Clustal W program of the ETS domain 
(Thompson et al., 1994) and is shown in Figure 1.1. The same 
group presents an alignment of genes retaining the conserved 
Pointed domain, as shown in Figure 1.2. 
The divergence between Ets-1 and Ets-2 in vertebrates came before 
the split between amphibians and other vertebrates (Degnan et al., 
1993). A second series of duplication events seems to have 
occurred specifically for the vertebrate lineage, giving rise to 
paralogues within each group Ets-l/Ets-2, PEA3/ERM/ER81, 
Erg/ Fli-1, Erf / Pe-1, Elk/ Sap-1/ Net, Elf-1/ Mef/ Nerf, Spi-1/ Spi-B. 
These block duplications are supported by some striking 
chromosomal locations, such as Ets-1 and Fli-1 neighbouring on 
chromosome 11 q23.24, and Ets-2/Erg neighbouring on 
chromosome 21 at q22 (Kasahara et al., 1996; Katsanis et al., 
1996). 
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In the tree constructed by Laudet et al., distant relations of the 
WHTH family provided a root for the tree, which was located 
between Spi-1 and others as previously predicted (Laudet et al., 
1999). Evolutionary rates were measured for each gene between 
species and the results indicated that evolution was comparable 
with that of other transcription factors such as the nuclear 
receptors (Laudet, 1997). 
1.1.3 Ets DNA binding sites 
Most Ets proteins bind as monomers to DNA sequences, except for 
GABP, which is dimeric, containing a purine rich core GGAA/T 
(Karim et al., 1990; Urness and Thummel, 1990; Hagman and 
Grosschedl, 1992; Janknecht and Nordheim, 1992; Nye et al., 
1992; Woods et al., 1992). The sequences that flank the core target 
modulate the binding specificity and affinity, often containing 9-15 
bases of DNA that make contact with the protein (Graves and 
Petersen, 1998). Experimental evidence for the core GGAA binding 
site initially came from methylation interference analysis which 
determined that the two guanine residues act as contact points for 
both Ets-1 and PU.l protein binding (Gunther et al., 1990; Klemsz 
et al., 1990). Also, a mutant core sequence of CCAA was not able to 
bind PU .1 (Klemsz et al., 1990). 
DNA mutagenesis studies have identified the subgroups of 
sequences around the core site. Significant overlap is seen within a 
9bp region, though a major difference is seen in some proteins (e.g. 
Elk-1, Fli-1, Elf-1, E74) which will only tolerate an A at position 
GGAA, whereas others like Ets-1, GABPa., SAP-la can have either 
an A or T (Shore and Sharrocks, 1995). Protein-protein interactions 
are likely to change the specificity and affinity of Ets binding by 
causing preferential binding of one Ets protein over another 
through a strengthened interaction. 
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Figure 1.1 Phylogeny tree of the Ets family of transcription 
factors Adapted from Kas et al., 2000. All known members of the 
Ets gene family are shown of human and Drosophila origin. Branch 
lengths indicate the relative similarity of the ETS domain between 
members. 















Figure 1.2 Phylogeny tree of the Ets factors containing the 
Pointed domain Adapted from Kas et al., 2000. An alignment of 
the Pointed domain, including 12 mammalian and 2 Drosophila 
factors. Branch lengths indicate relative similarity. 
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Elk-1 and SAP-1 for example both bind the GGAT sequence of the 
c-fos serum response element only in conjunction with the DNA 
bound serum response factor (Hipskind et al., 1991; Dalton and 
Treisman, 1992). Another example of binding affinity is GABPa, 
which will bind DNA more strongly in the presence of GABPJ3 
(Thompson et al., 1991). The different binding specificity of ets 
genes may reflect an important mechanism by which the factors 
regulate different genes expression patterns (Wasylyk et al., 1992). 
1.1.4 Regulation of DNA binding 
A pnmary level of regulation by transcription factors occurs via 
sequence specific DNA binding. Furthermore, regulation of the 
binding is also critical. Binding is known to occur through the 
GGAA site as already discussed, and the ETS domain may play a 
role in such binding specificity. However, several studies have 
indicated that regions outside the ETS domain are important for 
regulating DNA binding. 
Ets-1 is the most widely studied example of the Ets factors and 
now is known to have three regions that have a negative influence 
on DNA binding. First, a central region of approximately 70 amino 
acids (Lim et al., 1992), a second 90 amino acid region upstream of 
the ETS domain (Wasylyk et al., 1992) and finally a region in the 
carboxy terminus (Hagman and Grosschedl, 1992; Lim et al., 
1992). 
In 1992, Lim et al. published their findings from a study of the 
oncogenes v-myb and v-ets, which are fused with the viral gag gene 
in E26 avian retrovirus. The cellular precursor c-ets-1 gives rise to 
v-ets which undergoes two point mutations and substitution of the 
C-terminal 13 amino acids by a different 16 amino acid sequence. 
The DNA binding domain was thought to be present at the C-
terminus, so a comparison of the DNA binding between v-ets and 
c-ets was of interest. The polyoma PEA3 element was used as a 
known Ets binding site (EBS) and results indicated weak binding of 
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c-ets-1 but strong binding of v-ets. Also, fragments of c-ets-1 
showed strong DNA binding suggesting that the full-length 
molecule has a repressed binding domain. v-ets counterparts of the 
c-ets deletion fragments differing by only a few mutations retained 
DNA binding activity. The regions of repression were mapped to the 
C-terminus end and a middle region. Truncations deleting these 
regions resulted in the loss of the DNA binding capability. The C-
terminus in v-ets is altered compared to that of c-ets and retains 
high DNA binding activity (Lim et al., 1992). 
Lim et al. ( 1992) proposed a mechanism for the repressor action of 
the C-terminus and central repressor domains on DNA binding. 
Both domains contact each other masking the intervening ETS 
domain and preventing its contact. Models propose that an 
inhibitory molecule (two a-helices N-terminal to the ETS domain 
and a single C-terminal a-helix) alters the DNA binding potential of 
Ets-1. The C and N-terminal a-helices function cooperatively and a 
conformational change of one N-terminal a-helix allows relief of the 
intramolecular inhibition (Petersen et al., 1995; Jonsen et al., 
1996; Skalicky et al., 1996). 
Hagman and Grosschedl ( 1992) provided further evidence for the 
importance of the C-terminal amino acids in DNA binding 
regulation (Hagman and Grosschedl, 1992). They reported that 
Ets-1 and PU .1 both bind the mb-1 promoter (B-lymphocyte 
specific mb-1 gene) in vitro though with different efficiency. The 
cause of this is the presence of an inhibitory C-terminal domain in 
Ets-1 and Ets-2, which is absent in PU .1 and v-Ets. Substituting 
the C-terminus of the v-Ets protein with Ets-1 C-terminus 
repressed DNA binding. This was not the case for the substitution 
with the PU .1 C-terminus (Hagman and Grosschedl, 1992), which 
may be due to a lack of the central repressor domain in PU .1. The 
C-terminal inhibitory domain of Ets-1 was predicted to interfere 
directly with DNA binding and not homo-dimerisation. Repressor 
domains of DNA binding are therefore not present in PU.1 because 
the deletion of either carboxy or amino sequences did not result in 
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enhanced DNA binding (Hagman and Grosschedl, 1992; Wasylyk et 
al., 1992). This mechanism of regulation may be specific to certain 
factors only. 
Wasylyk et al. ( 1992) examined the DNA binding of deletion 
mutants of the c-ets-1 (p68) gene (chicken Ets 1 p68 gene). They 
found that binding was abolished when an amino terminal region 
was removed and that this region in Ets-1 and Ets-2 is able to 
inhibit DNA binding. 
1.1. 5 Ets target genes 
Well over 200 Ets target genes have been documented 
(Sementchenko and Watson, 2000). These target genes are involved 
in cell proliferation, differentiation, development, hematopoiesis, 
apoptosis, metastasis, tissue remodelling, angiogenesis and 
transformation. The various Ets target gene interactions are an 
important area of investigation. 
Early Ets-1 targets were discovered in the long terminal repeats of 
the human T-cell leukemia virus 1 (HTLV-1) and Moloney murine 
sarcoma virus (Gunther et al., 1990; Gegonne et al., 1993). GABPa 
and GABPP were shown to interact with the Herpes Simplex Virus 
and the Adenovirus E4 promoter region (LaMarco et al., 1 991 ; 
Watanabe et al., 1993). These target sites provided an early 
indication that ets genes might play a role in transformation and 
tumour associated processes. 
More recently Ets factors have been found to bind to sites not 
predicted by their in vitro consensus sequences (Sementchenko 
and Watson, 2000). The J-chain transcription factor NF-JB (found 
to be identical to PU. l) is an example of this. It contains an 
AAGAAA core sequence rather than the GGA core (Shin and 
Koshland, 1993). It has been found to bind sequences such as the 
macrophage scavenger receptor at AGAGAAGT (Moulton et al., 
1994) and also the IL-lP at GCAGAAGT (Buras et al., 1995; 
Kominato et al., 1995). It therefore seems that target gene 
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specificity and affinity to the EBS is controlled by cis-elements, as 
demonstrated by the ability of many Ets factors to act in synergy 
with other transcription factors. Another example is the Ets-1 
cooperation with CREB and AMLl non-consensus binding in the 
promoter activation of the human T-cell receptor beta chain (Halle 
et al., 1997). Halle et al. ( 1997) propose that the low affinity 
binding may mediate cooperative concentration dependent 
regulation of a promoter and that high affinity binding is involved 
in constitutive activation. Ets factors may also be in competition 
with other transcription factors. Fli-1 for example, acts as a 
repressor of retinoblastoma (Rb) (Tamir et al., 1999), as an 
activator for the tenascin-C (TN-C) promoter and a repressor of 
collagen promoter activity (Shirasaki et al., 1999). Ets-1 however is 
capable of activating both TN-C and collagen promoter activities 
(Shirasaki et al., 1999). 
Other Ets factors interact specifically with matrix type promoters 
including the collagenase promoter (MMP-1), (by Erg and Ets-2) 
and the stromelysin (MMP-3) promoter. Erg was seen to inhibit the 
stromelysin promoter, while Ets-2 stimulated both stromelysin and 
collagen (Buttice et al., 1996). A synergistic interaction is also 
observed when stromelysin is activated by the CBP / p300 protein 
and Ets-2 (Jayaraman et al., 1999). Erg however was not able to 
synergise with CBP/p300, which may explain the different activity. 
The matrix type promoters are discussed in further detail later. 
1.1.6 Regulation of function via protein-protein 
interactions 
The regulation of gene transcription involves combinatorial 
interactions of transcription factors. Many protein-DNA and 
protein-protein interactions are able to influence promoter activity. 
While many transcription factor families bind DNA as hetero or 
homodimers most Ets proteins have been observed to bind DNA as 
monomers (Liang, 1994a; Werner et al., 1995; Kodandapani, 1996). 
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The transcriptional activity of Ets proteins is more often modulated 
by their synergistic interaction with other factors than with 
themselves. Synergistic control is a mechanism by which tissue-
specific gene expression may be controlled by transcription factors 
unique to each cell lineage or differentiation state (Li et al., 2000). 
This is likely to be important in the case of the ets family of 
transcription factors, contributing to the complexity of their 
regulation of gene expression. This is exemplified in the interaction 
of Ets-1 with the tissue restricted AMLl transcription factor, which 
is regulated in a cell dependent manner (Kim et al., 1999). 
Another example of synergistic interaction is the transcriptional 
activation of the Human T cell lymphotrophic virus type 1 (HTLV-1) 
LTR by Tax-1, that is controlled by cooperation between NFKB, 
Ets-1 and Tax-1 (Gitlin et al., 1993; Seeler et al., 1993). Tax/Ets 
cooperation affects the parathyroid hormone related protein 
(PTHrP) P2 promoter. The co-operation is performed through a 
quaternary interaction of Tax, Ets-1 and Sp-1 with the DNA. Tax 
appears to facilitate the Ets-1 / Sp-1 interaction (Dittmer et al., 
1997). 
In other situations, Ets members are recruited to bipartite binding 
sites, forming ternary complexes as is the case for Elk-1 and SAP-
1. The proteins Elk-1 and SAP-1 are recruited by the serum 
response factor (SRF) to the serum response element (SRE) to 
stably contact the EBS within the SRE. Sequences C-terminal to 
the ETS domain are capable of repressing DNA binding (Dalton and 
Treisman, 1992; Rao and Reddy, 1992). 
An example of heterodimerisation in the Ets family is the GABP 
complex. This is made up of two of each GABPa and ~ subunits, 
when bound to a target such as Herpes simplex virus I immediate 
early genes (Thompson et al., 1991). Binding is highly dependent 
on both subunits being present, as GABPa is able to weakly bind 
on its own but in complex with GABPP it forms stable DNA 
contacts. GABPP is unable to bind on its own yet it makes the 
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physical contact with DNA once in complex formation (LaMarco et 
al., 1991; Thompson et al., 1991; Brown and McKnight, 1992). 
Oligomerisation of other Ets proteins may also be important, as 
demonstrated by Elk-1, which self-associates on the c-fos SRE 
(Gille et al., 1996). Intermolecular association of two Elk-1 proteins 
and two SRF molecules occurs through the C-terminus at the 
phosphorylation site. It is therefore possible that oligomerisation is 
more important than previously thought, considering that there are 
many repeats of multiple EBS on promoters and enhancers (Gitlin 
et al., 1991; Wasylyk et al., 1991; Seth et al., 1993; Coffer et al., 
1994; Seth et al., 1994; Villena et al., 1994). 
The Pointed domain is a conserved region found in a subfamily of 
ets factors made up of a monomeric 5-helix bundle, which is 
implicated in homo-dimerisation (Slupsky et al., 1998). Homo-
dimerisation of Pointed leads to a 'permanent signal activity' in 
signal transduction of the leukemic cells (Golub et al., 1994; 
Papadopoulous et al., 1995; Romana et al., 1995; Golub et al., 
1996; Jousset et al., 1997; Lacronique et al., 1997; Peeters et al., 
1997; Ho et al., 1999). ERG is part of this subfamily and is capable 
of forming homo-dimers or hetero-dimers with other Ets proteins 
including Fli-1, Ets-2, ER81 and PU.I via either the Pointed or ETS 
domains (Carrere et al., 1998). 
PU. 1 is also known to act as an oncoprotein in erythroid 
precursors, as its activation causes erythroleukaemia in mice, 
through its interference with erythroid differentiation, this is 
thought to occur via its interaction with GATA-1, a zinc finger 
transcription factor. PU. I represses GATA-I transcriptional 
activation by binding to the zinc finger region of GATA-1, known to 
bind DNA (Martin and Orkin, 1990). The transactivation domain of 
PU. I is also necessary for the repression, though it is not involved 
in binding GATA-1. A possible mechanism for the repression 
involves the PU.I ETS domain mediating the binding to the GATA-I 
finger region and the transactivation domain either recruiting other 
factors or inhibiting activities required for transcriptional 
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activation. This model is supported by evidence of the interaction 
of PU .1 transactivation domain with both retinoblastoma protein 
(Rb) and TATA binding protein (TBP) (Hagemeier et al., 1993). The 
protein-protein interactions that bind Rb to a promoter is 
implicated in transcriptional repression (Weint~aub et al., 1995). 
Ap-1 is a transcription factor that responds to a large range of 
stimuli making it an important signalling molecule (Wisdom, 1999). 
Adjacent Ets and Ap-1 binding sites are found in many promoter 
elements (Wasylyk et al., 1993; Westermarck and Kahari, 1999), 
making their cooperative effect important for cytokine gene 
expression (Gottschalk et al., 1993; Wang et al., 1994), MMP 
expression (Gutman and Wasylyk, 1990; Crawford et al., 1996; 
Jayaraman et al., 1999) and viral gene expression (Wasylyk et al., 
1990; Nothias et al., 1993). Ap-1 and Ets-1 appear to act 
synergistically as their separate over-expression results in only 20 
times transcriptional activation but jointly resulted in 250 times 
activation at the polyoma enhancer (Wasylyk et al., 1990). 
Transcriptional activation of the HTLV-1 LTR was also 
synergistically affected by Ets-1 and the ubiquitous factor Sp-1. 
Further, it was shown that Ets-1 binds through protein-protein 
contacts with Sp-1 before contacting the DNA (Gegonne et al., 
1993). 
A variety of stimuli can induce Ets-1 and Ets-2. For example, the 
human Ets-1 promoter may be induced by serum, Ap-1 and Ets-1. 
Ets-2 is stimulated by serum, bacterial lipopolysaccharide or 
protein kinase C (Bhat et al., 1987; Boulukos et al., 1990; Majerus 
et al., 1992). Ets-1 and Ets-2 may also be phosphorylated, as is the 
case for Ets-1 in thymocytes undergoing mitogenic stimulation by 
calcium (Pognonec et al., 1988). An implication of this is that Ets-1 
has a role in early T-cell activation. It is also hyper-phosphorylated 
during mitosis, when transcription is often blocked, suggesting a 
negative regulation of transcriptional activity. 
Competition between ets family members is also likely to play a 
role in transcriptional activation due to the conservation of the ETS 
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domain. The synergistic transactivation of MMP-1 is achieved 
through ERG and Ap-1 interaction, while ERG represses 
transcriptional activation of MMP-1 by Ets-2. Repression in this 
case is dependent on the ERG-Ets2 interaction (Buttice et al., 
1996; Basuyaux et al., 1997). 
As for Ap-1, adjacent binding sites for NF-KB and Ets-1 have been 
observed in many genes. NFKB is another ubiquitous transcription 
factor, often having a role in immunity, inflammatory and stress 
responses (Gilmore, 1999), and binding sites are found in lymphoid 
genes including IL-2, IL-2 receptor (John et al., 1995), IL-3 
(Gottschalk et al., 1993), viral enhancer genes including the HIVl 
enhancer (Seth et al., 1993) and signalling molecule genes. 
Functional cooperation between multiple Ets proteins such as Ets-
1, Elf-1 and PU.I with NF-KB is required for transcriptional 
activation of HIV I, HIV II (Bassuk et al., 1997) and others. 
1.1. 7 Ets transcription factors and functionality 
Transcriptional Repressor Activity of Ets 
To date, most Ets protein studies have focused on transcriptional 
activation. However, recent reports identify several Ets members 
with transcriptional repressor activity (O'Neill et al., 1994; Sgouras 
et al., 1995; Maira et al., 1996; Lopez et al., 1999). The functional 
roles of the repressor members appear to be much like those of 
activators. For example, in cell proliferation and differentiation and 
possibly in regulating this balance. An identical extracellular signal 
can result in quite different responses, depending on cell type and 
development stage. Because of the cell dependent response, it is 
important for correct function that ets genes execute the proper 
signal responses. 
Yan has the ability to act as an inhibitor of differentiation in 
several developmental processes, preventing an incorrect response 
of neuronal and non-neuronal cell types to extracellular stimuli 
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(Rebay and Rubin, 1995). It negatively regulates the sevenless EGF 
and FGF receptor pathways as a downstream . factor. Yan 
express10n in the Drosophila developing eye is restricted to 
undifferentiated cells, being downregulated upon differentiation. A 
similar expression pattern is seen in other developmental stages. 
A further role of Yan may be in inhibiting cells entering the cell 
cycle without the appropriate signal. Consistent with this is the 
observation of increased apoptosis at the morphogenetic furrow of 
the eye disk, effected by an activated Yan, which blocks entry to G 1 
on receiving a proliferation signal (Rogge et al., 1995). 
Cell culture transfection assays have demonstrated the ability of 
Yan to antagonise Pointed-P2 activity, an Ets family member 
involved in transactivation (O'Neill et al., 1994; Treier et al., 1995). 
This antagonism of Pointed proteins and D-Jun activity in 
developmental systems is usually seen to occur in response to ERK 
or JNK protein kinase activation (O'Neill et al., 1994; Riesgo-
Escovar et al., 1994; Treier et al., 1995). As yet no Yan target genes 
are known and the mechanism of repression remains unidentified. 
It is proposed that Yan is phosphorylated by MAPK and degraded 
in the cytoplasm (Rebay and Rubin, 1995) allowing for activation of 
its normally downregulated targets, possibly via other ets 
transcription factors such as Pointed (Klambt, 1993; Scholz et al., 
1993). 
Ets-2 repressor factor (ERF) is ubiquitously expressed and forms a 
subfamily with PE-1 (Klemsz et al., 1994). Its strong transcriptional 
repressor activity is derived from a C-terminal domain, not found 
in PE-1. It was identified through its interaction with the H 1 
element of Ets-2, which it was able to regulate (Sgouras et al., 
1995). ERF activity is dependent on the Ras/ERK pathway, as its 
phosphorylation is required for export of ERF from the nucleus. 
ERF is normally localised in the cytoplasm, but migrates to the 
nucleus when ERK is inactivated (Le Gallic et al., 1999). ERF is 
always phosphorylated prior to the G 1 phase of the cell cycle. 
Sgouras et al. proposed that ERF represses transcription of a set of 
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genes normally activated on G 1 phase entry. Hybrids of ERF either 
with other ets genes or with ERF itself are able to inhibit 
tumourgenic phenotypes associated with abnormal ets expression, 
as for oncogenic transformation of E26, and Fli-1 transformation of 
EWS in Ewing sarcoma. Therefore, such abnormal expression of 
ERF repressed genes by overexpressed transactivating Ets proteins 
may be the cause of tumourgenic activity of many Ets members 
(Sgouras et al., 1995). 
Genes involved in cell proliferation including Ets-2, fos, JunB and 
Rb all contain EBS in their promoter regions. They may be ERF 
targets, being released from repress10n when ERF 1s 
phosphorylated under mitogenic stimulation and cell proliferation. 
Protein phosphorylation of ERF and other Ets members may be 
highly important in regulating gene transcription of G 1 phase entry 
(Sgouras et al., 1995). The ubiquitous expression of ERF suggests 
it may play a universal role in regulating cell cycle machinery 
(Mavrothalassitis and Ghysdael, 2000). 
TEL was identified by its chromosomal translocation in some 
chronic myelomonocytic leukemias (Golub et al., 1994). A knockout 
mouse model (by homologous recombination) has proven TEL to be 
essential in development, as its deletion resulted in embryo 
lethality at day El0.5-11.5 (Wang et al., 1997). The DNA binding 
affinity of TEL is lower than that of an isolated ETS domain, 
suggesting intramolecular repression is occurring in TEL. TEL and 
its family group TEL-B/TEL-2 share the B-domain (as for Ets-1 
and Fli-1) where it modulates transcriptional activation. Data 
published to date suggest that TEL mediated repression would 
depend on interactions with co-repressors, likely to be involved in 
histone deacteylation. However, this may not be the sole 
mechanism of repression (Bartel et al., 2000). 
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Ets function in carcinogenesis 
Many Ets family members are known to play important roles in 
development and progression of cancer. Several mechanisms of Ets 
involvement in cancers have been elucidated and will be described 
in further detail. 
Fli-1 was first identified as a site for retroviral integration in Friend 
virus-induced erythroleukemias (Ben-David et al., 1991). Fli-1 is 
now recognised as having a broader role in cell proliferation, 
differentiation and survival. Genetic mutation of Fli-1 often occurs 
during malignant transformation and progression of certain 
tumours. Human and mouse Fli-1 encode two proteins, p51 and 
p48, and the gene is localised near the Ets-1 gene on mouse 
chromosome 9 and human chromosome 11. This implies that a 
common ancestral gene duplication event gave rise to the two ets 
genes (Ben-David et al., 1991; Watson et al., 1992). Fli-1 has 81% 
homology with Erg-2 of the same subgroup, both containing helix-
loop-helix structures in N- and C-terminal ETS domains (Rao et al., 
1993). A, Fli-1 specific region and the N-terminal ETS domain 
contain sequences for transcriptional activation. A C-terminus 
region is also involved in transcriptional activation. In vitro studies 
have shown that this C-terminal region may contain both 
activation and repression activities. When this region was deleted, 
an increase in reporter gene transcription was observed (Rao et al., 
1993). Human and mouse Fli-1 genes show high homology within 
the promoter region (Barbeau et al., 1996; Dhulipala et al., 1998). 
Starck et al. localised the region of promoter activity and found it 
contains one GATA and two EBSs (Starck et al., 1999). Mutations 
in either of the EBS abolished promoter activity and subsequently 
Spi-1 /PU.1 was shown to bind here in the activation of 
transcription m erythroleukemic cells. Importantly, sequences 
within intron 1 of Fli-1 containing GATA and EBS are capable of 
increasing transcription from the minimal promoter, and the 
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factors binding to these regions were identified as Spi-1 and GATA-
1 (Barbeau et al., 1999). 
Fli-1 is involved in a translocation event associated with the 
paediatric form of the tumor Ewings Sarcoma. This disease is 
characterised by fusion of the C-terminal Fli-1 and N-terminal 
region of an RNA binding protein of the Ewing Sarcoma gene (EWS) 
(Delattre et al., 1992). Both Fli-1 and EWS/Fli-1 proteins recognise 
identical DNA binding sequences and retain DNA binding 
specificity through the C-terminal ETS binding domain. However, 
the transactivation potential of the EWS/Fli-1 oncogene is much 
greater than wildtype Fli-1 (May et al., 1993; Bailley et al., 1994; 
Mao et al., 1994). Point mutations in the Fli-1 C-terminal ETS 
domain of the oncoprotein abolish DNA binding, but not oncogenic 
function. From this study, it was concluded that transactivation of 
the oncoprotein is distinct from its DNA binding capability 
(Jaishankar et al., 1999). 
The EWS/Fli-1 fusion protein exists in two forms, 60% of fusion 
products are type 1, which include exons 1-7 of EWS and 6-9 of 
Fli-1. Type 2 also includes the fifth exon of Fli-1. Comparison of 
the two proteins demonstrates a greater transactivation potential of 
type 2 yet similar DNA binding potential and associates type 2 
patients with a worse prognosis (Lin et al., 1999). Protein 
interactions with Fli-1 wildtype and EWS/Fli-1 revealed an RNA 
polymerase II subunit called hsRPB7 binds EWS/Fli-1 but not 
wildtype. This interaction could be responsible for enhanced 
promoter activity of EWS/Fli-1 and hence its greater 
transactivation potential than Fli-1 (Peterman et al., 1998). 
The ErbB2 (HER2 / neu) receptor tyrosine kinase is overexpressed 
in human breast and other epithelial cancers as a result of 
activation of the ErbB2 oncogene. Many in vitro transfection 
experiments have described positive and negative regulatory 
elements on the ErbB2 promoter (Hudson et al., 1990; Suen and 
Hung, 1990; Hollywood and Hurst, 1993; Chen and Gill, 1994; 
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Grooteclaes et al., 1994; Mizuguchi et al., 1994; Scott et al., 1994; 
Bosher et al., 1995; Bosher et al., 1996; Chen and Gill, 1996; Chen 
et al., 1997; Raziuddin et al., 1997). The proximal promoter (220bp) 
contains the most positive acting regulatory elements including a 
conserved CCAAT box, non-conserved TATAA box and a conserved 
EBS adjacent to a polypurine polypyrimidine mirror repeat. Most 
notably in this region was a single DNase I hypersensitive 
chromatin site spanning the mirror repeat and EBS (Scott et al., 
1994). Mutation of the EBS severely reduces ErbB2 promoter 
activity (Scott et al., 1994; Xing et al., 2000). Many different ets 
transcription factors are expressed in human breast cancer cells 
including GABPa, Elk-l, Ets-2, PEA3, ERM, ERBl, NET, Elf-l, 
ESX/Elf-3, Elf-5. Of these, PEA3, Elf-3 and Elf-l have been 
examined for potential transactivation roles of ErbB2 (Benz et al., 
1997; Chang et al., 1997; Scott et al., 2000). Transient transfection 
of Elf- l was shown to stimulate ErbB2 promoter activity in some 
breast cancer cell lines in an Ets-specific manner. Also, 
endogenous Elf-1 protein readily binds to the EBS of the ErbB2 
promoter, however Elf-1 endogenous mRNA and protein levels are 
not correlated with co-expression of ErbB2 in tumour and cell 
lines. PEA3 and Elf-3 do show correlation of mRNA and protein to 
that of ErbB2 (Scott et al., 2000). Ets recruitment to the ErbB2 
EBS is likely to be cell context dependent and rely on other 
promoter regulating factors. Triplex formation at the mirror repeat 
element can inhibit the ETS protein binding at the EBS and 
consequently prevent ErbB2 transcription (Ebbinghaus et al., 
1993; Noonberg et al., 1994; Porumb et al., 1996; Ebbinghaus et 
al., 1999). As well as the negative regulation of the mirror-repeat 
element, the EBS may control tissue-specific regulation (Chang et 
al., 1997) and development specific regulation via the EBS and 
cooperative interactions with other elements such as AP2 (Bosher 
et al., 1995; Bosher et al., 1996). 
PTHrP is expressed in most normal tissues and in aggressive 
tumours with a malignant metastatic phenotype, particularly of the 
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breast, pituitary, ovary and prostate (Dittmer et al., 1994; Dittmer 
and Nordheim, 1998). Ets-1 is likely to be involved in regulation of 
PTHrP and indeed a relationship between Ets-1 and Sp-1 has been 
established. Sites for both transcription factors are found in the 
human PTHrP P2 promoter and the murine PTHrP promoter 
(Karperien et al., 1997). PTHrP expression as well as Ets-1 
expression is induced in endothelial and vascular smooth muscle 
cells by mitogens (Dittmer and Nordheim, 1998). It therefore 
follows that Ets-1 is acting upstream of PTHrP, regulating its 
expression in many tissues and tumours. 
Ets function in development 
Knockout mice provide a model for studying the role of Ets-1 in T 
and B-cell processes (Bories et al., 1995; Muthusamy et al., 1995). 
Ets-1 appears to be crucial for the survival and maturation of these 
cell lineages yet it is not required for their development. Regulation 
of Ets-1 during T cell activation is both transcriptionally and post-
translationally controlled (Pognonec et al., 1988; Bhat et al., 1989). 
Once T cells are activated, a transcriptionally active form of Ets-1 
is inactivated, which is linked with T cell apoptosis (Pognonec et 
al., 1988; Bhat et al., 1990; Rabault and Ghysdael, 1994; Bories et 
al., 1995; Muthusamy et al., 1995). 
Ets-1 has other roles, including cell adhesion and endothelial 
organisation during angiogenesis (Mattot et al., 2000), vascular re-
organisation (Grevin et al., 1993; Kola et al., 1993). It appears to 
not be crucial in embryonic vascularisation as indicated by normal 
blood vessel development in Ets-1 knockout mice (Bories et al., 
1995; Muthusamy et al., 1995; Lelievre et al., 2000). However, this 
may be attributed to functional redundancy with other ets genes 
such as Erg and Fli-l, which have similar patterns of expression. 
Knockout mice models of the Fli- l gene have given insight to its 
role in hematopoietic development and maintenance (Spyropoulos 
et al., 2000). It is clearly a key factor in megakaryocyte maturation, 
as knockout mice have severely reduced megakaryocyte and 
Chapter 1. Introduction and literature review 
27 
derived platelets (Hart et al., 2000; Spyropoulos et al., 2000). It is 
able to trans-activate the GATA-I gene, previously shown to be 
important in erythrocyte maturation (Hromas and Klemsz, 1994). 
In lymphoid lineages it may be important in the survival and 
proliferation of a T cell progenitor (Melet et al., 1996), being highly 
expressed in quiescent T cells but not during T cell activation 
(Anderson et al., 1999). Transgenic mice over-expressing Fli-1 show 
a hyper-responsiveness to mitogenic signals and reduced apoptosis 
(Zhang et al., 1995). 
Ets function in tissue and organ development 
The extracellular matrix (ECM) is an important feature of cell 
structure, providing support as well as an interaction for cell 
function. The ECM is synthesised, deposited and degraded 
throughout embryogenesis, the female reproductive cycle, 
angiogenesis and wound repair, making the balance of synthesis 
and degradation crucial for normal cell function. When this 
balance is upset, pathological conditions may arise and ets factors 
have been implicated in this as they play an important role in the 
transcriptional activation of ECM degrading targets such as serine 
proteases, matrix metalloproteinases and their inhibitors (TIMPS) 
(Trojanowska, 2000). Ets factors may also be involved more widely, 
including the targeting of matrix proteins like tenascin, collagen, 
fibronectin and others. 
Tissue remodelling is an important part of wound healing which 
implicates a role for Ets factors via matrix metalloproteinases 
(MMPs). Some MMPs, for example urokinase plasminogen activator 
(uPA) and tissue-type plasminogen activator (tPA), are induced in 
this process (Yang et al., 1997). Migrating keratinocytes express 
collagenase 1 (MMP-1), stromelysin-2 (MMP-10) and gelatinase 
(MMP-9), uPA, tPA and are involved in re-epithelisation and are 
downregulated at termination of this process (Parks, 1999). Dermal 
cells also express a range of MMPs, and expression is continued 
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through repair to scar formation. A different subset of MMPs is 
expressed by immune cells in the inflammamatory response, 
indicating specificity of expression for the different processes 
(Trojanowska, 2000). 
1.1.8 Matrix Metalloproteinases and the Extracellular 
Matrix 
Matrix metalloproteinases (MMPs) are a family of proteolytic 
enzymes responsible for the degradation of the extracellular matrix 
(ECM). They are usually grouped according to substrate specificity 
and include the collagenases, gelatinases and the stromelysins. 
The expression of the MMP genes is usually tissue-specific, except 
for gelatinase A, which is widely expressed. Of particular interest 
are stromelysin-1 and collagenase, which are expressed primarily 
in stromal fibroblasts. The type of collagenase discussed here is the 
interstitial form in humans (MMP-1), which does not have a murine 
homologue, but murine collagenase-3 (MMP-3) is expressed in a 
similar manner to that of human MMP-1. 
The ability of MMPs to breakdown the matrix proteins implicates 
them in tumourigenesis, as structural barriers of basement 
membranes and stromal ECM must first be weakened for tumour 
formation (Stracke et al., 1994). Most MMP promoters contain what 
is referred to as the 'oncogene-responsive-unit', which is also found 
in many other genes promoter and enhancer regions (Gutman and 
Wasylyk, 1991). It consists of an AP-1 element which binds dimeric 
combinations of the Fos and Jun family of oncoproteins and also 
one or more PEA3 elements capable of binding members of the Ets 
family of oncoproteins. Specific interactions between these cis-
acting elements may therefore be important in controlling positive 
and negative regulation of MMP tissue restricted patterns in both 
normal and neoplastic tissues (Crawford and Matrisian, 1996). 
Indeed, mutations in either the AP-1 or PEA3 elements of 
interstitial collagenase promoter reduce basal activity and 
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responsiveness of the promoter to external stimuli (Gutman and 
Wasylyk, 1990; Wasylyk et al., 1990; Westermarck et al., 1997). 
Evidence for MMPs role in tumourigenesis has come from several 
MMP knockout mice. When MMP-7 was removed, a reduction in 
intestinal tumours was observed (Wilson et al., 1997), MMP-2 
deficient mice exhibited a reduction in angiogenesis and tumour 
progression (ltoh et al., 1998), and MMP-11 knockout mice show 
reduced tumourigenesis when chemical mutagens are 
administered (Masson et al., 1998). 
The role of ets in this tumourigenesis is apparent through the co-
expression of ets with matrix degrading proteases often seen in 
invasive tumours, whilst it is notably absent from non-invasive or 
benign tumours (Calmels et al., 1995). Ets-1 coexpression with 
collagenase 1 (MMP-1), urokinase-type plasminogen activator (uPA) 
and stromelysin (MMP-3) is known to occur in lung carcinomas 
(Wernert et al., 1994; Bolon et al., 1995) and skin angiosarcomas 
(Naito et al., 1994). Also, the role of Ets-1 in regulating MMPs in 
tumours is evidenced by a single nucleotide polymorphism in the 
MMP-1 promoter, creating an EBS that increases Ets-1 binding 
and enhances promoter activity role (Rutter et al., 1998). 
ElA-F, the human homologue of PEA3, was found to activate 
MMP-1, MMP-3 and MMP-9 and was also found to be involved in 
the induction of tumourgenesis in MCF-7 cells (Kaya et al., 1996). 
Further, Ets-1, Ets-2 and PEA3 overexpression are all found to 
increase activity of MMP-1,-3 and -9 promoters (Buttice et al., 
1996; Gum et al., 1996; Westermarck et al., 1997). A further study 
using antisense oligonucleotides to ElA-F in a squamous cell 
carcinoma resulted in the inhibition of both MMP-9 expression and 
invasiveness (Hida et al., 1997; Hanzawa et al., 2000). 
The synergistic interaction between Ets and AP-1 factors has been 
well documented. Specifically in the case of MMPs, the Ets factors 
Ets-1, Fli-1 and PU .1 are known to differentially regulate AP-1 
dependent MMP-1 promoter activation (Westermarck et al., 1997). 
In this study, the effects of each Ets factor were observed in 
Chapter 1. Introduction and literature review 
30 
NIH3T3 fibroblasts. Ets-1 was shown to increase the activity of 
MMP-1 alone and greatly increase activity in conjunction with c-
Jun and JunB. In contrast, neither PU .1 nor Fli-1 had any effect 
alone, while Fli-1 was able to enhance the effect of c-Jun. However, 
PU .1 inhibited MMP-1 induction by both c-Jun and JunB. MMP-1 
5' deletion constructs showed that in the case of PU .1 inhibiton, 
the AP-1 site was necessary (Westermarck et al., 1997). In another 
study, the Ets factor Erg was shown to interact with Jun/Fos and 
potentiate the induction of MMP-1 promoter activity (Angel and 
Karin, 1991). Further to this, Buttice et al. showed that Ets-2 
activates both MMP-1 and MMP-3, while Erg only induces MMP-1. 
Erg inhibits this induction of MMP-3 by Ets-2. Erg was shown to 
be recruited by Fos/ Jun in the transcriptional activation of MMP-1 
but not MMP-3 (Buttice et al., 1996). 
This AP-1 dependent regulation, which seems to be different for 
different Ets members reflects the importance of promoter specific 
sequences and protein-protein interactions. Another example of the 
specific sequence requirement is seen in the case of CREB binding 
protein (CBP) and p300, which bind to Ets-1 (Yang et al., 1998). 
CBP/p300 cooperates with Ets-1 and Ets-2 but not PEA3 or Erg2 
in activation of MMP-3 promoter (Buttice et al., 1996; Jayaraman 
et al., 1999). 
An analogous situation to the MMP control by Ets is seen for the 
TIMP-1 promoter, which contains an EBS adjacent to an AP-1 site 
(Edwards et al., 1992; Logan et al., 1996). C-Ets-1 and AP-1 
complex was capable of activating transcription of TIMP-1 in an F9 
embryonic carcinoma cell line (Logan et al., 1996). Interestingly, 
EHF (Ets homologous factor) appears to have tumour suppressor 
activity as it represses Ets-2 stimulation of MMP-1 and MMP-3 
promoters (Kleinbaum et al., 1999). 
Tumour studies have shown expression of Ets factors are not 
aligned with the ECM enzyme. Ets-1 for example is localised to 
endothelial and fibroblast stromal cells (Wernert et al., 1994) as 
opposed to the tumour cell. Stromal fibroblasts may therefore play 
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a role in the synthesis of matrix proteases thereby supporting 
tumour growth (Trojanowska, 2000). 
Antisense Ets-1 oligonucleotides were transfected to a glioma cell 
line in which Ets-1 and uPA expression was inhibited and glioma 
cell migration and invasion was stopped (Kitange et al., 1999). This 
suggests an involvement of Ets-1 in induction of protease enzymes 
and hence tumourigenesis. Further studies supporting this include 
the stable expression of the Ets-1 DNA binding domain in mouse 
epithelial mammary cells of both normal and cancerous lines, 
which inhibited expression of uPA and reduced cell migration and 
invasion in both cell types (Delannoy-Courdent et al., 1998). 
The data in support of the role of Ets factors in the function both of 
the normal and neoplastic mammary gland is overwhelming. 
Normal ets expression in the mammary gland contributes to its 
development as early as primary epithelial bud formation in the 
embryo and Ets-1 is detected later in epithelial duct extremities. 
Ets-1 expression also coincides with invasiveness (Delannoy-
Courdent et al., 1998). During tubulogenesis in normal and 
invasive cells, Ets-1 is co-expressed with plasminogen (uPA). In 
invasive cells, Ets-1 activates uPA leading to proteolytic events to 
degrade ECM and hence promote tumour metastasis (Delannoy-
Courdent et al., 1996). The PEA3 subfamily shows a high level of 
expression in the developing embryo mammary gland and during 
tubular morphogenesis later in mammary development (Chotteau-
Lelievre et al., 1997). As already mentioned, ElA-F (the human 
form of PEA3) was able to upregulate the transcription of MMPl, 3 
and 9 (Higashino et al., 1995), and this conferred an invasive 
phenotype on human breast cancer cells (Kaya et al., 1996). These 
observations suggest that PEA3 members may take part in 
epithelial-mesenchymal interactions by regulating MMP gene 
expression and in turn the remodelling of the ECM (Chotteau-
Lelievre et al., 1997). Abberant forms of PEA3 are also shown to be 
associated with breast cancer in both mice (Trimble et al., 1993; 
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Chotteau-Lelievre et al., 1997) and humans (Baert et al., 1997; 
Xing et al., 2000). Trimble et al. (1993) observed high PEA3 RNA 
expression in mouse mammary tumours, but low expression in 
surrounding mammary epithelium. Also, when mammary tumours 
metastasised to the lung, the lung tumour showed an over-
expression of PEA3 that was not detected in normal lung tissue 
(Trimble et al., 1993). 
Ets-2 studies reveal it has transforming potential in the mammary 
epithelia (Galang et al., 1996). Over-expression of Neu is a feature 
identified in approximately 20% of breast tumours. Galang et al. 
show that expression of a mutant form of Neu (mutated to become 
constitutively active) causes transcriptional activation of Ets, Ap-1 
or NFKB dependent reporter genes. This activation is mediated by 
the Ras signalling pathway. The Neu mutant mediates Ets-2 
transactivation activity by phosphorylating a specific threonine 
residue. Ets activation was also shown to be required for Neu-
mediated cellular transformation (Galang et al., 1996). Similar 
experiments have shown that Ets-2 mediates the regulation of 
anchorage dependent growth and cellular invasiveness of 
neoplastic mammary epithelial cells (Sapi et al., 1998). Also, a 
deleted Ets-2 gene reduced mammary gland tumour growth in mice 
carrying the polyoma virus middle T oncogene (N eznanor et al., 
1999). The reduction in size of the tumour was correlated with a 
more differentiated state of early hyperplastic growths. Ets-2 was 
thought to regulate the progression of these tumours (Neznanor et 
al., 1999). 
Tissue Inhibitors of Metalloproteinases 
MMP activity can be specifically inhibited by tissue inhibitors of 
metalloproteinases (TIMPs) that bind to the zinc binding site of 
MMPs. The regulation of MMPs important in tissue remodelling via 
TIMPs may also involve the use of Ets factors. It is also likely that 
TIMPs themselves are regulated in part by Ets factors. 
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There are four members of this family, TIMP-1, -2, -3, -4. TIMPS 
are potentially responsible for changes in the morphology and 
growth stimulation of many cells (Gomez et al., 1997). Specifically, 
TIMP-1 and -3 are anti-angiogenic (Gomez et al., 1997) and TIMP-2 
is involved in MMP-2 activation (Murphy and Knauper, 1997). The 
roles of TIMPs that have been documented are somewhat 
contradictory, which may be a result of several independent roles, 
including inhibition of MMPs and also involvement in the cell-
surface-targeted MMP activation cascades (Gomez et al., 1997). 
TIMP-3 can induce apoptosis in both normal and malignant cells 
(Bian et al., 1996; Ahonen et al., 1998; Baker et al., 1998), 
implicating a further role in the survival of malignant cells. 
Structurally, the TIMP-1 promoters of human, mouse and rat 
homologues all lack a TATA box but contain a conserved 22bp SRE 
at 75bp upstream of the major transcription start site (Gewart et 
al., 1987; Campbell et al., 1991; Bugno et al., 1995; Clark et al., 
1997; Bahr et al., 1999). The SRE is critical for promoter 
responsiveness to growth factors, cytokines and viruses. It 
contains elements for AP-1, STATs and PEA3 transcription factors. 
The AP-1 site is critical for both basal and inducible transcription 
(Campbell et al., 1991; Edwards et al., 1992; Bugno et al., 1995; 
Logan et al., 1996; Clark et al., 1997). 
1.2 BrETS, Elf-5 and Ese-2 
1.2.1 BrETS 
The initial discovery of the BrETS gene resulted from a screen of 
bovine mammary cDNA clones (L'Huillier et al., unpublished). A 
partial cDNA sequence was isolated and sequenced and a 
subsequent blast search revealed homology to the Ets family of 
proteins. Later, the mouse homologue was identified and the cDNA 
sequence elucidated (L'Huillier et al., unpublished). Northern blot 
analysis demonstrated that two transcripts were expressed in 
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murine mammary cells, of approximately 1.5kb and 2.5kb, as seen 
in Figure 1.3. The transcripts were later cloned and sequenced 
(L'Huillier et al., unpublished). Characterisation of the two 
transcripts revealed alternate polyadenylation sites, which were 
shown to be responsible for the 1.5 and 2.5 kb mRNA species 
(Langley, 1999). 
Analysis of the murine cDNA revealed an open reading frame of 
765 bp representing a 255 amino acid protein. The ETS domain 
was found to be located in the C-terminus at positions 161-242 
and a conserved B domain was found at the N-terminus at 
positions 47-118 amino acids. The B domain may be associated 
with protein-protein interactions with the serum response factor, 
as in Elk-1 (Ling et al., 1997). 
The expression of BrETS was studied in a variety of tissues. Of 
these, high expression was seen in the mammary gland (see Figure 
1.3) with less expression detected in the salivary gland (L 'Huillier et 
al., unpublished). No expression was detected in other tissues 
studied including liver, lung, kidney, spleen, heart or brain. This 
pattern of expression was later found to be more widespread (Zhou 
et al., 1998), possibly due to a weakly hybridising probe and the 
use of total RNA in the experiments by L 'Huillier et al. 
With the highly specific expression in the mammary gland, the 
temporal expression pattern was then examined in the same tissue 
(L'Huillier et al., unpublished). Temporal analysis of mammary 
gland tissues from virgin, pregnant, lactating and involuted mice 
revealed strong expression of BrETS from day 6 of pregnancy, 
throughout pregnancy and lactation with a sharp decline at day 2 
of involution, as indicated in Figure 1.4. 
1.2.2 Elf-5 
In 1998, Zhou et al. published their findings on a novel ETS factor, 
which they termed Elf-5 of the Ets-like-factor subfamily (Zhou et 
al., 1998). The gene was identified in both mouse and human, and 
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appears to be identical to BrETS. Its Human chromosomal position 
was localised to 1 lpl3-15, a region that frequently undergoes loss 
of heterozygosity in carcinomas of the heart, kidney and prostate. 
The expression pattern of poly(A)+ mRNA Elf-5 was shown to be 
highly specific to epithelial tissues and was detected in mouse 
tissues including the lung, kidney, stomach, ovary, tongue, bladder 
and both 2-day and 10-day pregnant mammary gland. It was not 
evident in the liver, heart, small intestine, spleen, thymus, 
pancreas, skeletal muscle, colon or fat samples. Interestingly, a 
differential pattern of the two transcripts was observed in some 
tissues in the mouse, with the 2.5kb transcript predominantly 
expressed in the neonatal and embryonic lung, kidney and adult 
ovary. The 1.5kb transcript was more abundantly present in the 
adult tongue and developmental stages of the stomach. 
In the human adult, the 2.5kb transcript was expressed more 
strongly in the kidney and prostate whilst being low in the placenta 
and lung. Of several human cancer lines tested, only T4 7D (a 
breast tumour cell line) expressed Elf-5, which may be due to re-
arranged alleles. 
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GMG SG Br He Sp Ki Lu Li L7 P18 PIO Vlr 
J , 
Figure 1.3 Spatial expression pattern of BrETS. Tissues are 
from mouse if unspecified. Two isoforms are indicated by arrows at 
the right of the diagram. Abbreviations are as follows : GMG/ goat 
mammary gland, SQ/salivary gland, Br/brain, He/ heart, Sp/ 
spleen, Ki/ kidney, Lu/ lung, Li/ liver, L7 / 7 day lactating 
mammary gland, P18/ 18 day pregnant mammary gland, PIO/ 10 
day pregnant mammary gland, vir / virgin mammary gland. 
(L'Huillier et al., unpublished) 
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Figure 1.4 Temporal expression pattern of murine BrETS. 
BrETS expression was examined by Northern blot analysis, 
throughout the stages of mouse mammary gland development. 
Abbreviations: V/virgin, P4/pregnant day 4, LO/lactating day 0, 
12/involuted day2, Li/liver. The two transcript sizes are shown to 
the right of the figure. (L'Huillier et al., unpublished) 
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Murine Elf-5 cDNA was found to be 1437bp in size, encoding an 
ORF of 759 bp corresponding to a 253 amino acid protein. The two 
transcript sizes were given as 2224bp and 1528bp. The human 
ELF-5 cDNA isolated from a lung library revealed one transcript 
only, encoding a 255 amino acid protein. Mouse and human amino 
acid sequences were aligned and found to be 95% similar with only 
one substitution within the ETS domain. A conserved Pointed 
domain was also found along with several phosphorylation sites for 
casein kinase II, protein kinase C and tyrosine kinase. The ETS 
domain retains 67% homology to Elf-3 (human}, 49% homology to 
NERF, 48% to Drosophila E74 and 46% to human Elf-1 (Zhou et 
al., 1998). 
Phylogeny relationships show that hELF-5 and mElf-5 are 
orthologous genes (traced back to a speciation event) and that ELF-
3 and ELF-5 are paralogous (traced back to gene duplication). A 
recent study of Elf-3 and Elf-5 examined the ability of these genes 
to control Whey Acidic Protein (WAP) transcription via a MAF-1 
(Ets-1) site and an adjacent Ets-2 site (Thomas et al., 2000). Elf-3 
is expressed in the virgin mammary gland and in early pregnancy 
when cells are proliferating and declines in late pregnancy when 
epithelial cells terminally differentiate and produce milk. Its 
expression is low throughout lactation but increases again at 
involution when apoptosis of the epithelia occurs. Its expression is 
restricted to epithelial cells in the ducts and lobular structures of 
the mammary gland. Both Elf-3 and Elf-5 were able to activate a 
WAP promoter construct in mammary cell lines, though Elf-3 is 
more potent than Elf-5. Both were shown to be independent of the 
lactogenic hormones. Point mutations of either of the Ets-1 or -2 
sites inactivated the transactivation capability. Mutations in both 
Ets sites simultaneously had only a slightly greater effect, implying 
a cooperative interaction between Ets factors. 
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1.2.3 ESE-2 
Simultaneous to the Elf-5 publication another group Oettgen et al., 
(1999), published findings of the novel ets factor human ESE-2 of 
the epithelium specific factor subfamily. ESE-2 contains 65% 
homology with ESE-1 in the ETS domain. Sequence analysis 
revealed ESE-2 is identical to ELF-5. 
Human ESE-2 was found to express two splice products differing in 
the 5' sequence and the cDNA lengths were found to be 2451bp 
(ESE-2a) and 2317bp (ESE-2b). The reason for the divergent 5' 
sequence was predicted to be alternative 5' exons and implicated 
alternative transcription start sites possibly from proximal and 
distal promoters (Oettgen et al., 1999). Polyadenylation sites were 
found along with an ATTTA motif thought to be involved in mRNA 
turnover (Savant-Bhonsale and Cleveland, 1992). In the human, no 
transcript was found homologous to the mouse 1.5kb transcript. 
In the human adult a highly restricted pattern of expression of 
hESE-2 was found. This included tissues with high epithelial cell 
content such as kidney, prostate, small intestine, colon, ovary, 
pancreas, liver and placenta, and throughout the gastrointestinal 
tract. The highest expression was found in the salivary gland 
followed by the mammary gland, fetal kidney and trachea. Human 
ESE-2 retains the C-terminal ETS domain and N-terminal Pointed 
domain. Differential expression of the two transcripts was observed 
with the kidney only expressing ESE-2a and the prostate 
expressing higher levels of ESE-2b than ESE-2a. 
Both ESE- I and ESE-2 are expressed in differentiated but not 
undifferentiated keratinocytes. In vitro analysis shows ESE-2 is 
induced later during differentiation than ESE- I, which may allow 
for temporally different activation of different epithelium specific 
genes. ESE-1 and -2 regulate the two prostate specific genes PSA 
and PMSA oppositely. ESE-1 represses PSA while ESE-2 activates 
it. The opposite occurs for PSMA activation. ESE-2 is likely to be 
critical in the regulation of PSP (a salivary gland gene) with a 
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different effect from ESE-1, which is also expressed in the salivary 
gland. 
Examination of the DNA binding properties of ESE-2 reveals it has 
an N-terminal regulatory domain that inhibits DNA binding and 
this is not present in ESE-1 (Oettgen et al., 1999). 
1.3 Objectives of this research 
In this project the overall objective was to characterise the 
promoter region of the mouse Ese-2 gene. Specifically, this involved 
the mapping of genomic clones from a mouse 129 library and the 
determination of the orientation of each clone. Appropriate 5' 
regions were sub-cloned, sequenced and characterised. Computer 
analyses were performed to identify potential transcription factor 
binding sites and to locate any other typical promoter features 
such as a TATA box. The transcription start site(s) were then 
identified using primer extension and the sequence verified by 5' 
RACE. Subsequent to this initial analysis a functional 
characterisation of the Ese-2 promoter was performed. The 
approach involved the use of deletion constructs of the proximal 5' 
reg10n attached to the reporter construct Chloramphenicol 
acetyltransferase gene (CAT). These were transfected both stably 
and transiently into cell lines including mouse mammary lines 
HCl 1, CommalD and a human breast tumour line T47D. Further 
to this, any regions of apparent importance were searched further 
with the goal of identifying specific sites of regulation. 
The localisation of 5' promoter and regulatory elements would aid 
in the understanding of how the gene is regulated in the context of 
the mammary gland. This would also be useful in allowing the use 
of site directed mutagenesis to artificially control the regulation of 
the gene. 
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Growth Media 
(i) Luria broth 
Suspend 25g of LB Base in 11 of distilled water and autoclave for 
15min at 121 °C. Millers Luria Broth Base was purchased from 
lnvitrogen. 
(ii) Luria agar 
Suspend 37g of Millers LB agar (Invitrogen) in 11 of distilled water. 
Heat to boiling with stirring to dissolve and autoclave for 15min at 
121 °C. Cool to 50°C and pour 20ml each into sterile petri dishes. 
(iii) Terrific broth 
To 37g of Terrific Broth base (Invitrogen) add 11 of distilled water. 
Autoclave for 15min at 121 °C. 
(iv) S.O.C. media 
Dissolve 2g of bactotryptone, 0.5g of yeast extract, 1ml of lM NaCl 
and 0.25ml of lM KCl in 97ml of distilled water. Once dissolved, 
auotclave and cool. Prepare a stock solution of 2M Mg2+ from 1 M 
MgCh.6H20 and lM MgS04.7H20 and filter sterilise. To prepare 
media, make up to 20mM Mg2+ by adding 1 ml of the 2M Mg2+ stock 
solution. Finally add 1ml of a 2M glucose stock solution to a final 
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concentration of 20mM. Filter the media through a 0.2µm filter 
unit. 
(v) DMEM-F12 media 
Dissolve one packet of DMEM-F12 media (Invitrogen) in 11 of 
distilled water. Add 1.2g sodium bicarbonate and stir until 
completely mixed. Adjust the pH to 7 .1 using 5M NaOH and stir for 
a further 20min. Filter the media in a sterile hood using a vacuum 
filter unit. Store at 4°C. 
For HCl 1 and CommalD cell media, supplement 180ml of the 
above stock media by adding 8% fetal calf serum (FCS), insulin 
( 1 mg/ ml), epidermal growth factor (EG F) ( 1 Ong/ ml), bovine serum 
albumin (BSA) (300µg/ml) and antibiotics (penicillin/streptomycin 
lOmg/ml). Store the media at 4°C. 
For T47D cells, prepare MEM-a by adding one packet of powdered 
media (Invitrogen) to one 1 of distilled water and 2.2g of sodium 
bicarbonate. Stir until dissolved and filter sterilise. Supplement 
180ml of media with 20ml FCS, 2µg/ml insulin, and lµg/ml 
hydrocortisone. 
2.1.2 Bacterial strains 
Cell strains used in this study are listed in Table 2.1. Glycerol 
stocks of cells were stored in 50% glycerol at -80°C. 
Table 2.1 Bacterial strains 
Species Strain Genotype Source 
E.coli STBL2 F- Invitrogen 
E.coli XLl-Blue MRF' Stratagene 
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2.1.3 Eukaryotic cell lines 
Cell strains used for cell culture experiments are listed in Table 
2.2. Stocks of cells were stored in 10% DMS0/25% FCS/ 65% 
media in liquid nitrogen. 
Table 2.2 Eukaryotic lines 
Species Cell line Originating tissue Source 
Mouse CommalD Mammary gland, mid- J. Demmer, 
pregnant AgResearch 
Mouse HCll Derivative of Comma 1 D J. Demmer, 
AgResearch 
Human T47D Breast cancer cell line P. L 'Huillier, 
AgResearch 
2.1.4 Plasmids 
Plasmids used in this study are listed in Table 2.3. Plasmid DNA 
was stored in water or TE buffer at -20°C. 
Table 2.3 Plasmids and bacteriophage 
Plasmid Description Source 
pBLCAT2 4.5kb, Ampr, CAT, Promega 
SV40 poly A, HSV tk 
promoter 
pBluescript KS+ 2958bp, Ampr , T3 and Stratagene 
T7 RNA pol initiation 
sites, Lacz 
pBluescript SK+ 2958bp, Ampr , T3 and Stratagene 
T7 RNA pol initiation 
sites, Lacz 
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pCHl 10 7128bp, Ampr, Lacz, Promega 
SV40 early promoter 
pEGFP-Nl 4.7kb, Kanr /Neor, CLONTECH 
EGFP, SV40 poly A 
pGEM3 2967bp, Ampr, SP6 and Promega 
T7 RNA pol initiation 
sites 
pGEM-TEasy 3015bp, Ampr, lacZ, Promega 
T7 and SP6 RNA pol 
initiation sites 
Lambda Phage FIX II red and gam genes, T3 and Stratagene 
Library T7 pol initiation sites 
2.1.5 Oligonucleotides 
The oligonucleotides used in this work were purchased from 
Invitrogen. The sequences of the oligonucleotides are listed in Table 
2.4. Start position is given relative to the major transcription start 
site at + 1 and the second column describes the method the 
oligonucleotide was used in. 
Table 2.4 Oligonucleotide sequences 
Oligonucleotide, start Method Sequence 5' - 3' 
position for Ese-2 
1.1 l(ATG), +59 Southern ACCTAGCCACCACTTGTCTT 
blot analysis CACGGTGATG 
1.11(1), -22 Southern CTACAGGTGCCTTTATTTCT 
blot analysis 
1.11(2), + 176 cDNA Southern ATCTGTTCAGCAATG 
blot analysis 
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5'seq., +l Sequence, GGTCCGCTGGTGCTGGG 
and Southern 
blot analysis 
AAP,N/A 5'RACE GGCCACGCGTCGACTAGTAC 
GGGIIGGGIIGGGIIG 
Exon2 ATG mod. PCR GTTACGGAGATCTACAACACC 
Bgill, +6136 CTGGAATATC 
Exon2 ATG mod., PCR GTTACGGACTCGAGCAACAC 
+6136 CCTGGAATATCAGAG 
Exon2 ATG mod.2, PCR GTTACGGAGCTCGAGATCAC 
+6136 CCTGGAATATCAGAG 
Far 5' #104, -2561 PCR GATCATCCAAACATCCATT 
Far 5' #146, -2519 PCR GATCAAATGTGATGCTTACGC 
TTAGAG 
Far 5' #30, -2635 PCR TTCCTGCCCTTCCCACTT 
Far 5' #50, -2615 PCR CAGCTCATCTTCACCCACAG 
Far 5' #84, -2581 PCR TTCCCATAGCTTAGTGTTTG 
Far 5' Sad, -2665 PCR GAGCTCAGTTCTTCCCCCACC 
ACCC 
Far 5' Sphl mod., PCR TCCGTCTTTGTTACTTTGTGAA 
-2528 TC 
Far 5' Xbal, -1805 PCR CAGTCAATCTCTAGAACCCA 
Forward + 1, -59 Sequence AACGGACCTGTCTGTAGG 
analysis 
GSPl, +442 cDNA 5'RACE TACAGGTACTCCCCACAGA 
GSP2, +366 cDNA 5' RACE GCTGCAGGCCGGTGATGTTG 
AAGTGA 
Intron 1 2700, +2926 Sequence CTTCTGCCATTGAGA 
analysis 
Intronl 4200,+4181 Sequence GATGATGCTATACCC 
analysis 
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Intron 1 5500, +5433 Sequence CACAGAATGCTACAG 
analysis 
Intronl 6000,+6016 Sequence GTGTAAAGCACTTGA 
analysis 
Intronl 770, +855 Sequence CCAAAGACTCAGACC 
analysis 
PE 35, +46 Primer CCTTCTGTCTGGACCTAGCCA 
extension CCACTTGTCTTCAC 
2.1.6 Chemicals, enzymes and radioisotopes 
(i) Chemicals 
Chemicals used in this study were purchased from one of the 
following suppliers: 
Sigma Chemical Co., St Louis, MO, USA 
Roche Diagnostics NZ Ltd, PO Box 62-089, Akl 
Invitrogen NZ Ltd, PO Box 12-502, Akl 
Progenz Ltd, PO Box 180-029, Akl 
Amersham Pharmacia Biotech, PO Box 56-364, Akl 
Biolab Scientific Ltd, Private Bag, Akl 
Bio-Rad Laboratories PTY Ltd, PO Box 300-571, Akl 
Global Science and Technology Ltd, PO Box 101-253, Akl 
(ii) Enzymes 
Restriction enzymes were purchased from Roche Diagnostics Ltd. 
Other enzymes were purchased from the suppliers as listed in 
Table 2.5. 
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Table 2.5 Enzymes 
Enzyme Source 
DNA Polymerase I (Kienow fragment) Invitrogen 
DNasel Roche 
Elongase PCR system Invitrogen 
Expand PCR system Roche 
Ribonuclease A Invitrogen 
RNase H Roche 
RNase Tl Invitrogen 
Superscript II RNase H-RT lnvitrogen 
T4 DNA ligase Roche 
T4 DNA ligase (pGEM-Teasy) Promega 
T4 DNA polymerase Roche 
T4 polynucleotide kinase Invitrogen 
T7 RNA polymerase Promega 
Taq DNA polymerase Roche 
Terminal transf erase Invitrogen 
(iii) Radioisotopes 
The radioisotopes used in this study were purchased from 
Amersham, and are listed in Table 2.6. 
Table 2.6 Radioisotopes 
Radioisotope Specific activity Use 
[y-32P]-dATP 3000 Ci/mmol Labelling 
oligonucleotides 
[a-32P]-dCTP 3000 Ci/mmol Labelling cDNA 
by random 
pnmmg 
l 4C-Chloram phenicol 50µCi CAT detection 
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2.1.7 Solutions 
The solutions used in the study are listed in Table 2. 7. 
Table 2. 7 Solutions 
Solution Composition 
lOX MOPS 41.8% MOPS 
50mM NaOAc 
lOmM EDTA 
Alternate DNA Loading dye 6X 0. 25% bromophenol blue 
0.25% xylene cyanol 
30% glycerol 
Dispase 9 .6mg/ ml neural protease from 
Bacillus polymyxa (Roche Diag.) 
DNA denaturing solution 1.5M NaCl 
0.5M NaOH 
DNA loading dye lOX 15% ficoll 
0.25% bromophenol blue 
0.25% xylene cyanol 
lM EDTA pH 8.0 
1%SDS 
DNase STOP buffer 20mM Tris-Cl pH8 
lOmM EDTA 
1% w/v SDS 
600mM NaCl 
400µg/ ml Proteinase K 
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Formaldehyde loading dye (2X) 50% deionised formamide 
20% deionised formaldehyde 
10% MOPS (lOX) 
40µg/ ml ethidium bromide 
0.02% bromophenol blue 
0. 02% xylene cyanol 
lmM EDTA pH 8.0 
5% glycerol 
Formamide loading dye 95% deionised formamide 
(STOP dye) 20mM EDTA pH 8.0 
0.05% xylene cyanol 
0.05% bromophenol blue 
Hybridisation buffer 7%SDS 
(Church and Gilbert) lmM EDTA 
0.25 M Na2HP04 pH 7.2 
Plasmid DNA extraction: 
Solution I SOmM glucose 
lOmM EDTA 
25mM Tris-Cl pH 8.0 
RSB buffer 1 OOmM Tris-Cl pH7.4 
lOmM NaCl 
3mM MgCh 
RSB buffer with NP-40 1 OOmM Tris-Cl pH7.4 
lOmM NaCl 
3mM MgCb 
0.02% Nonidet P-40 
SM buffer SOmM Tris-Cl pH7.5 
lOOmM NaCl 
8mM MgS04 
0.01 % gelatin 
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Solution II 0.2mM NaOH 
1%SDS 
Solution III 3M potassium acetate 
2M acetic acid 
Solution Z PBS 
3.6µ1/ml BME 
SSC (20X) 3.0M NaCl 
0.3M sodium citrate pH 7 .0 
TAE buffer 40mM Tris-acetate 
2mM EDTA pH 8.0 




TBE buffer 80mM Tris-borate 
8mM EDTA pH 8.0 
TCA (100%) 500g trichloroacetic acid 
227ml H20 
TE buffer 1 OmM Tris-Cl 
lmM EDTA pH 8.0 
Trypan Blue PBS 
0.16% Trypan blue 
Trypsin/ EDTA 0.25% Trypsin 
lOmM EDTA 
5mg Phenol Red 
lXTBS 
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2.2 Methods 
2.2.1 Bacterial growth 





Transformed cells were spread onto LB agar medium containing 
the appropriate antibiotic. Plates were grown for 12-16hrs at 37°C 
until colonies were approximately 1mm in diameter. 
(ii) Liquid cultures 
Using a sterile toothpick or loop, a single colony was transferred to 
a 3ml (mini preparation) or 100ml (maxi preparation) LB or TB 
medium in a 21 flask with the appropriate antibiotic. Cultures were 
incubated at 37°C on a rotary shaker (300rpm) until an OD6oo of 
0.4 was reached. 
2.2.2 Preparation and transformation of chemically 
competent cells 
Preparation of XLl-Blue cells followed the method described by 
Inoue et al. ( 1990). 
XLl-Blue cells were grown overnight on LB agar plates with the 
appropriate antibiotic(s}, ten colonies of 2-3mm diameter were used 
to inoculate 250ml Terrific Broth culture in a 11 flask. This was 
grown at 18°C with shaking (225rpm) to an OD6oo of 0.6. The cells 
were then chilled on ice for lOmin, centrifuged at 2500xg for lOmin 
at 4°C, and the pellet resuspended in 80ml of ice cold TB. The 
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suspension was chilled on ice for a further lOmin, centrifuged for 
lOmin at 2500xg 4°C and resuspended in 20ml of TB plus 1.5ml 
DMSO (7%). After another lOmin incubation on ice, the cells were 
aliquoted and frozen in liquid nitrogen. Competent cells were 
stored at -80°C. 
For heat shock transformation of XLl-Blue MRF' cells, plasmid 
DNA or ligation mixture (1-20ng DNA) was added to 80µ1 of 
competent cells. Ligations containing low melting point agarose 
were diluted to <0.02% agarose before addition of competent cells. 
The cells and DNA were incubated on ice for 30min and then heat 
shocked at 42°C for lmin. Cells were snap cooled on ice and 500µ1 
of LB was added. The transformed cells were then incubated at 
37°C for 60min before plating onto LB agar and antibiotic, and 
were grown overnight at 37°C. 
For transformation of STBL2 cells (Invitrogen), the procedure is the 
same except the heat shock is performed in a 15ml falcon tube, at 
42°C for 25sec. The cells were incubated in S.O.C. media at 30°C 
prior to plating. They were grown overnight at 30°C for 16hrs. 
2.2.3 Preparation and transformation of competent 
cells for electroporation 
Electrocompetent E.coli XLl-Blue-MRF' cells were prepared 
according to the protocol given by Sambrook et al. (1989). 
This involved the innoculation of 5ml of LB media by a single 
colony of XLl-Blue-MRF' cells. This was grown overnight at 37°C 
with shaking at 250rpm. 2.5ml of the overnight culture was then 
used to inoculate 500ml of LB media in a sterile 21 flask. This was 
allowed to incubate at 37°C, shaking at 250rpm until an OD6oo of 
0.5 - 0.6 was reached. The culture was cooled in an ice bath for 
15min prior to transferral to two 250ml centrifuge bottles. The cells 
were pelleted by centrifugation at 4200xg for 15min at 4°C, in the 
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Sorvall GSA rotor. Once the supernatant had been removed each 
pellet was resuspended in 250ml of ice-cold distilled water. The 
centrifugation and resuspension steps were repeated, with a final 
centrifugation pelleting the cells ready for use. Cells for immediate 
use were resuspended in an equal volume of ice-cold water. For 
storage of electrocompetent cells, the pellet was resuspended in ice 
cold 10% glycerol and water solution. This suspension was 
aliquoted into 700µ1 eppendorf tubes and snap frozen in a dry-
ice / ethanol bath. The cells were stored at -80°C. 
STBL2 cells for electroporation were prepared in the same way. 
Electroporation of XLl-Blue-MRF' cells was performed according to 
the Gene Pulser Electroprotocol using the Pulse controller (Bio-
Rad). 10-lOOng of ligation mixture in a volume of 1-2.5µ1 was 
added to a 1. 5ml eppendorf tube already containing 50µ1 of 
electrocompetent cells. Once the contents were mixed, they were 
transferred to a clean electroporation cuvette (0.2cm). The cuvette 
was placed in the electroporation chamber and the pulse was 
applied at 2.5kV, 25µF, 200ohms. Immediately following the pulse, 
1ml of S.O.C media was added, the suspension transferred to a 
1.5ml eppendorf tube and incubated at 37°C for 1hr, shaking at 
225rpm. The cells were aliquoted onto LB agar with ampicillin and 
incubated at 37°C for approximately 15hrs. 
The procedure for STBL2 cell electroporation was the same with 
the exception that cells were incubated at 30°C prior to and 
proceeding plating. 
2.2.4 Isolation of nucleic acid 
(i) Small scale extraction of plasmid DNA 
Bacteria containing the plasmid were grown overnight in a 3ml 
liquid culture with antibiotics that was inoculated with a single 
colony from an agar plate. The plasmid DNA was recovered from 
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half this culture by alkaline lysis (Sambrook et al., 1989), the 
minipreparation method by Berghammer and Auer, 1993, or the 
Qiagen proprietary method 'concert minipreparation'. 
(a) Alkaline lysis 
Bacteria were recovered by centrifugation at 12000xg for 30sec. 
The bacterial pellet was resuspended in 100µ1 of Solution I, and 
lysed with the addition of 200µ1 Solution II. After Smin incubation 
on ice, 150µ1 of Solution III was added to precipitate proteins and 
chromosomal DNA. The preparation was centrifuged for 15min at 
lOOOOxg to pellet protein and chromosomal DNA. Plasmid DNA 
was removed as the supernatant and precipitated in ethanol. 
(b) Minipreparation by Berghammer and Auer, 1993. 
The bacterial pellet was resuspended in 80µ1 of lysis buffer and 
incubated at room temperature for 5 min. The suspension was 
then boiled for 60sec and immediately snap-cooled on ice. 
Centrifugation at maximum speed in a microcentrifuge for 15min 
removes the cell debris and genomic DNA so that the plasmid DNA 
remains in the supernatant. 
(ii) Large scale extraction of plasmid DNA 
Bacteria were grown overnight at 37°C as a 100ml culture. The 
plasmid DNA was extracted either by alkaline lysis or by Qiagen 
ion exchange column (Biolab). 
(a) Alkaline lysis 
Crude extraction was performed as per small scale preparation in 
section 2.2.4(i)(a). The plasmid DNA was then resuspended in 5ml 
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H20 and 5ml LiCl was added, with incubation at 4°C overnight. 
The RNA was pelleted by centrifugation at lOOOOxg for lOmin in 
the Sorvall SS34. DNA was recovered by precipitation with ethanol 
and resuspended in 5ml H20. Remaining RNA was removed by 
incubating the DNA with RNase A added to a final concentration of 
0.02µg/µl. This was then extracted twice with phenol / chloroform 
( 1: 1), once with chloroform, and precipitated in ethanol. Recovered 
DNA was resuspended in water or TE and stored at -20°C. 
(b) Qiagen purification 
Purification of plasmid DNA was performed using the Qiagen Maxi 
Kit protocol. Cells were lysed and DNA was loaded onto a pre-
equilibrated Qiagen-tip by gravity flow. Cell debris and RNA was 
washed through before elution of the DNA. DNA was precipitated in 
0. 7volume of isopropanol, washed twice in 70% ethanol and 
resuspended in DEPC treated water. This method was used for 
DNA preparations required for cell culture transfections. 
(iii) RNA extraction by TriZOL 
Cultured cells were washed twice in PBS and lysed in the plastic 
culture dish by the addition of TriZOL (1.5ml per 10cm dish). 
Genomic DNA was sheared by pipeting the lysate with a 1ml 
eppendorf pipette several times. The lysate was transferred to a 
2ml tube and incubated at room temperature for 5min. Following 
the addition of 200µ1 chloroform, the tube was shaken for 15sec 
and incubated for 3min at room temperature. The lysate was then 
centrifuged in a microfuge at 12000xg for 15min and the aqueous 
phase separated to a new tube. This was precipitated with one 
volume of isopropanol and the RNA pelleted at 14000xg for 1 Omin 
in a microfuge. The RNA pellet was washed twice with 70% ethanol 
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and allowed to air day for lOmin. It was finally resuspended in 50-
100µ1 of DEPC treated water. 
Extracted RNA was analysed by Northern blot hybridisation. 
2.2.5 Purification of nucleic acids 
(i) Phenol/ Chloroform extraction 
For all protein removal, nucleic acids were extracted twice with 1 
volume of Tris-saturated phenol:chloroform, (1:1). Phenol was 
removed by an extraction with chloroform. Nucleic acids were then 
precipitated in 0.3M NaOAc and 2 volumes of ethanol at -20°C 
before recovery by centrifugation (lOOOOxg for 15min). Ethanol was 
removed and the pellet washed thoroughly twice in 70% ethanol, 
dried under vacuum and resuspended in water or TE. 
(ii) GFX spin column extraction 
Purification by GFX spm column (Amersham Pharmacia Biotech) 
was performed as per the kit instructions. Briefly, this involved 
dissolving the reaction mixture or agarose sample in 500µ1 of 
capture buffer. For agarose, the sample was heated to 65°C until 
completely dissolved. This was applied to the column and 
centrifuged at lOOOOxg in a microcentrifuge for 30sec. 500µ1 of 
wash buffer was then added to the column, and centrifuged again 
at lOOOOxg for 30sec. The column was removed to an eppendorf 
tube, and 50µ1 of TE or water applied and allowed to incubate for 
lmin at room temperature. The column was finally centrifuged at 
lOOOOxg for lmin to elute the nucleic acid. 
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(iii) Lambda DNA extraction 
Genomic DNA cloned into the Lambda Fix II library (Stratagene) 
was extracted using Lambda SORB (Promega) or WIZARD lambda 
preps DNA purification system (Promega). 
(a) ASORB 
DNA was extracted from phage lysates stored at 4°C. In a 
centrifuge, 10ml of lysate and 100µ1 of ASORB were mixed and 
rotated at room temperature for 30mins. The suspension was then 
centrifuged at 14000xg in the Sorvall SS34 rotor for 15min. 
Supernatant was removed and the pellet resuspended in 1ml of SM 
buffer. This was transferred to a 1.5ml eppendorf tube and 
centrifuged in a microfuge at 15000xg for 2min. This SM buffer 
was removed and centrifugation was then repeated. The pellet was 
resuspended in 250µ1 of lOmM Tris-Cl pH7.8 and 250µ1 of lOmM 
EDTA. The suspension was heated to 67°C for 5min, centrifuged 
again as above and the supernatant collected. The supernatant 
was extracted twice with phenol/ chloroform/ isoamyl alcohol 
(24:24: 1), once with chloroform/isoamyl alcohol (24: 1) and 
precipitated in ethanol and ammonium acetate. 
(b) WIZARD A preps DNA extraction system 
40µ1 of nuclease mixture was added per 10ml of lysate and 
incubated at 37°C for 1 Smin. 4ml of phage precipitant was then 
added and allowed to incubate on ice for 30min. This was then 
centrifuged at lOOOOxg in a microfuge for lOmin and the 
supernatant removed. The pellet was resuspended in 500µ1 of 
phage buffer and the centrifugation repeated. The supernatant was 
collected, mixed with 1ml of purification resin and pipeted into the 
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WIZARD minicolumn syringe barrel. The resin and lysate mixture 
was gently forced through the column using a syringe plunger. 
Following this, the column was washed by pushing 2ml of 80% 
isopropanol through. The minicolumn was then transferred to an 
eppendorf tube and centrifuged for lOOOOxg for 2min to dry the 
resin. 100µ1 of water preheated to 80°C was applied to the column 
and immediately centrifuged at 1 OOOOxg for 20sec to elute the 
DNA. Purified lambda DNA was stored at -20°C. 
2.2.6 Electrophoresis 
(i) Agarose gel electrophoresis of DNA 
Electrophoresis was performed according to Sambrook et al. 
(1989). Gels were made containing 1-2.5% agarose (SeaKem) 
dependent on the size and separation of DNA required. They were 
made in either lX TAE or lX TBE, with 300ng/ml ethidium 
bromide (EtBr). Electrophoresis was carried out in Horizon or Owl 
electrophoresis tanks, in a buffer of either lX TAE or lX TBE. Prior 
to loading, DNA samples and markers were mixed with glycerol 
loading dye. A voltage of between 50-lOOV was applied and 
separation achieved in 1-3hrs. Fractionated DNA was visualised on 
a UV transilluminator screen or UV gel doc (Bio-Rad) and 
photographed onto Polaroid or thermal paper respectively. 
(ii) Agarose gel electrophoresis of RNA 
Electrophoresis was carried out as described by Sambrook et al. 
(1989). 
Gels contained 1.6% agarose, lX MOPS and 0.66M formaldehyde. 
For Northern blot analysis, total RNA was quantified by 
spectrophometry at OD260 and 1 Oµg loaded after incubation at 
65°C for Smin with one volume of formaldehyde loading dye. 
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Electrophoresis was performed at 100V for 3-8hrs at 4°C. Dyes 
containing ethidium bromide allowed visualisation by UV. 
(iii) Denaturing polyacrylamide gel electrophoresis 
Gels contained 4-6% w/v acrylamide (19:1) or (29:1) w/w 
acrylamide:N,N'methylene-bis-acrylamide, 7M urea and lX TBE 
buffer. Polymerisation was initiated with the addition of APS to 
0.1 % and TEMED to 0.04%. The nucleic acid to be analysed was 
mixed with one volume of formamide loading dye and heat 
denatured at 65°C for 5min. 
Polyacrylamide sequencing gels were run on Gibco BRL sequencing 
apparatus Model SA. The gel dimensions were 20cm x 90cm x 
0.15cm. Prior to loading samples, the gel was pre-run for one hr at 
65W. Samples were loaded through a shark-tooth comb and 
electrophoresed for 3-5hrs at 65W. Gels were transferred to 3MM 
Whatman paper, vacuum dried and visualised by autoradiography. 
Polyacrylamide gels of 4-6% were used for sequencing and 
identifying primer extension products. Both mini gel apparatus (10 
x 8 x . 15cm) and large apparatus (20 x 20 x .15cm) were used. 
Samples were loaded into preformed wells after heat denaturation 
with loading dye. Electrophoresis was performed at 100V for 1-
8hrs. Gels were transferred to 3MM and dried before exposure to 
autoradiograph film. 
2.2. 7 Radiolabelled nucleic acids 
(i) Radiolabelled cDNA probes 
DNA to be labelled was excised from agarose after electrophoresis 
and extracted by GFX spin column into a final volume of 50µ1 of 
distilled water. 25ng of DNA was denatured by heating to 100°C for 
5 min in a water bath before addition to the Rediprime random 
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pnmmg mix (Amersham). 2.5µ1 of [a-32P]-dCTP was added and 
mixed. The reaction was initiated on transferral to a 37°C 
incubator and allowed to proceed for at least 20min. Labelling was 
terminated by the addition of 5µ1 of 0.2M EDTA. Radioactive 
incorporation was measured for each probe by washing a sample in 
trichloroacetic acid to remove unincorporated nucleotides. Prior to 
hybridisation, the probe was denatured with 0.2 volumes of 4M 
NaOH for 5min. 
(ii) T4 polynucleotide kinase labelling 
Oligonucleotides to be end-labelled were diluted to a final 
concentration of lpmol/µl. 5µ1 of the oligonucleotide was added to 
a 1.5ml eppendorf tube containing 9.5µ1 of distilled water. 5µ1 of 
5X exchange buffer was added along with 5µ1 of [y-32P]d.ATP 
(lOµCi/µl, 3000 Ci/mmol). The reaction was initiated with the 
addition of 5U of T4 polynucleotide kinase and incubated at 37°C 
for lOmin. The reaction was terminated with the addition of EDTA 
to 5mM. Incorporation was determined by TCA precipitation and 
scintillation counting. Unincorporated nucleotides were removed 
using a spin column (ProbeQuant column, Amersham). 
(iii) Terminal transferase labelling of oligonucleotides 
15pmol of oligonucleotide was end-labelled by terminal transferase 
(Tdt). The reaction took place in an eppendorf tube containing 
distilled water, 4µ1 of 5X Tdt buffer, 3µ1 of 5mM CoCb, 4µ1 of 
[a32P]dCTP, the oligonucleotide and 1 µl of Tdt. The labelling rection 
was allowed to proceed for a minimum of 20min at 37°C. 
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(iv) Removal of unincorporated nucleotides 
Purification of DNA labelling reactions was performed using 
ProbeQuant G-50 micro columns (Amersham). The sample to be 
purified was applied to a column of resuspended resin without 
disturbing the resin bed. This was centrifuged at 735xg for 2min 
and the purified sample collected in the bottom of the support 
tube. 
2.2.8 Enzyme Reactions 
(i) Restriction enzyme digestions 
Plasmid DNA was digested with the appropriate restriction enzyme 
at an excess concentration of 2-3U per µg. Digests included IX 
buffer as specified by Roche Diagnostics. Digests were performed in 
a volume of distilled water such that the enzyme concentration was 
less than IO%. All digests were carried out in a water bath at 37°C 
for at least 2hrs. Reactions were terminated by agarose gel 
electrophoresis or GFX purification. 
(ii) Dephosphorylation 
Plasmid DNA was digested with the appropriate restriction enzyme 
as above, and purified by GFX spin column. The eluted DNA was 
mixed with IX dephosphorylation buffer and I U of calf alkaline 
phosphatase (Roche). The reaction was incubated at 30°C for 
30min followed by incubation at 50°C for 30min. 
Dephosphorylation was stopped by incubation on ice and 
purification by GFX column. 
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(iii) Kienow Fragment end filling 
The Kienow fragment of DNA polymerase I was used for the blunt 
ending of restriction fragments used in blunt ended cloning, as 
described in section 2.2.9(i). DNA was digested with the 
appropriate restriction enzyme and the fragment required was 
purified from agarose gel, or straight from the digest by GFX spin 
column. The eluate was approximately 50µ1, to which 6µ1 of 1 OX L 
buffer (Roche) was added. 0.6µ1 of lOmM dNTPs were added and 
2µ1 of klenow enzyme. The reaction was allowed to proceed at 37°C 
for 30mins. Reaction products were then purified again by GFX 
spin column. 
(iv) Taq polymerase tailing reaction 
The PCR product to be tailed was purified by GFX spin column. Up 
to 7µ1 of PCR product ( 100-500ng) was added to an eppendorf 
containing 0.2mM dATP and 1µ1 of lOX Taq reaction buffer. 5U of 
Taq DNA polymerase (Roche) was added and the total volume of the 
reaction made up to 10µ1 with distilled water. The reaction 
proceeded at 70°C for 15-30min. 1-2µ1 of this reaction was used in 
a ligation reaction. 
2.2. 9 Ligation reactions 
(i) Cloning blunt ended fragments 
Both vector DNA and the fragment of DNA to be cloned, were 
digested with the appropriate restriction enzyme. If necessary, 
these were separated by agarose gel electrophoresis and the 
fragment excised. Excised DNA was purified by GFX spin column 
and blunt ended using the klenow fragment of DNA polymerase I 
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as described already. Blunt end vector DNA was then 
dephosphorylated using calf alkaline phosphotase as described, to 
reduce the chance of self-ligation. Blunt end and dephosphorylated 
products were purified again and the concentration calculated by 
UV spectrometry at OD2so/OD260. Control ligations were performed 
with vector only, containing vector DNA, SX buffer and water. Also 
a reaction including vector DNA, buffer and lU of T4 DNA ligase 
was used to test the possibility of self-ligation occurring. Ligation 
reactions were performed in the presence of SX buffer, 1 U of T4 
DNA ligase with a 3 or 6 fold molar excess of insert over vector. All 
reactions were incubated at 16°C overnight. 
(ii) Cloning using cohesive termini 
Vector DNA was digested with restriction enzyme(s) the same as or 
compatible to those used in the digestion of DNA to be cloned. If 
this was a single enzyme, then the vector DNA was 
dephosphorylated following restriction enzyme digestion. Ligation 
reactions were performed in SX buffer with 1 U of T4 DNA ligase 
(Roche) and a 3 or 6 fold molar excess of insert DNA over vector 
DNA. The ligation reactions were incubated at 16°C for a minimum 
of 4hrs. 
(iii) Cloning using a T-overhang vector 
For PCR products that did not have an existing or manufactured 
restriction enzyme site at the required position, a T-tail was 
attached for cloning. This method of cloning used the pGEM-Teasy 
vector (Promega). PCR performed with Taq (Invitrogen) or Elongase 
(including Taq and Pyrococcus species GB-D thermostable DNA 
polymerises, Roche) generates an addititional A nucleotide on the 
ends of the product. Where a proof reading enzyme was used the 
A-tail was added in a separate reaction. The ligation reaction 
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incorporated 50-300ng of PCR product, rapid ligation buffer, 50ng 
of pGEM-Teasy vector and 3U of T4 DNA ligase. The total reaction 
was performed in a 10µ1 volume made up with distilled water. 
Incubation of the reaction was either at room temperature for 1hr 
or overnight at 4°C for low efficiency reactions. 
2.2.10 DNA Sequencing 
Manual Sequencing was performed according to the Sanger-
dideoxy mediated chain termination method (as described by 
Sanger et al. ( 1977)). 
DNA was sequenced from the T7 pnmer usmg Sequenase (USB 
Chemicals). Denaturation of 5µg of double-standed DNA was 
performed in 10µ1 of 0.2M NaOH for lOmin. The DNA was then 
precipitated in ethanol and 0.3M NaOAc, washed in 70% ethanol 
and resuspended in 7µ1 of distilled water for annealing. 0.5pmol of 
T7 primer was added to the DNA along with Sequenase reaction 
buffer (20 mM Tris-Cl pH 7.5, 50mM MgCb, 250mM NaCl). This 
mix was heated to 65°C in a heating block and allowed to cool to 
30°C. Reaction mixes containing 3µM dATP, dGTP, dTTP, lµl of 
O. lM DTT, 0.5µ1 [a-32P)-dCTP and 2U of Sequenase were added to 
the annealing mix and chain extension was allowed to proceed for 
5min at room temperature. Four termination mixes (15µM ddNTP, 
150µM dNTP) were prepared in eppendorf tubes and pre-warmed to 
37°C in a heating block. 3.5µ1 of the reaction mixture was added to 
each termination reaction and incubated for a further 5min at 
37°C. The reaction was stopped by the addition of an equal volume 
of STOP dye and samples were heat denatured at 65°C for 5min. 
Electrophoresis was on 4% polyacrylamide / 7M urea denaturing 
gels as described in section 2.2.6(iii). 
Automated DNA Sequencing was performed at the Waikato 
Sequencing Facility, University of Waikato. 
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2.2.11 Southern blot hybridisation 
DNA electrophoresis was as described in section 2.2.6(i), except no 
EtBr was added to the gel. After electrophoresis, gels were stained 
with a solution of water and EtBr (300ng/ml) and photographed 
under UV illumination. The gel was then washed with water for 
l 5min. Prior to transfer the gel was washed in two successive 
amounts of denaturing solution. The DNA was transferred to 
Hybond-N+ membrane (Amersham) by capillary transfer m 
denaturing solution, as described by Sambrook et al. (1989). 
Transfer was allowed to proceed for 16 hrs. The nylon membrane 
was rinsed in 2X SSC prior to crosslinking in a UV Stratalinker. 
Membranes were prehybridised in Hybaid bottles for at least 1hr at 
60°C in Church and Gilbert hybridisation buffer (7% SOS, 0.001M 
EDTA, 0.25M Na2HP04.2H20). Radiolabelled cDNA or 
oligonucleotide probe was added after denaturation with a fresh 
aliquot of hybridisation buffer. Hybridisation was performed in a 
Hybaid oven at 60°C for 16hrs. 
When hybridisation was complete, membranes were washed in 2X 
SSC / 0.5% SOS for 1 min at 55-65°C with gentle rocking. This 
was followed by a wash in lX SSC / 0.5% SOS for 15min. If 
required, a third wash in O. lX SSC/ 0.1 %SOS was performed. 
Alternately, hybridisation was performed using the high efficiency 
hybridisation system (Progenz). Prehybridisation was performed 
using the lOX washing and prehybridisation solution (HS 114) 
diluted to lX. Prehybridisation was carried out in either a rotating 
hybaid bottle or on the bench in a container at room temperature. 
The prehybridisation solution was removed after 20min and 
replaced with hybridisation buffer (HS l 14F). Double stranded 
probe was denatured before adding to the hybridisation buffer and 
membrane. Hybridisation was performed in a hybaid oven at 55-
650C for 16hrs. Washing of the membrane was performed at room 
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temperature usmg the wash and prehybridisation solution. The 
washing cycle was repeated five times, consisting of gentle shaking 
of the membrane in lX wash and prehybridisation solution for 7 -
1 Omin at room temperature. 
Membranes were sealed in a plastic bag and visualised by 
autoradiography. 
Prior to a membrane being re-probed it was stripped in boiling 
0.1 % SDS until cooled. This was repeated and then the membrane 
was washed in 2X SSC. Autoradiography confirmed the stripping 
process. 
2.2.12 Northern blot hybridisation 
RNA electrophoresis was as described in section 2.2.6 (ii). After 
electrophoresis, gels were washed for 10-20 min in lOX SSC to 
remove formaldehyde and the RNA transferred to Hybond-N 
membrane (Amersham) by capillary transfer in lOX SSC, as 
described by Sambrook et al. ( 1989). Transfer was allowed to 
proceed for 16hrs. The nylon membrane was rinsed in 2X SSC 
prior to crosslinking in the UV Stratalinker. Transfer to the nylon 
membrane could be visualised under UV due to the addition of 
EtBr to the RNA samples. 
Membranes were prehybridised in Hybaid bottles for at least 1hr at 
60°C in Church and Gilbert hybridisation buffer (7% SDS, 0.001M 
EDTA, 0.25M Na2HP04.2H20). Radiolabelled cDNA probe was 
added after denaturation with a fresh aliquot of hybridisation 
buffer. Hybridisation was performed in a Hybaid oven at 60°C for 
16hrs. 
Washing of the membranes was performed in the same manner as 
for Southern blot hybridisation. Membranes were sealed in a 
plastic bag and visualised by autoradiography. 
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2.2.13 5' RACE 
Initial analysis by 5' RACE was performed on early lactating (1 day 
or 4 day) mouse mammary gland RNA and also a sample of 
polyadenylated 4 day lactating RNA. Oligonucleotides included 
gene specific primer 1 (GSPl) for first strand cDNA synthesis and a 
nested gene specific primer 2 (GSP2) annealing 5' to GSPl, which 
was employed in the final PCR amplification reaction. For 
oligonucleotide sequences, refer to section 2.1.5. The position of 
GSPl was approximately 350nt 3' of the putative transcription 
start site so that a reasonably short product would be generated 
but still be long enough to extract by column. 2.5pmol of GSPl and 
lµg of RNA were denatured at 70°C for lOmin. First strand cDNA 
synthesis was completed with Superscript II RNase H-RT (200U) 
(Invitrogen) at 42°C for 30min in the presence of lOx Platinum PCR 
buffer (Invitrogen), (MgCb (2.5mM), dNTPS (0.4mM), DTT (lOmM)). 
The reaction was terminated by incubation at 70°C for 15min and 
RNA was removed by the addition of RNase Tl (3000U) (Invitrogen) 
and RNase H (3U)(Roche) for 30min at 37°C. Purification of cDNA 
was accomplished using a GFX spin coloumn (Amersham). Eluted 
DNA was then 'C' tailed with Tdt (25U) (Roche) in lOmM Tris HCl 
pH 8.4, 25mM KCl, 15mM CoCb, 200µM dCTP. Before addition of 
enzyme the reaction was denatured at 94°C for 3min and snap 
cooled on ice. Following addition of enzyme the reaction was 
allowed to proceed at 37°C for lOmin and stopped by incubation at 
65°C for lOmin. The tailed cDNA was then finally amplified in a 
PCR reaction using oligonucleotides GSP2 at 400nM and abridged 
anchor primer (AAP) at 400nM. PCR was performed in a Perkin 
Elmer thermal cycler in the presence of l.5mM MgCb, 200µM 
dNTPs and 1 U of Taq DNA polymerase (Roche). Initial denaturation 
was at 94°C for 2min followed by 35 cycles of denaturation (94°C, 
30sec), annealing (50°C, 30sec) and extension (72°C, 60sec). A final 
elongation step was performed at 72°C for 5mins. PCR products 
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were analysed on a 1 % agarose gel, visualised by EtBr and UV 
illumination. 
2.2.14 Primer extension 
Primer extension reactions were performed with 1-1 OOµg of RNA 
from 16 day lactating or 18 day pregnant mice. lOpmol of 
oligonucleotide (PE35) homologous to position +46 to +81, was 
labelled by T4 polynucleotide kinase (Invitrogen) as described 
already. The labelled oligonucleotide was run on an 8% 
polyacylamide gel and the band excised and eluted in 1 OmM Tris-
Cl pH8.0. lOOµg of RNA was annealed with 7.5 x 104cpm PE35 in 
hybridisation buffer (1.5M KCl, O. lM Tris-Cl, lOmM EDTA) at 45°C 
for 2hrs after a 5min denaturation at 75°C. All reaction 
components (30mM Tris-Cl pH 8.3, 15mM MgCh, 8.2mM OTT, 
0.22mg Actinomycin D, 0.22mM dNTPs) were preincubated for 
lmin at 42°C before the addition of 25U of Superscript II RNase H 
(lnvitrogen). Extension was carried out at 42°C for 1hr at which 
time 2µg of RNase A was added to degrade the template. The 
extension product was extracted in phenol/ chloroform twice, 
chloroform once and precipitated in ethanol and salt. The sample 
was loaded onto a 4% polyacrylamide gel after the addition of 2X 
STOP dye and heat denaturation at 65°C for 5min. The products 
were visualised after 1 day by autoradiography and the size of the 
products was determined by comparison with sequence reactions 
from a subclone (5' Sacl 4.9) using the same primer (PE35), run 
alongside the extension reaction. 
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2.2.15 PCR amplification 
(i) PCR using Taq DNA polymerase for short products (<5kb) 
A master mix was prepared in a sterile eppendorf tube on ice, 
using filter pipette tips and freshly autoclaved distilled water. A 
standard reaction consisted of lX PCR amplification buffer plus 
MgCh, 20mM of each dNTP, lOOpmol of each forward and reverse 
primer, template DNA (O. l-2µg) and water to a final volume of 
100µ1. The reaction was transferred to individual thin-walled PCR 
tubes and inserted into a Perkin-Elmer thermocycler for 
amplification. The first denaturation step was performed at 94°C 
for 5min. Whilst hot, 0.5µ1 of Taq DNA polymerase (SU /µI) was 
added. Typically, the amplification cycle consisted of 94°C, 30sec 
denaturation; 50°C, 30sec annealing; 72°C, lmin extension for 30-
35 cycles, with a final extension of 5min at 72°C. Products were 
visualised on an agarose gel under UV light. 
(ii) 'Elongase' PCR for long products (Invitrogen) 
PCR reactions were prepared on ice usmg distilled water, filter 
pipette tips and fresh autoclaved eppendorf tubes. A master mix 
was prepared containing 200µM of each dNTP, 200nM of each 
forward and reverse primers, approximately lOOng of genomic DNA 
template or 25pg of other DNA template. This was made to a final 
volume of 20µ1 per reaction, with water and aliquoted into 
individual PCR tubes. A second master mix was prepared, 
containing a total of 10µ1 of A and B buffer depending on required 
MgCb concentration, 1 µI of elongase enzyme mix and water to 
30µ1. For example, l.5mM MgCb requires 5µ1 of each A and B 
buffers. This was aliquoted into the tubes containing master mix 
one, mixed and centrifuged briefly to collect contents at the bottom 
of the tube. Amplification was performed in a Perkin-Elmer 
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thermocycler, beginning with denaturation at 94°C for 30sec, then 
35 cycles of denaturation (94°C, 30sec), annealing (50-60°C, 30sec) 
and extension (68°C, 60sec per kb of target). 
(iii) 'Expand High Fidelity' PCR for long products (Roche) 
The Expand system utilises Taq DNA polymerase and Pwo DNA 
polymerase. PCR set up was performed on ice, using sterile 
equipment. The first master mix consisted of 200µM of each dNTP, 
300nM of each primer, O. l-0.75µg of template DNA and water to 
make a final volume of 25µ1. The second master mix was made up 
of lOX Expand buffer (including MgCh) and 0.75µ1 of enzyme mix. 
Water was added to master mix two to a final volume of 25µ1. 25µ1 
of each mix was pipeted together into PCR tubes. The PCR was 
performed in a Perkin-Elmer thermocycler and followed the cycle 
given above in (ii). A final prolonged extension incubation was given 
following the 35 cycles of 7min at 72°C. 
2.2.16 Cell culture 
(i) Storage and retrieval of cells 
For storage of cells, cells were harvested as described below, but 
resuspended in freezing mix following centrifugation. Freezing mix 
contains 10% DMSO, 25% FCS and 65% lX media. The 
resuspended cells were aliquoted in 1ml amounts in 1.5ml 
cryovials and frozen at -80°C in an isopropanol container. They 
were transferred after 24 hrs to liquid nitrogen for long-term 
storage. 
Cells were retrieved from liquid nitrogen by incubating the cryovial 
at 37°C until defrosted. The volume was then doubled with the 
addition of FCS, mixed and incubated at 37°C for lOmin. The cells 
were transferred to a 10cm dish and the volume increased to 10ml 
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usmg media supplemented with growth factors and allowed to 
incubate overnight at 37°C. They were then lifted from the plate 
and split to continue growing. 
(ii) Dividing and counting cells 
Once cells reach 80-100% confluence, they were divided to allow 
them to continue growing. Media was removed from cells and they 
were washed twice with 10ml of PBS. HCl 1 cells were lifted with 
the addition of 2ml trypsin/EDTA and incubated at 37°C for 5min. 
CommalD cells were lifted using 0.5ml of dispase diluted in 1.5ml 
of Solution A and incubated at 37°C for 5min. The CommalD cells 
were scraped off the plate using a cell scraper. Cells were 
transferred to a 10ml falcon tube and centrifuged at 500xg for 
5min. The supernatant was removed and cells resuspended in 2-
5ml of fresh media. An aliquot of cells (30µ1) was diluted in 30µ1 of 
Trypan blue solution and pipetted onto a counting chamber. Cells 
were counted under a microscope and calculated per ml of media 
resuspended in. 
(iii) Transfection 
Cells to be transfected were plated to a density of 0.75x105 
(cells/well) for HCl 1 in DMEM-F12 supplemented with growth 
factors, and 5xl05 for CommalD cells also in supplemented 
DMEM-Fl2. The numbers given are for a single well of a 6 well 
plate and the cells were left to re-attach overnight. 
(a) Lipofectamine 2000 (Invitrogen) 
Transfection was performed with 1 µg of construct DNA and 0.2µg 
of pCH 110 control plasmid. The DNA was mixed and added to 
Lipofectamine 2000 (LF2000) (3µ1) previously diluted in 50µ1 of 
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DMEM-F12 media. This was allowed to complex at room 
temperature for 20min. The DNA-LF2000 complex was then added 
to each well and gently mixed. Cells were left for 48hrs at 37°C and 
5% CO2 without changing the media. 
(b) Fugene6 (Roche) 
Optimisation of DNA amounts for transfection by Fugene6 reagent 
resulted in the use of lµg DNA construct with 0.2µg PCHl 10 
plasmid. These were mixed and added to a diluted volume of 
Fugene6 (3µ1) in 97µ1 of serum free DMEM-F12 and allowed to 
complex at room temperature for 15min. The mixture was added 
drop-wise to the well of cells, mixed and incubated at 37°C with 5% 
CO2 for 48hrs. 
(c) Addition of Hormones 
Cells to be tested with the addition of several hormones or growth 
factors were transfected in the same way as given above for 
Fugene6. Twelve hrs after transfection, the hormone or factor was 
added and the cells were allowed to continue growing for a further 
48 hrs. The hormones added were Progesterone (10-7M), and 13-
Estradiol ( 1 O-7M). 
(d) Serum dilution series 
Cells were transfected as already described with 1 µg molar ratio of 
each construct, and pCH 110. Transfected cells were incubated 
overnight in media containing 8% FCS. The media was removed 
and replaced with media containing either 0.1,1,5,10 or 20% FCS. 
The cells were then allowed to replicate for 48hrs before harvest 
and assay. Each construct was transfected in duplicate for each 
serum dilution. 
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(e) Stable transfection 
HCl 1 cells were grown to confluence in a 10cm plate, lifted and 
counted. Cells were plated for transfection at 0.75x105 for HCl 1. 
Two wells of a 6-well plate were prepared for each construct to be 
transfected and the cells left overnight to re-attach. The cells were 
given fresh media and transfected by the LF2000 procedure as 
described, with the exception that 1 µg of linearised construct DNA 
was transfected with 1 OOng of a puromycin cassette plasmid 
instead of pCH 110. Cells were grown overnight at 37°C and the 
following day they were lifted from the 6 well plate and each well 
re-plated on a 10cm plate in fresh media. 
Prior to the cells being treated with puromycin, a test experiment 
was performed using a dilution series of puromycin to determine 
the minimum amount required to kill all cells. Cells were plated 
into six wells and given a varying amount of puromycin (0.2, 
0.5,1,2,3,5 µg/ml). 2µg/ml was the amount required for all cells to 
die after 48hrs incubation. 
Cells were allowed to grow for 48hrs at 37°C before the first 
addition of puromycin for selection of positive cells. Puromycin was 
added to a final concentration of 2µg/ml into normal media. Cells 
were incubated at 37°C with sufficient changes of media and 
puromycin until they reached 80-90% confluence. Cells were then 
trypsinized (HCl 1) from plates and several aliquots were frozen, 
while others were allowed to grow on for harvest and assay. 
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2.2.1 7 Cell culture assays 
Cell culture assays were performed on the extract obtained from 
transfected cells after 48 hrs growth. Media was removed from cells 
and the cells were washed 3 times in ice-cold PBS, which was 
removed between washes. After the last wash was removed cells 
were lysed in 1ml of lX lysis buffer (either ELISA kit lysis buffer, or 
thin layer chromatography (TLC) CAT reporter lysis buff er). The 
cells were allowed to incubate at room temperature in the buffer for 
15min (TLC) or 30min (ELISA). For cells harvested in the TLC 
buffer, they were scraped from the plate and the cells and lysis 
buffer pipetted into a 1.5ml eppendorf tube. Cells harvested in 
ELISA buffer were not scraped but the extract pipetted from the 
plate into an eppendorf tube. All extracts were immediately put on 
ice for 1 Omin and then vortexed and centrifuged for 3min at 
1 OOOOxg. Extract was kept on ice for assays to be run immediately, 
or stored at 80°C. 
(i) BCA protein assay kit (Pierce) 
In a microwell plate (96 wells), 25µ1 of each standard Bovine Serum 
Albumin (BSA) was pipetted into the first row. The standard BSA 
was diluted from 2000µg/ml stock to 0,20,50, 100,200,500, 1000 
and 2000µg/ ml. 25µ1 of each unknown sample was added to the 
next row(s) of wells. The working reagent was freshly prepared by 
mixing 50 parts of BCA reagent A with 1 part of BCA reagent 8. 
200µ1 of this was pipetted into each well and mixed. The covered 
plate was incubated at 37°C for 30min and absorbance read at 
0Dsgsnm on an ELISA plate reader. 
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(ii) ~-Galactosidase ONPG assay 
In a microwell plate, 150µ1 of solution Z, 30µ1 of ONPG (4mg/ml) 
and 40µ1 of unknown sample were mixed. For standard ~-
. galactosidase (~-Gal), a dilution of stock ~-Gal (lOOOU /ml) was 
prepared between 0-2U/ml with 0.25M Tris-Cl pH7.8. The plate 
was covered and mixed, and incubated at 37°C for 30min. The 
absorbance was read at 405nm on an ELISA plate reader. 
(iii) ELISA CAT assay (Roche) 
CAT enzyme standards were prepared by diluting CAT enzyme 
stock solution in sample buffer at concentrations of 0-lng/ml. 
200µ1 of each standard was pipetted into a well on the microtitre 
plate supplied with the kit. 200µ1 of each sample was also pipetted 
into wells on the plate, covered and incubated at 37°C for 2 hrs. 
The solution was removed and the wells washed 5 times with 250µ1 
of washing buffer for 30sec each. Anti-CAT-DIG working dilution 
(0.2µg/ml) was prepared and 200µ1 added to each well. The plate 
was covered and incubated at 37°C for 1 hr. This solution was 
removed and the plate washed 5 times in washing buffer. 200µ1 of 
anti-DIG-POD working dilution (150mU/ml) was added to each 
well and incubated again at 37°C for 1 hr. Once the solution was 
removed, the wells were washed 5 times in washing buffer. POD 
substrate was mixed with substrate enhancer (lmg/ml) and mixed 
at room temperature for 30mins before adding 200µ1 of this to each 
well. The plate was incubated at room temperature for 10-40min 
until colour had developed sufficiently to be read at OD4osnm. 
(iv) CAT enzyme assay by thin layer chromatography (Promega) 
Cell lysate to be tested was heated for lOmin at 65°C. 100µ1 of this 
was pipetted into a clean 1.5ml eppendorf tube and 5µ1 of n-
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butyryl CoA (5mg/ml) and 17µ1 water added. Lastly, 3µ1 of 14C-
chloramphenicol (0.05Ci/mmol) was added, the contents mixed 
and incubated at 37°C for 5 hrs. The reaction was terminated with 
the addition of 500µ1 of ethyl acetate. The samples were vortexed 
for lmin and centrifuged for 3min at lOOOOxg. The upper organic 
phase was transferred to a new tube and the samples speedvac 
dried until no liquid remained. The sample was resuspended in 
20µ1 of ethyl acetate and 10µ1 of each was spotted onto a silica 
plate. The chromatograph was run in a pre-equilibrated tank 
containing chloroform/methanol (97:3) until the solvent was three 
quarters up the plate. It was then dried at room temperature, 
wrapped in plastic wrap and exposed to autoradiographic film for 
1-5 days. 
The auotradiograph of the TLC CAT result was aligned with the 
original TLC plate and the bands were excised and scintillation 
counted to quantify the amount of CAT. Duplicates of each 
construct were averaged and then standardised against the 
negative construct (0). 
(v) DNase I Hypersensitive assay 
Cells to be harvested for DNase assay were grown to confluence in 
a 15cm plate in the appropriate media. HC 11 cells were lifted from 
the plate by treatment with trypsin and Comma1D by dispase 
treatment. Cells were pipetted immediately into 50ml falcon tubes 
and placed on ice. They were centrifuged at 500xg for lOmin at 4°C 
and washed twice in cold PBS. The pellet was resuspended in 5 
volumes of RSB buffer including NP-40. This was incubated on ice 
for lOmin and centrifuged at 700xg for lOmin. The pellet was 
washed twice in RSB buffer (without NP-40) to obtain an OD260 of 
0.4 for a 1 / 100 dilution. 100µ1 aliquots of this suspension were 
then incubated with DNasel (0-50µg/ml, Roche) for 10mins at 
37°C. The reactions were stopped with the addition of DNase STOP 
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buffer. These were left to incubate at 37°C overnight on a rotator. 
The DNA was then extracted twice with phenol/ chloroform, once 
with chloroform and then treated with RNase A (0. lmg/ml) and 
RNase Tl (1500U/ml) for 2hrs at 37°C. The extraction was 
repeated and DNA precipitated in ethanol and salt. The DNasel 
products were digested with a 10 fold excess of restriction enzyme 
and analysed by Southern blotting. 
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Chapter 3. Identification and analysis of 
the murine Ese-2 5' region 
3.1 Introduction 
Promoter regions of the ets genes have not been widely studied. 
Most analysis concentrates around the open reading frame 
although in some cases the presence of several isoforms of a gene 
requires a brief study of alternative 5' exons, multiple promoters 
and start sites. The few ets gene promoter regions that have been 
studied are discussed at the end of this chapter. Some sequence 
analyses of human ESE-2 has previously been done (Oettgen et al., 
1999b), and these identified two isoforms for the gene detected in 
human kidney and prostate. Rapid Amplification of cDNA Ends 
(RACE}, performed using the 'Ready-for-RACE clontech cDNA' kit 
from lnvitrogen, showed that ESE-2a differs from ESE-2b at the 5' 
end as a result of alternative 5' exons (Oettgen et al., 1999b). Such 
alternate exons are presumably due to two different transcription 
start sites derived from a proximal and distal promoter. This is in 
contrast to the mouse sequence, which has two isoforms as a 
result of alternative polyadenylation (Langley, 1999). 
Promoter analysis usually involves the cloning and sequencing of 5' 
flanking regions so that specific regions involved in gene regulation 
can be characterised. The regulation of Ese-2 was of interest and in 
order to locate regions of importance for Ese-2 transcriptional 
regulation, the promoter has been characterised. 
This chapter deals with the initial characterisation of the proximal 
promoter region of murine Ese-2. Prior to the investigation reported 
in this thesis, genomic and cDNA murine libraries had been 
screened to isolate clones containing the full-length coding 
sequence and upstream sequence. Individual clones were inserted 
into lambda bacteriophage (Stratagene) by L'Huillier et al., 
(unpublished). The two cDNA transcripts had been sequenced from 
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this data and some initial restriction mapping had been performed 
on several of the genomic clones isolated (L 'Huillier et al., 
unpublished). However, the orientation had not been determined. 
These clones were further analysed in the current investigation and 
restriction maps were generated for those clones that contained 
some 5' sequence according to Southern blot analysis with a 5' 
probe. Fragments were isolated from the 5' regions and were 
subcloned and mapped extensively to allow smaller clones to be 
sequenced. 
The availability of the draft mouse genomic sequence shortly before 
this publication allowed a greater level of information to be mined. 
Sophisticated promoter prediction software has been utilised and 
results are reported here, together with experimental data. This 
experimental information came from sequence analyses by primer 
extension and 5' RACE methods, to identify transcription start 
sites. Potential regulatory sites were later identified by computer 
analysis of consensus transcription factor searches, and is 
discussed later in the chapter. 
3.2 Results 
3.2.1 Reference material for Chapter 3 
Several genomic clones had been previously isolated from a mouse 
129 genomic library. One of these was discovered to contain 
upstream Ese-2 gene sequence (),3.2), and was used for further 
cloning. A subclone from this (5' Sac-I 4.9) was used for promoter 
analysis. A number of oligonucleotides were produced from 
sequence generated from this clone, and were used throughout this 
chapter. Sequence information is given in Chapter 2, Materials and 
Methods. Figure 3.1 is a representation of the genomic clone A.3.2, 
and includes the subclone 5' Sac-I 4.9kb as well as oligonucleotide 
positions and transcription start sites (as determined later in the 
chapter). 
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3.2.2 Analysis of the Lambda genomic clones 
Clones from the 129 mouse genomic library that were known to 
contain some 5' sequence based on hybridisation to a 5' cDNA 
probe (Pst-1 400bp, predominantly hybridising to exon 2) included 
A2. 1, A2. 4, 11,3. 1, A3. 2. Some overlap was found between these 
clones, reducing the number that would need full mapping to 
identify a suitable 5' region. Clones A3. l and 11,3.2 have significant 
overlap, and as a result only one was mapped (11,3.1). The alignment 
of the lambda clones is depicted in Figure 3.2. 
In order to identify the region of the immediate 5'UTR, restriction 
maps were generated to allow the alignment of probed regions. The 
initial mapping was done using a series of restriction enzymes with 
single and double digests. Preliminary digestion was performed 
with the enzymes BamHI, Xbal, Hindlll, Sad, BglII and XhoI, as 
seen in Figure 3.3(A). Combinations of two of these enzymes gave 
information for the ordering of fragments. Where one enzyme gave 
the same size fragment as in a double digest, it was assumed that 
the fragment was un-digested by the second enzyme. An initial 
alignment of the fragments was generated by probing with a single 
oligonucleotide (1.11(2) for example, as seen in Figure 3.3(B)), so 
that bands containing a common sequence could be identified in 
each digest. Where these enzymes did not give enough information, 
further digests were performed using enzymes such as Asp7 l 8, 
Clal, Stul, EcoRI, Pstl, Hindll, and Dral. 
The overall orientation of each clone was determined by performing 
a Southern analysis using oligonucleotide probes. Each gel of 
digested DNA was transferred by the Southern technique onto 
Hybond N+ nylon membrane (Amersham, as described in Chapter 
2) and later hybridised in Church and Gilbert solution in the 
presence of a labelled oligonucleotide [y32P]-dATP (Amersham Life 
Sciences). Oligonucleotides used for orientating the clones were 
based on the cDNA sequence, including 5'seq, 1.1 l(ATG), 1.11(1), 
1.11 (2) in 5' to 3' order respectively so that use of a 5' 
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Sall SacI SacI i Sa1I 
Exon 1 Exon 2 Long arm 
Short arm i 
Scale : --- 1kb 1.11(2) 
5' Sac! 4.9kb 
SacI H H X H B Exon 1 H H SacI 
s' I I I I I 3, 
Scale: 1kb 
Initiation sites +l 




Probe binding sites, 




1. 11 ( 1) S'Seq. PE 35 
1.11 (ATG) 
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Figure 3.1 Genomic clone 1..3.2 and subclone 5' Sacl 4.9kb. The 
uppermost line represents the 16kb 1..3.2 genomic clone containing 
exon 1 and 2, intron 1 and 5' upstream sequence. This clone 
contains the sequence for the 5' oligonucleotides shown for 5' Sad 
4.9kb, as well as the 1.11(2) oligonucleotide (in exon 2). The two 
Sad sites are marked. This fragment was subcloned and is 
depicted by the second horizontal line. Restriction sites B (Barn.HI) 
X (Xbal) and H (Hindlll) are shown above the line, which contain 
the oligonucleotide sequences for 5'Seq., 1.1 l(ATG), 1.11(1) and PE 
35. The exon 1 sequence is shown at the bottom of the figure. The 
first intron boundary is marked, along with the initiation sites 
determined by primer extension. The major transcription site is 
labelled + 1, and minor sites are 2, 3, 4 and 5. Oligonucleotide 
locations are given below the sequence. 
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(A) 
5' Sac! Sac! Sad 3' 
I I A.3.2, 16kb 
I I A.3.1. 14kb 
Exon 1 Exon 2 
- 5' probe 
(B) 
EcoRI EcoRI 
A.2. 1. 19kb 
- 5' probe 
A.2.4. 16kb 
Scale: - 1kb 
Figure 3.2 Lambda genomic clones containing overlapping 
sequence (A) )..3.1 and )..3.2 contain approximately 10kb of 
overlapping sequence, )..3.2 extends further 5'. Neither contain exon 
3. The 5' probe (Pstl 400bp) from bovine cDNA predominantly 
hybridised to exon 2, and also partially to exon 1. (B) )..2.1 and )..2.4 
genomic clones contain 19 and 16kb of sequence respectively. )..2.4 
is completely duplicated by )..2.1. The orientation of these clones 
was not determined. However absence of overlap with )..3.2 
restriction sites suggests they extend further 3', the 5' probe 
potentially hybridises to exon 3 which is not present in )..3.1/)..3.2. 
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oligonucleotide compared to 1.11 (2) meant the overall orientation 
of the clone could be determined. 
3.2.3 Subcloning and sequencing of the 5' UTR 
The clone 1..3.2 contained approximately 9kb of 5' DNA sequence 
plus approximately 6kb of the gene including exons 1 and 2 and 
intron 1 (depicted in Figure 3.1). The exact position of the first 
exon was unknown, so a fragment spanning the approximate area 
was subcloned for further analysis. This encompassed 4.9kb from 
the Sad sites and was cloned into pBSIIKS (Stratagene). The 
resulting clone (5' Sacl 4.9kb) was confirmed to be accurate by 
digestion with enzymes digesting at known sites (Hindlll, BamHI, 
Xbal). Further, a Southern blot of these digests was hybridised in 
successive rounds (stripped between hybridisation) by 
oligonucleotides 5'seq and 1.1 l(ATG) which bound at the BamHI-
Hindlll 1.3kb fragment and 1.11(2), which did not hybridise. This 
suggests the ATG translation start codon is indeed present in this 
subclone, along with an intron that separates the ATG containing 
exon from the sequence encoding the 1.11 (2) oligonucleotide. This 
can be seen from the probe binding sites shown in Figure 3.1. 
The clone 5' Sacl 4.9 was then further subcloned into fragments for 
sequencing, again into the vector pBSIIKS (Stratagene). Fragments 
were required to be less than 1.5kb in length to allow complete 
sequence verification from both ends, with some overlap. The 
subclones of 5' Sacl 4.9 are indicated in Figure 3.4, and the 
complete sequence is given in Appendix 1. 
Either the T3/T7 or the forward/reverse combination of primers 
was used for sequencing from each end of each clone, by 
automated sequencing either at the Waikato or Massey University 
DNA sequencing facilities. The location of the first exon-intron 
boundary was noted by comparison with the cDNA sequence, 
shown in Figure 3. 1. This indicated that the ATG codon would 
indeed be in exon 2. 





(A) Fractionation of DNA restriction enzyme digestion products by 
agarose gel electrophoresis 
M B H X S Bg Xh 8/H Xh/H Xh/X S/H SIX Bg/B Bg/X 
(B) Autoradiograph of a Southern blot, hybridised with the 1.11(2) 
oligonucleotide 
M B H X S Bg Xh B/H Xh/H Xh/X S/H SIX Bg/B Bg/X 
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Figure 3.3 Preliminary mapping of the 1..3.2 genomic clone (A) 
An agarose gel photographed under UV light. The gel shows 1..3.2 
DNA digested with restriction enzymes as indicated above the 
photo. Abbreviations are as follows: M- 1kb Marker, B- BamHI, H-
Hindlll, X- XbaI, S- Sad, Bg- BglJ.I, Xh- Xhol. When two enzymes 
were used, both abbreviations are given for that lane. (B) Southern 
blot analysis of the agarose gel from part (A), probed with the 
1.11 (2) oligonucleotide to allow the alignment of restriction 
fragments. Marker sizes are indicated to the left of the marker lane, 
in kb. 





H E H H E B E H H 
I I I 
( )( ) 
0.65kb 0.76kb 
( ) <··· 
1.22kb 1.34kb 0.9kb 0.8kb 
S'seq 
Scale: 1kb 
Figure 3.4 Restriction map depicting the clone 5' Sacl 4.9 
Restriction sites are as follows: S - Sad, H - Hindlll, E - EcoRI, B -
BamHI. Subclones for sequencing are indicated by the lines ending 
with arrows and their approximate size is shown below. The 
dashed line represents sequence generated from a vector priming 
site (T7). The location of the 5'seq oligonucleotide hybridisation is 
shown by a bold line below the subclones. 





3.2.4 Identification of multiple transcription start 
sites 
The experimental identification of a transcription start site or the 5' 
termini of mRNA can be achieved by several methods. These 
include primer extension, ribonuclease protection assay and 5' 
RACE. Each has limitations, so to overcome these and achieve a 
reliable result two complementary methods were used as 
verification. Several software packages are available for the 
prediction of transcription start sites and promoters. A brief study 
using these programs was conducted and is presented in Chapter 
4. 
The location of transcription start sites for the munne Ese-2 
promoter was first investigated using primer extension. 
Primer extension is a widely used method for the determination of 
initiation sites. Reverse transcription 1s initiated from a 
radiolabelled primer, producing cDNA products, the size of which is 
measured by rate of migration through a sequencing 
polyacrylamide gel. The nucleotide lengths of the cDNA products 
are estimated so that the initiation site of the RNA can be identified 
on the genomic sequence. In cases of multiple transcription start 
sites, the yield of each product is proportional to the strength of 
initiation from that site. 
Initial primer extension experiments using mouse pregnant 
mammary gland total RNA as a template and PE 35 as the primer 
did not show any products (data not shown). The concentration of 
the RNA was later increased 10 fold to 1 OOµg, which was found to 
give five products, which could possibly represent five different 
initiation sites. A total of six separate experiments confirmed the 
presence of these same product sizes. Three different preparations 
of RNA were used in these experiments. One of these 
autoradiographs is shown in Figure 3.5. Clearly the major 
transcription start site is the distinct G nucleotide (labelled 1 in 
Figure 3.5), where as any distinction between the other 
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transcription start sites is less clear. The position of this product at 
nucleotide G is therefore labelled as the major transcription start 
site, and is given the position number+ 1 in all sequence references 
here-in. Four less abundant products represent mmor 
transcription start sites, and are at positions -2, -4, -8 and -41. 
Primer extension does not confirm the sequence of the product, 
only the length. 5' RACE is useful because the actual sequence is 
obtained. This ensures that the correct gene is being analysed and 
also that there are no further 5' exons. 
The first step in 5' RACE involves the use of a gene specific primer 
that is homologous to sequences downstream of the predicted 
initiation site (Frohman, 1993). First strand cDNA synthesis is 
performed from this primer. The cDNA then has a homopolymeric 
tail added to the 3' end. The modified cDNA is then amplified by 
PCR using a nested gene specific primer and a novel deoxyinosine-
con taining anchor primer that anneals to the homopolymeric tail. 
The products of the PCR reaction can then be cloned and 
sequenced. Several control reactions were performed due to an 
initially high background, possibly resulting from non-specific 
binding of the anchor primer. Single oligonucleotide primer 
reactions were also run to ensure that neither primer was binding 
non-specifically (seen in Figure 3.6(A)). 
This procedure was performed on three different RNA samples from 
mouse mammary gland. Thirty-eight clones were picked and 
sequenced manually to determine their length. The majority of 
clones were clustered about 93bp upstream of the ATG as is shown 
in Figure 3.6. The Figure shows an example of the sequenced 
clones, where the stretch of 'G' nucleotides is the anchor primer, 
and the length of the clone is taken from the nucleotide prior to the 
first G. 
Of the clones sequenced, eighteen were from a one day lactating 
mouse mammary gland. Eleven ended within seven nucleotides of 
the major site, and seven others near the second cluster of sites 
further 5'. Fourteen clones derived from the polyadenylated RNA 
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sample (mouse mammary gland RNA from a day 17 pregnant 
animal) were sequenced, revealing an equal split in clones 
terminating at both sites. 
5' RACE results show a scattered pattern of lengths of mRNA 
transcripts. This suggests a secondary structure problem that is 
not seen in the primer extension. RACE has confirmed the 
sequence of the 5' untranslated mRNA, and the location of the sites 
from RACE are all in near proximity to those found by primer 
extension. 
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CC A A AC G GA CC T GT CT GT AG GT GT C -27 
ACT TA T A T C AC A C G G CT AC AG GT G C -12 
4 3 2 1 
i i i i 
C T T T A T T T C TA C G G T C C G C T G G T G C +13 
T G G G A G C G C G C T T G C C T T C T C T T G C +38 
C T T G A A A G C C T T C T G T C T G G A C C T A +63 
G C C A C C A C T T G T C T T C A C G G T G A T G 
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Figure 3.5 Primer Extension results (A) Two pnmer extension 
reactions in lanes 1 ( 1 Oug RNA) and 2 ( 1 OOug RNA) run alongside a 
sequencing reaction from the same primer (PE 35) on genomic 
DNA. Arrows indicate the primer extension products, labelled 1 to 
5. (B) Sequence of Ese-2 cDNA (includes ATG, and also some 5' 
genomic sequence), arrows indicate positions of products, and 
hence start sites. 
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(A) 5' RACE product and controls on Agarose 
M RACE 3 
1kb 
0 . 4 
0.1 
(B) 5' RACE subclones 
M 1 2 3 
0.4kb-




4 5 6 7 8 
4 5 6 7 8 9 10 11 
GATC GATC GATC GATC 
Chapter 3. Analysis of murine Ese-2 5' region 
94 
(D) Sequence of 5' UTR and lengths of clones 
2 1 2 7 1 
+ + + + + C C AAA C G G A C C T G T C T G TA G G T G T C -27 
2 1 1 
+ + + 
A C T T A TA T C A C A CGGCTACAGGT G C -12 
8 1 6 5 
+ + + + 
C T T TA T T T C TA C G GT CC G CT G GT G C +13 
1 
+ 
T G G GA G C G C G C T T G C C T T C T C T T G C +38 
C T T GA A A G C C T T C T G T C T G GA C C TA +63 
G C C AC CA C T T G T C T T C A C G GT GA T G 
Figure 3.6 5' RACE experimental results (A) 5' RACE PCR 
product and control reactions fractionated on a 1 % agarose gel. 
Lane M is a 1kb marker, with actual sizes shown on the left (in kb). 
The RACE lane is the PCR reaction containing two primers, 
template cDNA that had been tailed by terminal transferase. Lanes 
3, 4, 5, 6, 7 and 8 all contain negative control reactions. (B) Cloned 
products of the 5' RACE that have been digested to release the 
approximately 400bp product. (C) Manual sequencing of the 5' 
RACE clones, with the nucleotide above the lane. Shown are six 
clones sequenced on the acrylamide gel. Arrows indicate the 
nucleotide at the 5' end of the transcript. (D) Locations of 5' clone 
ends, shown in reference to the actual cDNA sequence, with the 
ATG translation start codon at the 3' end of the sequence shown. 
The nucleotides marked in bold are the sites identified by primer 
extension and the major transcription start site is underlined. The 
numbers above the arrows refer to the number of RACE clones 
mapping to each product size. 
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3.2.5 Computer predicted analysis of potential 
regulatory regions 
Computer predicted analyses of promoter sequences have 
previously been performed on many genes to identify potential 
binding sites, based on consensus sequences, for known 
transcription factors. However, the identification of a potential 
binding site does not mean that it is functional. 
A computer analysis was performed to search for the presence of 
potential regulatory elements in the Ese-2 promoter and first 
intron sequence, using the programs TFSEARCH (Akiyama, 1995) 
and Matlnspector V2.2 (Quandt et al., 1995). 
As is often observed in promoters with multiple transcription start 
sites, there is no typical TATA box present in Ese-2 within at least 
1.5kb upstream of the major transcription start site (Crawford et 
al., 1999). Outside of this region there are consensus TATA 
sequences, but they would not be expected to operate in cis, as 
typical boxes operate at -25bp from the transcription start site 
(Wiley et al., 1992). However, a degenerated TATA box may be 
operational. At -25bp a DNA sequence, which has 5 of 6 
nucleotides conserved with the consensus sequence, is present. 
No CCAAT box was identified by the computer search in the 
immediate 5' region, though several consensus CCAAT elements do 
lie further 5' (-557, -667, -835bp). Typically, a functional CCAAT 
box would be present closer than this to the TATA-box, though 
neither CCAAT nor TATA are necessary features of a promoter. 
Analysis of the proximal 2.5kb upstream region from the start site 
revealed a multitude of potential sites. Several hundred consensus 
binding sites were identified. Many would appear to be 
inconsequential and deciding which elements are relevant is 
difficult without functional analysis. The use of promoter 
recognition programs may help determine those elements of 
importance, and is performed m Chapter 4. In this study, the 
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elements discussed are those that have been previously found in 
other mammary gland genes and ets transcription factors. These 
are shown in Figure 3.7, which shows only the first 1017bp 
upstream, as no unique sites were found further 5'. The consensus 
sites include activator protein-I and -2 (Ap-1, Ap-2) (Briggs et al., 
1986; Faisst and Meyer, 1992; Lee et al., 1991; Lee et al., 1987; 
Yamauchi et al., 1996) at more than 10 and 5 positions 
respectively, GATA elements in multiple locations (Faisst and 
Meyer, 1992; Whyatt et al., 1993;Aird et al., 1994; Kawana et al., 
1995;), three octamer 1 binding sites (Oct-1) (Sturm et al., 1988; 
Roth et al., 1991; Faisst and Meyer, 1992;) with 100% consensus 
sequence, and two Signal Transducer and Activator of 
Transcription (STAT) sites with 100% sequence homology to the 
consensus sequence. One serum response factor (SRF) consensus 
site was identified in the 5' promoter region, which is known to be 
important in combination with Ets factors. In addition, potential 
regulatory sites that occur in the proximal 5' region to the major 
start site include two GC-box elements all within 1kb of this site, 
two YYl (Yin and Yang-1) elements at -701 and -763, three Sp-1 
sites (Briggs et al., 1986) located between -100 and -900bp, and 
also two NF-KB elements with 100% identity to the consensus at 
positions -618 and -669. c/EBP (CCAAT/Enhancer binding 
protein) consensus elements are found in at least 7 locations 5' of 
+ 1. Their potential importance is related to a known influence of 
c/EBPP on cell fate determination during mammary gland 
development (Seagraves et al., 2000). Lastly, of the elements 
recognised were multiple ETS binding sites. In particular, an Elf-1 
site at -2. 5kb and multiple c-Ets-1 sites (Faisst and Meyer, 1992; 
Tymms and Kola, 1994). 
Following the analysis of the proximal and 5' promoter regions, the 
first intron was examined for consensus binding sites that may 
play enhancer roles in the transcriptional regulation of Ese-2. The 
first intron sequence contained hundreds of consensus binding site 




Ap-1 CCAAT Ap-2 Sp-I/ GC box c-Ets-1 
-867 TGGGTAGTTCTCAGTGAGACAGCTGACAGCTTGCAAGCCAATCAGGACCCCCCGCCCCCGTGTTGTTCTGGATGT 
GATA- I YYI cl EBPP Ap-1 
-792 !TGACACTGCAGCTCCACGCTCCCTTCATATCGCCATTTCTAAAACAGAGGACACTGGGAAAGGGGGAAAGCTGT 
YYI NFKB CCAAT 
-717 CACATGGCTCCTGGTATTCAAACATGGCGCCCTTTGGGTGCTTAGAGTGGAAAGGCCAGTGAAGCACTGCTCCCT 
Ap-1 Sp-I NFKB 
-642 GACTCTCTCCCTGCCCCCTGATCGGAAGGTCCCCACCAGGATCAATAGAAGGAAATATGTAGCGCCTAAGGACAG 
CCAAT Ap-1 STAT C/EBPp 
-567 GCTTCCAGGTGATTGGCTGACATTACCAAGTATGGCCTTCCCAGCAACCCAAGGACAGATTCCATTATTGCATTA 




c-Ets-1 Cl EBPp 
-342 CGGGACTTGGCCAGCCCAGGCAAAGGNTNCAATGAACAGACACCAGGCCTGAATTTCCTTCCCTCCNGCTTGCTC 
GATA-I Ap-2 c-Ets-1 
-267 AACGGAGACTGCTCCAGCCAGCACTCCACNTATCCCCCTNGGGGCAAGAATTCTCTGCTCATTTCCTGGGTCCCC 
C/EBPP Sp-I/ GC box 
-192 TCGGTGGGTGGTGGGAGCTGGGCACAAAAGCAGGAGAAAGGTAAACTTTCTGCATGTGAAAACCACCCCCCACCC 
Ap-2 Ap-1 Ap-1 
-117 CCGAGGAGCCGTGTCACACCGTATGTCACCGTCATCAAAGGGGCTGTGCATAAACCTGAAAAACCAAACGGACCT 
-42 
Ap-1 .I. GA TA-I t .1..1..1. 
GTCTGTAGG~GTCACTTATATCACACGGCTACAGGTGCCTTTATTT'tT'fc~TCCGCTGGTGCTGGGAGCGCGCT 
lntron I boundary 
+34 TGCCTTCTCTTGCCTTGAAAGCCTTCTGTCTGGACCTAGCCACCACTTGTCTTCAC GT ... 
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Figure 3. 7 Sequence of murine Ese-2 gene promoter The 
proximal sequence is shown from -101 7bp relative to the major 
transcription start site at + 1, as determined by primer extension. 
The sequence includes exon 1 (bold), a putative TATA box also in 
bold and the transcription start sites marked with open arrows. 
Potential regulatory factor binding sites are underlined with solid 
lines for sense orientation and broken lines for antisense. Factors 
are named above the sequence. 
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sequences. Those that have been identified in other specific 
mammary gland genes and ets genes are mentioned here. In 
particular there were several AP-1, GATA and C/EBP~ sites. Ets 
sites were limited to one Elf-1, one Elk-1 and four c-Ets-1. The Elf-
1 site was in the first 1kb of intron sequence, and the Elk-1 at 
approximately 2kb. Two NF-KB sites were identified, both in the 3' 
end of the intron. Only one GC- box was found with the computer 
search. The importance of these sites cannot be predicted from this 
method of analysis, but may become useful when deletion studies 
are being performed. 
Repeat sequences were detected usmg RepeatMasker (Smit and 
Green, 2000). In the 5' promoter region an alternating pyrimidine-
purine repeat (TG) was located, along with three SINE (short 
interspersed nucleotide elements) elements. One of these was a B 1 
element, typical of a rodent repetitive sequence, corresponding to 
the human Alu repeat sequence (Bois et al., 1998). In the first 
intron, several simple repeats were located (T'ITITG), (CA), 
(TGGGGG), (GA). Also, three MIR (mammalian wide interspersed 
repeats) (Smit and Riggs, 1995) and two low-complexity AT rich 
stretches and a MER58 element were found in the first intron. 
The regulatory elements discussed above are only a sample of 
those detected in the analysis and are those that are consistent 
with other ets genes regulatory sequences. Another use for this 
data is in the comparison of the mouse Ese-2 sequence with that of 
the human, recently published in the human genome project. 
Regions of homology between the species in the promoter and other 
regulatory regions give clues as to the location of important 
regulatory regions. Conserved regions between species often 
suggest a slower rate of evolution because they are more important 
than those areas evolving quickly. Alignments of mouse and 
human promoter and intron 1 sequences are performed in the 
following chapter. 
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3.3 Discussion 
This chapter describes the preliminary identification and 
characterisation of the Ese-2 promoter region. Firstly, this involved 
the localisation of a genomic clone containing a suitable sequence 
of DNA oriented 5' to the cDNA start. This was subsequently 
subcloned and sequenced so that regions involved in Ese-2 
regulation could be analysed. 
In order to identify the actual promoter region, primer extension 
analysis was performed. A total of five transcription start sites were 
identified by repeated primer extension experiments. The most 
abundant band was labelled as the major transcription start site 
and numbered as + 1. The sequence of these start sites were 
confirmed by 5' RACE. 5' RACE results showed two main clusters 
of products, each ranging in size over 8-10 nucleotides. Both 
clusters were grouped around the region of the nucleotides 
identified by primer extension as transcription start sites. 5' RACE 
resulted in a total of thirteen different product sizes. The scattering 
effect seen by this method could be due to secondary structure 
formation that prevents full reverse transcription. This is more 
likely in 5'RACE than primer extension due to the length of the 
product. Also, three products of 5' RACE were longer than the 
longest primer extension product. This was unusual and may 
imply that a more distal initiation site is present that was not 
detected by pnmer extension or possibly a distal exon. 
Alternatively, a contamination of genomic DNA could explain the 
longer products. 
Limitations of primer extension include the low assay temperature 
(37°C), which could permit RNA to form secondary structures that 
might interfere with movement of the reverse transcriptase along 
the template RNA. It is also the preferred temperature for RNase 
degradation. In order to overcome this, primers were designed in 
close proximity to the predicted site (based on early 5' RACE 
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attempts) so that extension products would be short and secondary 
structure minimised. 
The RACE technique requires the use of a PCR reaction, which 
introduces a degree of variability. Certain populations may be 
amplified at a higher rate due to length, annealing of primers, 
which results in a biased representation of the starting template. 5' 
RACE was therefore performed with different RNA samples, 
including polyadenylated RNA and different states of development 
of the mammary gland. RACE also requires a minimised secondary 
structure, as this may effect the reverse transcription by inhibiting 
the enzyme from reading along the template. This may have been 
the cause of the RACE results in this study, and was thought to be 
critical in the identification of start sites for Fli-1. Fli-1 is an ets 
gene, found to contain two major initiation sites. However eighteen 
shorter products of 5' RACE were also seen (Barbeau et al., 1996). 
The ends of these clones were non-randomly distributed over 
387bp of sequence, not corresponding to any previously published 
mouse Fli-1 cDNA 5' ends. The shorter products were located in 
two main clusters, the more 3' cluster corresponding to the 3' end 
of the first exon. Barbeau et al., explain this phenomenon of 5' 
RACE as an artifact due to a highly stable hairpin structure 
predicted to be formed by the first exon. This secondary structure 
may interfere with the reverse transcriptase step in 5' RACE 
causing smaller products that are made due to incomplete reverse 
transcriptase synthesis. 
Perhaps the best-characterised ets promoters are those of Ets-1 
and Ets-2. ETS-1 transcription initiation sites were identified by 
primer extension and S 1 nuclease protection analysis (Jorcyk et 
al., 1991). A total of fourteen different sites were located, spanning 
a region of 137bp by Sl nuclease mapping. Primer extension also 
identified multiple sites, though the 3' sites were more favoured. 
This was explained as a result of inefficient procession of the 
reverse transcriptase to upstream regions (Jorcyk et al., 1991). 
This phenomenon was also observed here with Ese-2 pnmer 
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extension. The smaller bands were slightly favoured, though it is 
not known if this is an artifact of reverse transcriptase inefficiency 
or not. 
Mavrothalassitis et al. ( 1990) determined ETS-2 transcription 
initiation sites in a similar manner. Again, multiple (8) major sites 
were found, as well as many minor sites by both S 1 nuclease and 
primer extension. To determine the effect of any secondary 
structure, an in vitro synthesised RNA template of the same region 
was included in the analysis. No extra bands were seen with this 
template, indicating no secondary structure problems 
(Mavrothalassitis et al., 1990). 
More recently a method for determining the transcription start site 
has become available, that involves detecting RNA transcripts that 
have a 5' cap. This is now the preferred method to determine the 
RNA 5' end (Suzuki et al., 2001). 
Both ETS-1 and -2 lack a typical TATA box. They are found to 
contain consensus sites for regulatory elements including SRE-
like, GC-rich, EBS and Ap-2 elements (Mavrothalassitis et al., 
1990; Jorcyk et al., 1991). In contrast to these promoters, the Elk-
1 promoter was shown to contain a single transcription start site 
and a typical TATA box. Potential binding sites for transcription 
factors included Sp-1, Ap-1, cAMP response element binding 
protein and the CCAAT binding protein, as well as binding sites for 
Egr-1 and SRF/TCF (Lehmann et al., 1999). 
Interestingly, the Ese-2 major start site lies approximately 25bp 
downstream of a degenerate TATA box element. The consensus 
sequence of the TATA box (TATAAA) is found to be altered in the 
Ese-2 sequence (TTATAT). The presence of multiple start sites 
within a promoter is a feature seen in common with TATA-less 
promoters. The functionality of the Ese-2 potential TATA box is not 
known at this point. 
A TATA-box at -25bp relative to the transcription start site is found 
in less than 50% of proximal promoters (Crawford et al., 1999). In 
such promoters it is bound by TFIID, an essential element for all 
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mRNA transcription (Roeder, 1991; Smale, 1994). In TATA-less 
promoters, other initiator sequences are important for 
transcription and TFIID component binding including Sp-1 binding 
sites or interactions of binding sites within the proximal promoter 
(Martinez et al., 1994; Smale, 1994; Emami et al., 1995; Ernst and 
Smale, 1995b; Weis and Reinberg, 1997). The proximal promoter of 
a gene contains many DNA sequences that bind transcription 
factors (TFIID and others), accurately position RNA pol II for 
transcription initiation and also direct the rate of polymerase 
initiation (Roeder, 1991; Smale, 1994; Ernst and Smale, 1995a; 
Yean and Grall, 1997). This does not take into account the effect of 
distant enhancers or chromatin structure, so overall conclusions of 
regulation within the natural context of the whole genome are 
difficult to support. 
The use of computer programs to generate information on potential 
promoters and transcription start sites is becoming more robust. 
Such programs are more sophisticated than using simple 
consensus binding sites as they incorporate information on 
distances and sequences from known promoters. The use of a 
transcription factor search engine is of some use and may help 
validate an experimental result, or suggest other locations are 
possibly not detected experimentally. 
The consensus binding site search for potential regulatory 
transcription factors has identified a complex range of possible 
target sites. This process must be treated with caution and results 
taken as an indication only that a certain element may be able to 
bind and not that it necessarily does. Analysis often results in the 
identification of hundreds of consensus sequences, which would be 
difficult and time consuming to confirm. Though the threshold for 
mismatches can be altered in such searches, factors are known to 
tolerate some variance in binding sequence, so again care must be 
taken. 
The transcription factor search was used on the first intron as well 
as the 5' promoter region. The first intron of Ese-2 is very large, 
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approximately 6kb, which has been previously documented in 
other genes as potentially harbouring enhancer elements (Aronow 
et al., 1989). Often enhancer elements operating from a distance 
cause greater or no change (due to redundancy) to regulation than 
is seen in proximal elements (Crawford et al., 1999). Functional 
redundancy in regulatory regions may be widespread for enhancer 
or tissue-specific regulatory regions in particular as seen in the 
Adh Drosophila locus (Fang and Brennan, 1992; McKenzie et al., 
1994) and the mammalian globin gene (Gumucio et al., 1993). Ese-
2 is tissue specific and its tightly regulated pattern of expression 
may be due to enhancer elements acting from a distance. 
An in depth discussion of the potentially important transcription 
factors is given in the main discussion, Chapter 6. 
Thus far, in comparison to members of the Ets transcription factor 
family, Ese-2 has many features in common. Of those ets genes 
that have regulatory regions described, a majority appear to lack 
TATA and CCAAT consensus sequences, as is the case for Ese-2. 
This is common for house-keeping, growth related genes and 
oncogenes, the latter of these describing many ets factors. Both 
ETS-1 and ETS-2 human genes lack these sequences and again 
implicate other sequences as being critical in the replacement of 
their function within the proximal promoter. The TATA box 
normally defines the exact point of transcription, but it is also 
neither necessary nor sufficient for such initiation alone. 
Of potentially important elements, Sp-1, Ap-1, Ap-2, GC-elements 
all appear in ETS-1 and ETS-2, and also Fli-1. Two GC elements in 
the human ETS-1 promoter are located near a transcription start 
site and are postulated to play a role in transcription initation as 
shown in other multiple transcription start site and TATA-less 
promoters (Ishii et al., 1985; Miyamoto et al., 1988). Fli-1 also 
contains adjacent GATA and EBS, which has been described 
earlier as having a potentially important cooperative role (Barbeau 
et al., 1999). Likewise, Elf-3 has a partial overlap between EBS and 
NFKB (Oettgen et al., 1999a). 
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The importance of repeat sequences is somewhat less clear in the 
promoter than in other regions of the gene. J orcyk et al. ( 1 991) 
speculate that a polypurine-polypyrimidine stretch may be 
important in ETS-1 regulation. Certainly in other promoters, such 
a repeat is able to form a triple helix which is sensitive to S 1 
nuclease and able to bind nuclear proteins implicating they are 
involved in regulation (Gilmour et al., 1989). 
Functional analysis of these regions is required to confirm the 
involvement of any such factors in the regulation of Ese-2. The 
location of such sites provides a suitable basis for an experimental 
study of the features involved in Ese-2 regulation. 
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Chapter 4. Human genome analysis and 
sequence alignments 
4.1 Introduction 
With the recent publication of the draft human genome, a whole 
new raft of information is available for investigating features of 
genes. When this data is combined with other genomes, 
comparisons can be made which increase the capability to 
investigate the structure, function and evolution of genes. The 
more recent release of the mouse genome in particular provides 
another level of information. 
The human genome is much larger than other genomes recently 
sequenced. It is thirty times larger than the worm and fly, and-two 
hundred and fifty times greater than yeast. However, it does not 
have a proportional increase in the number of genes and indeed 
estimates are now predicting 25-35000 genes (Ewing and Green, 
2000). This means there is alot of non-coding DNA. Of this, 46% is 
made up of repeat DNA, which may or may not have a function. 
The remainder includes promoters, transcription regulatory 
sequences and other unknown features. The increase in size of the 
human genome from other genomes brings with it an increase in 
complexity, and makes the location of individual genes more 
difficult through the decrease in signal to noise ratio. 
Computational strategies, based on finding gene characteristics 
such as splice sites and coding regions, often lead to false 
positives. More reliable predictions are made through the use of 
expressed sequence tags (ESTs) and complementary-DNA 
homology comparisons to other genomes, because exons are more 
highly conserved than introns. 
The human genome has been compiled by the systematic 
sequencing of several thousand (10,000-20,000) Bacterial artificial 
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chromosome clones (Bae), each of 100-200kb, which come from 
known chromosomal locations. The sequenced fragments are 
assembled based on overlaps and then have a unique identifier 
assigned (accession number) by the high-throughput genome 
sequence division of the international nucleotide database 
(GenBank/EMBL/DDBJ). The overlap of the Bae clones is aligned 
and redundancy removed to create a contiguous DNA sequence for 
each chromosome. 
Many errors exist m the current data set and caution must be 
exercised with any analysis. Fragmentation of genes can cause 
misleading results, often predicting more than one gene present. 
Assembly errors may duplicate genes or give the wrong orientation. 
Also, the actual presence of a gene does not mean a protein will be 
expressed, and therefore expression studies must complement 
such information to confirm a protein. 
Wolfsberg, McEntyre and Schuler (2001) outline two main uses of 
the human genome sequence. Firstly, using a known DNA 
sequence or protein from a different source, the human sequence 
can be compared to find an apparent homologue. Indeed this 
approach has been used in this chapter as the mouse Ese-2 gene 
has a human homologue ESE-2 (Oettgen et al., 1999b; Zhou et al., 
1998). Secondly, a group of proteins can be identified that contain 
a conserved sequence or domain. For example, the ETS domain is 
highly conserved in this family of transcription factors and a 
search of this highlights the individual family members in the 
human genome. Such paralogues are often the result of gene 
duplication, where a conserved region is found in a set of genes 
(Wolfsberg et al., 2001). 
Variations in the DNA sequence can give information on regions of 
importance. Commonly utilised are single nucleotide 
polymorphisms (SNPs) of which 1.5 million have been documented 
to date. When these occur in coding regions, amino acid 
substitutions may occur, which may or may not be functionally 
important. 
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This chapter deals with the data gained from the published human 
and mouse genome working draft sequences, and utilises tools for 
its manipulation (National Centre for Biotechnology Information-
NCBI, and UCSC Human Genome Project Working Draft). Firstly, 
the basic sequence references are discussed followed by a more 
detailed study of the clones representing ESE-2 and its predicted 
gene structure. Exon-intron boundaries are identified, and 
different isoforms are discussed. Promoter prediction programs 
have been employed and offer a comparison to the experimental 
approach. The chapter focuses on the comparison between mouse 
and human (and bovine) sequence data for Ese-2. In particular, the 
chromosomal location (syntenic gene block), mRNA alignment and 
EST database information. Blast comparison is also performed to 
allow a comparison to other genes having some similarity. 
The first publication of the Ese-2 sequence was for the mouse (Acc. 
No. AF 049702) and the human (Acc. No. AF 049703) (Zhou et al., 
1998). The human sequence was isolated from a human lung 
cDNA library and was mapped to chromosome location 1 lp15-p13, 
which is known to undergo loss of heterozygosity in some cancers 
(Zhou et al., 1998). The human sequence was later recognised as 
having alternate 5' exons, predicted to result from two different 
promoters (Oettgen et al., 1999b). ESE-2 was labelled as either the 
ESE-2a (Acc. No. AF 115402) or ESE-2b (Acc. No. AF 115403) 
isoform (Oettgen et al., 1999b). ESE-2a encodes a protein of 265 
amino acids with a molecular weight of 31.3kD, and contains a 10 
amino acid extension at the 5' end to that of ESE-2b. ESE-2b 
therefore encodes a 255 amino acid protein of 30. lkD. ESE-2a and 
2b both contain a longer 3' UTR than that published for ELF-5 
(Zhou et al., 1998), thought this may be due to a lack of 3' RACE 
data. ESE-2b was equivalent to that published by Zhou et al. as 
human ELF-5. 
One ATG initiation codon exists in frame, with multiple termination 
codons in frame upstream of this for ESE-2a (no upstream 
termination codons present for ESE-2b). Oettgen et al., 1999 also 
Chapter 4. Human genome analysis 
109 
report both isoforms as having a poly(A) tract preceded by a 
consensus polyadenylation signal (ATAAA). An ATTTA motif after 
the polyA site has been identified, which is associated with rapid 
mRNA turnover (Savant-Bhonsale and Cleveland, 1992). 
4.2 Results 
4.2.1 Ese-2 sequence data 
All analyses completed in this investigation used the human 
genome draft data released in August, 2001. 
Analysis of the murine Ese-2 has not revealed any alternate 5' 
exons or promoters, though it 1s known that alternative 
polyadenylation results in two murine mRNA species (Langley, 
1999). These are 1.5 and 2.5kb mRNA species that differ in the 3' 
region, by a truncation in the shorter isoform. Elf-5 appears to lack 
exon 4 (shown in Figure 4.1). This is an anomaly of the UCSC 
genome browser, as when the sequence is BLAT searched, exon 4 
is present. However, this may also be a function of exon skipping 
that is observed in several EST clones (discussed later). 
4.2.2 Locuslink and chromosome structure 
Analysis of the human genome draft sequence identifies a single 
gene match for ESE-2 on chromosome 11 band position p13-15, as 
originally identified by Zhou et al., 1998. The ordered BAC clone 
that the sequence was constructed from is RP4-594L9, which 
overlaps clone RP1-53Cl8. The location of the gene (coding 
sequence and introns) in the working draft sequence of human 
chromosome 11 is 36972718 to 37006302 as seen in Figure 4.1. 
The gene is on the (-) strand, and runs from right to left in the 
diagram below. Human chromosome 11 working draft segment 
contains the complete gene sequence from partial exon 1 b (ESE-2b) 
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to partial exon 7 and spans 33585bp DNA. The alignment of the 
genomic DNA and the exon structure is shown in Figure 4.1. Intron 
boundaries conform to the gt-ag consensus splice donor and 
acceptor junctions. 
4.2.3 Comparison of Mouse and Human ESE-2 
(a) Chromosomal location 
Human ESE-2 is located on chromosome 1 lp13-15, flanked by the 
catalase (CAT) gene and ESE-3 (EHF). The murine Ese-2 gene is 
located on chromosome 2, in a region that shows close 
conservation with human chromosome 11, also flanked by the 
murine Catalase gene (Casl) and Ese-3. Figure 4.2 shows the 
Human Map View of Chromosome 11, focused around the ESE-2 
locus. Table 4.1 outlines the syntenic block of genes from 
chromosome 11 of the human, that are grouped in the same order 
on chromosome 2 of the mouse. ESE-3/EHF, located at 1 lp12 
retains the most homology with ESE-2 in the Ets transcription 
factor family. As discussed in Chapter 1, the ets genes appear to 
have been duplicated in groups of two, always from the same 
chromosomal region. This would appear to be the case for ESE-2 
and ESE-3 on chromosome 11 of the human and chromosome 2 of 
the mouse. 
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(A) 
Human Chromosome 11p13 (-) 
36972718 37006302 
-11-1 ----1---1----1--1 ELF-5 
111 I I I I ESE-2b 
111 I I I I ESE-2a 
1111 I I Elf-5 
ii i i i i i i 
76 5 4 3 2 la lb Exon No. 
(B) 
Exon and Intron positions of ESE-2 on chromosome 11. 
Start nt End nt Exon/Intron No. Length (bp) 
37006302 37006197 Partial exon lb (ESE2b) 105 bp 
37004320 37004064 Partial exon la (ESE2a) 256 bp 
3 7006196 36998273 Intron 1 gt-ag 5789a/7923b bp 
36998272 36998147 Exon 2 125 bp 
36998146 36986230 Intron 2 gt-ag 11916 bp 
36986229 36985995 Exon 3 234 bp 
36985994 36982575 Intron 3 gt-ag 3419 bp 
36982574 36982523 Exon 4 51 bp 
36982522 36975013 Intron 4 gt-ag 7509 bp 
36975012 36974943 Exon 5 69 bp 
36974942 36973479 Intron 5 gt-ag 1463 bp 
36973478 36973282 Exon 6 196 bp 
36973281 36972824 Intron 6 gt-ag 457 bp 
36972823 36972718 Partial exon 7 131 bp 
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Figure 4.1 Alignment of published Human and Mouse Ese-2 
sequences (A) Genomic DNA showing exon and intron positions on 
human chromosome 11. The genomic DNA spanning the exons of 
ELF-5 starts at 37006302 on the negative strand, and finishes at 
36972718. The sequence reads from right to left, with the 
untranslated exon 1 starting at the right of the diagram (due to the 
gene being on the antisense strand). ELF-5 refers to the human 
sequence published by Zhou et al., 1998, and ESE-2a and 2b are 
human sequences published by Oettgen et al., 1999. Elf-5 is the 
mouse homologue published by Zhou et al., 1998. Exon numbers 
are given below the sequence data. (8) The table represents the 
coordinates of the exons and introns in the template genomic DNA, 
relative to the position on chromosome 11. The gene is present on 
the negative strand, so numbers decrease from 5' to 3'. 
Comparison of the mRNA sequences submitted to the genome 
sequence shows that all 6 introns follow the consensus [gt-ag] rule. 
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Table 4.1 Syntenic Block of Chromosome 11 (human) vs 
Chromosome 2 (mouse). 
Chr 11 Human Mouse Chr 2 Gene name 
gene gene 
llpl3 FSHB Fshb 60cM Follicle stimulating 
hormone, Beta 
llpl3 FAX6 Fax6 58cM Paired box 
homeotic gene-6 
llpl3 RCNl Rcnl 58cM Reticulocalbinl 
llpl3 WTl Wtl Wilms Tumor 
llpl3 WITl Witl Wilms Tumor 
associated protein 
llpl3 HIPK3 Hipk3 Homeodomain 
interacting protein 
kinase3 
llpl3 CD59 Cd59 55cM CD59 antigen 
llpl3 LM02 Lmo2 LIM domain only 2 
llpl3 Ml1Sl Gpiap- Membrane component 
pending surface marker 1 
llpl3 CAT Casl 57cM Catalase 
llpl3- ELF5/ Elf5/ Epithelium specific 
pl5 ESE-2 Ese-2 factor 5 
llpl2 EHF/ Ehf/ Epithelium specific 
ESE-3 Ese-3 factor 3 
llpl3 CD44 Cd44 56cM CD44 antigen 
llpl3 RAGl Ragl 56cM Recombination 
activating gene-1 
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(b) Comparison of Ese-2 mRNA and genomic sequences 
The mouse genomic sequence data released in August 2001 was 
found to have 97% identity to that isolated in this investigation 
(not shown). Such differences are may be accounted for by 
sequencing and assembly errors. The mismatches that occur 
between sources of sequence mostly comprise gaps in longer runs 
of a single nucleotide. The results generated in this study were 
particularly variable for the automated sequence calling at 
distances over 400bp from the primer. 
Sequence comparison of the mouse Ese-2 gene (AF _049702) shows 
87% homology within the coding sequence to the human ESE-2. 
Comparison to the bovine cDNA sequence shown in Figure 4.3, 
reveals a homology of 88% to mouse and 92% to human (coding 
sequence only). The predicted amino acid sequence of human and 
mouse reveals a homology of 95% and only one amino acid 
difference in the ETS domain. Interestingly, there is good homology 
between the bovine 5'UTR and human ESE-2a 5' UTR (78%) seen 
in Figure 4.4. In comparison ESE-2b has significant homology with 
the mouse 5'UTR. 
Genomic sequence homology between the mouse and human is 
outlined in Table 4.3. The 5' promoter region and the first intron 
were of interest, as these areas were studied for enhancer 
properties. Regions of homology may indicate an important 
regulatory sequence due to conservation of such sequences 
through evolution. A pairwise alignment was performed between 
the mouse Ese-2 genomic sequence from the sequence data 
obtained in this investigation, extending from 2.6kb upstream of 
the transcription start site through the first intron, and the human 
working draft sequence of chromosome 11 to include 5' of the ESE-
2 gene. Regions of high homology are shown in the table. Briefly 
there are two short regions of high homology in the extended 5' 
region, which mapped to 5' upstream regions of the human 
counterpart. 
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Figure 4.2 Chromosomal location of ESE-2 (EU'S) on human 
chromosome 11 The diagram represents a detailed segment of 
chromosome 11 around the ESE-2 locus, showing selected genes 
only. Data were generated from the UCSC Human genome browser. 
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Human ESE-2 b GTCTTTATTTCCACTGCACGCTGGTGCTGGGAGCGC-CT-GCCTTCT 































































TCAATGATGCTGAAGAGACCAAGACTGGCATCAAAGACTATGCTGATTCCAGT TGCTTG +512 
TTAATGATCCTGATGAGACCAAGGCCACCCTCAAAGACTATGCTGATTCCAGT TGCTTG 
AAAACAAGTGGCATCAAAAGTCAAGACTGTCACAGTCATAGTAGAACAAGCCTCCAAAGT 












CTGAGATACTACTATAAAACGAGAATTCTGGAGCGGGTTGACCGGAGGTTAGTGTAC +8 09 
CTGAGGTACTACTATAAAACCGGAATTTTGGAACGGGTTGACCGAAGATTAGTGTAC 
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Figure 4.3 Partial cDNA sequence comparison of ESE-2 from 
human, mouse and cow The coding nucleotide sequence of Ese-2 
to 837bp is shown. The human sequence corresponds to the ESE-
2b sequence (AF_l 15403) and mouse corresponds to Ese-2 
(AF _049702). The bovine DNA was isolated during the initial 
investigation of Ese-2 (unpublished results), and the complete 
known sequence is shown. The ATG initiation and termination 
codons are in bold and the mouse transcription start site (bold and 
underlined) is numbered as + 1. Underlined sequences in the main 
sequence body represent the Pointed domain (first section) and the 
ETS domain in the second underlined section. Mismatches are in 
blue type. 












Figure 4.4 Bovine S'UTR aligned with human ESE-2a S'UTR 
Sequences are shown only partially where the alignment occurs. 
The best-fit alignment including the aligned sequence shown is 
78%. The major difference is in the length of the human exon, 
though the bovine may extend further 5'. Also, the location of the 
ATG is different. The ATG initiation codon is shown in bold. 
Mismatches are shown in blue. Human and bovine sequences are 
numbered with respect to the ATG codon at + 1. 
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The region immediately 5' of the first exon of the mouse also 
showed high homology, possibly representing the proximal 
promoter. The first exon of the mouse is very similar to that of 
ESE-2b first exon, and also a small region 3' of the exon has 
homology. In the first intron of the mouse there are 3 regions that 
are similar to the human. One of these is a part of the ESE-2a first 
exon. 
Some, but not all of the sequence similarities, span potential 
transcription factor binding sites as indicated in Table 4.3. 
4.2.4 Promoter prediction 
Computer based analysis of DNA sequence can be extended from 
simple consensus site transcription factor searches to 
sophisticated algorithms designed to predict transcription start 
sites and promoter regions. The basis for such programs varies, 
though a combination of transcription factor sites, locus distances 
and non-transcription factor sequence similarities are combined to 
generate a high level of information. Several such programs are 
available via the world wide web, including the Sanger Center Gene 
Finder program, which uses an algorithm based in combining 
characteristics describing functional motifs and oligonucleotide 
composition of these (Prestridge, 1995). Further programs exist 
such as 'Genscan" based on the prediction of exons, to locate the 
transcription start site (Burge and Karlin, 1997). Also, 'GRAIL' 
experimental gene discovery, which uses a neural net searching for 
specific elements such as TATA, CAAT and GC boxes (Hyatt et al., 
2000). A more sophisticated program was developed by the 
Berkeley Drosophila Genome Project called 'Genie" (Reese and 
Eeckman, 1995). Genie is based on generalised hidden Markov 
model principles. This program was used to predict transcription 
start sites of Ese-2, as outlined in Table 4.2. The search was 
limited by the amount of sequence entered, 2.6kb 5', exons 1 and 
2, intron 1 determined from this investigation, and the score was 
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restricted to those promoters returning a value above 0.8, where 
1.0 is a perfect match for a transcription start site. 
One predicted site agrees with the experimental data, but most 
striking is the number of other sites that are predicted to exist. The 
probability of other start sites and promoter regions may be high, 
though their use in the biological system examined in this 
investigation is not supported by the experimental analysis of 
mRNA transcripts. Other promoters may be used infrequently 
giving rise to few alternate mRNA transcripts. These may not be 
detected due to their very low expression, but may be important in 
tissues where Ese-2 has not been found thus far. Within the first 
intron of Ese-2, the region of homology with exon la of the human 
ESE-2a gene is not detected as a putative promoter. However, the 
homology is not complete between the mouse and human in this 
sequence, which may account for the promoter being present in 
the human but not the mouse. 
Table 4.2 Promoter prediction of the Ese-2 sequence 
Start End Score Promoter sequence and transcription 
start site (bold) 
779 829 1. 00 CAGGACACTTTTTAAACTCCCGCCTAAGGGCTGGAGAGATGGTGCTGTGG 
1201 1251 1. 00 ACAAAACATGTTTTAAAAATGCCTAGTGATACAGGGTCTCATTGTGTGGA 
1269 1319 0 . 85 AACTCACTGTGTAAATCAACCTGGCCTCAAACCCACAGATATCTGCCGCC 
1772 1822 0.88 TGAGAGATGTCCTAAAAACTGGGTAGTTCTCAGTGAGACAGCTGACAGCT 
1895 1945 0 . 92 ATCGCCATTTCTAAAACAGAGGACACTGGGAAAGGGGGAAAGCTGTCACA 
2622 2672 0 . 80 AGGTGTCACTTATATCACACGGCTACAGGTGCCTTTATTTCTACGGTCCG 
4209 4259 0 . 99 AGCCACCCTTCTTAAAGAGCCCGAAGGGTGGGAAAGTAACACCCCCTATC 
4807 4857 0.93 TCAGAAAGGAGATAAAAAGTTGCTGGAGGCTCTCAGTTCCAGGCCTGCCC 
4889 4939 0.89 TCTCACCAGTAAAAAAAAGAGCTCATTTGATTCCACCACCTTAGGGTGAT 
5048 5098 0.84 CATGGGAGTATAGGATCCCAGCTCAGTTGTCCAGCTGAGCAGGAGAGGGA 
5900 5950 0 . 99 TCACTGCTTTCATAAAAGACCTCCCCACGCCTCCCCCCCCAACCCCCACC 
6021 6071 0 . 87 CTAATGGGTATAATTTGCCATAAAAGGAATTATCGGAGGGAACCAAATCC 
6298 6348 0.86 CCCATAGACTTTAAAGACCTGGAGACTGCATTCTGTTCTCTTCCATTTGG 
6822 6872 0 . 99 AGTTTCCTTATATAAATGTGCCTGGGATGATGCTATACCCTTCAGATAGG 
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4.2.5 Expressed Sequence Tag information 
Expressed sequence tags (ESTs) provide a useful tool for searching 
for anomalies within genes. They give sequence information directly 
from cDNA sequence, representing the 'coding' portion of the 
genome. Sequence data from ESTs is collated with the human 
genome draft sequence (and other genome sequence data) and also 
separately in a database of ESTs alone (TIGR). From the 'UCSC 
genome browser' internet tool, the set of ESTs aligning to a specific 
gene can be observed. In this study, human chromosome 1 lp13 at 
position 36972252-37006397 was displayed and the ESTs aligned. 
An alignment of the available murine ESTs at the 5' end of Ese-2 
predicts a start position between nucleotide -11 and +12 with 
respect to the + 1 site determined in this study. This correlates well 
with the predicted major transcription start site identified by 
primer extension. It also reinforces the likelihood of multiple start 
sites as seen experimentally. The discrepancy of approximately 20 
nucleotides for the exact start site may be accounted for by the 
inaccuracy of sequencing near the 5' end of EST clones. 
When the full set of available ESTs were aligned to the ESE-2 gene, 
some anomalies could be observed (Figure 4.5). 
Firstly, there appears to be other splicing events occurring in the 
human gene after exon 3 and exon 5 (Human ESTs that have been 
spliced). Such splicing events appear to be a common feature of the 
human genome, as discussed later. However, in this instance the 
splicing is represented by a small number of EST sequences only 
and their importance should not be overemphasised. 
Secondly, exon 4 is not present in 21 of 51 mouse EST clones that 
would be expected to encompass this exon. The high percentage 
from a large number of clones is likely to represent a real feature of 
the gene. Skipping of exon 4 has not been reported in published 
reports of the gene. 
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Figure 4.5 UCSC Genome Browser from the August 6, 2001 
freeze on chromosome 11, position 36972252-37006397 
Selected tracks are shown, labelled in the centre of the diagram 
above the sequence. The Genbank accession numbers of sequences 
are listed to the left of the figure. The gene sequence runs from 
right to left as it is on the negative chromosome 11 strand. Band 
position refers to the nucleotide numbering on chromosome 11. 
Exon skipping can be seen for exon 4 under the 'Nonhuman ESTs 
from Genbank', where it is present and absent in some sequences. 
Two EST sequences appear to have an exon skipping event for exon 
5 also. 
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4.2.6 Blast Searches against Ese-2 
Following the comparison of the ESE-2 human and mouse 
sequences, a genome wide Blast search was performed to identify 
any regions of similarity with genes other than ESE-2, and with 
other organisms. 
Most obvious was the homology to other ets genes, due to the ETS 
domain being so highly conserved. The ETS domain of ESE-2 is 
highly similar to ESE-1 at the amino acid level (67%), and 65% 
similar to that of ESE-3. ESE-1 and ESE-3 retain 84% identity 
(Kas et al., 2000). ESE-2 has an ETS domain that retains only 
moderate amino acid homology with other family members. The 
highest is 49% to human NERF, 48% to Drosophila ETS4 and 
E74A, and 46% to human ELF-1 (Zhou et al., 1998). 
Outside of the ETS domain, some other genes showed apparent 
homology. In the 5' region of Ese-2 a sequence of 64bp matched 
with 90% homology to the cDNA sequence of the mouse 
dystroglycan 1 (DAGl) gene (Figure 4.6). The same region was also 
homologous (90%) to the mouse upstream region of the promoter of 
the uroplasminogen activator (uPA) gene. DAGl is a laminin-binding 
component that connects the subsarcolemmal cytoskeleton with 
the extracellular matrix. DAGl is a candidate gene for autosomal 
recessive muscular dystrophy, as its repression results in a loss of 
the connection between extracellular matrix and sarcolemma 
making muscle fibers susceptible to necrosis (Henry et al., 2001). 
The role of many ets genes and possibly Ese-2 in extracellular 
matrix regulation makes the sequence homology of interest. The 
sequence may contain sites for common factors to bind that are 
involved in a common function for both genes. 
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Similarly, uPA is involved in extracellular proteolysis, important in 
tissue remodelling and cell migration, which is important for 
mammary gland involution (Degen et al., 1987). The potential role 
of Ese-2 here again implies some common role of the homologous 
sequence. 
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Table 4.3 Genomic DNA alignment of human and mouse for the 
5' promoter and intron 1. Each row indicates a region of 
homology. The sequence given is that for the mouse, with any 
transcription factor binding sites in bold, and named in the last 
column, in order. Mouse sequence numbering is relative to the 
transcription start site at + 1. Human numbering is relative to the 






















Start Mouse sequence of conserved End % ID Binding 
site region site site 
-2484 TCTTTTGTTTTTGTTTTATATTAATCATCCCTTTTAACGACT -2430 87% Elf-1 
GGTCCAGAAGCCT 
-4026 -3972 




-177 GAGCTGGGCACAAAAGCAGGAGAAAGGTAAACTTTCTGCATG -127 92% C/EBPP 
TGAAAACCA 
-2142 -2092 






-2077 CCTTCTGTCTGGACCTAGCCACC -1889 GATAl 
+97 CTTTTCTTTGCTCTTTTGAATGAATTGAAAGGGGTGTCGGGG +145 89% n/a 
CTCAGAG 
-1869 -1821 
+2000 GAATTTTCCTCCTCTGACAAATTGGGCAAGGCTGG +2043 88% C/EBPP 
GTAGTTTGC 
-29 +14 
+3137 CACACCTAGTGCATGCTGGCTAAGTAGCCTGGCCTTTTGTGG +3198 87% n/a 
TGAGCTTAGACTTAATAAC 
+1390 +1450 















Figure 4.6 Sequence alignments between Ese-2, dystroglycan 
I (DAGI) and urokinase plasminogen activator (uPA) DAGI is 
homologous from positions 778 to 876 of the cDNA. uPA is 
homologous in the 5' promoter region. 487 to 405. Mismatches are 
shown in blue relative to the mouse sequence, where + 1 is the 
major transcription start site. 
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4.3 Discussion 
This chapter presents analyses based on current genome 
databases. Sequences which had been submitted to GenBank 
already spanned the cDNA for ESE-2, though genomic sequence 
was unavailable. The sequencing of the genome has amended this 
and now a complete set of data is available, albeit draft only. For 
the purposes of this research, the human genome data is very 
useful. In particular it facilitated a comparison of the known 
mouse genomic sequence in the 5' and first intron, which were 
studied here in detail. 
The coding sequence of ESE-2 showed good homology with murine 
Ese-2 (87%), which implies a similar function is maintained 
between species. Interestingly, both the mouse and human gene is 
expressed as two distinct isoforms. For the mouse, these differ in 
the use of polyadenylation signals, making a difference of 1kb 
mRNA size. In the human, alternative 5' splicing results in a 
difference of 10 amino acids seen as an extension in ESE-2a over 
ESE-2b. The whole of the first exon of ESE-2b is different from that 
of ESE-2a suggesting separate promoter usage (Oettgen et al., 
1999b). However, it must be recognised that this investigation 
dealt with cDNA obtained from murine mammary and that of the 
human ESE-2 investigation was from prostate. The tissue of origin 
of the sequence may play a role in the isoforms that were detected. 
Indeed, possibly two isoforms equivalent to the human were 
detected by Northern analysis in the CommalD cell line. These 
may be at very low levels and expressed at higher levels in tissues 
not examined here. The EST sequences referred to in the database 
were mostly generated from normal or tumourigenic mammary 
gland. 
When these sequences were compared to the known bovine 
sequence, it was discovered that the 5'UTR of bovine was very 
similar to the ESE-2a 5'UTR. In contrast, the mouse 5'UTR is 
similar to that of ESE-2b. Also, a section (43bp) of the ESE-2a exon 
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was found to have homology to sequence within the first intron of 
the mouse gene. This raises the possibility of an alternate promoter 
and first exon in the mouse that has not yet been detected. It is not 
known whether the bovine Ese-2 has two isoforms, as Northern 
data is not available. 
The presence of the two isoforms in both human and mouse 
supports the hypothesis that the isoforms have slightly divergent 
functions. Indeed, in both the mouse and human, a slightly 
different pattern of expression is observed for each isoform, 
supporting the hypothesis mentioned earlier. For example, Ese-2 
(2.5kb) is expressed in the mouse in neonatal and embryonic lung 
and kidney, and adult ovary, compared to the Ese-2 (1.5kb), which 
is not expressed in these tissues. In the human, the kidney was 
found to express only ESE-2a, whereas the prostate expressed 
both, but more ESE-2b than ESE-2a (Oettgen et al., 1999b). 
The sequence of the ESE-2 gene highlights its homology to the ets 
family of transcription factors through the ETS domain. This 
implies Ese-2 is a transcription factor, most closely associated with 
ESE-1 and ESE-3. ESE-1,2, and 3 are all epithelially expressed 
genes. The subgroup is phylogenetically grouped as discussed in 
Chapter 1. A predicted function of ESE-2 is an involvement in cell 
proliferation and migration. Evidence for this is from its homology 
with ESE-1, another gene showing epithelial restricted expression, 
known to be differentially regulated during differentiation of some 
epithelial cells (Andreoli et al., 1997). 
The second domain that retains homology to the Ets transcription 
factors is the Pointed domain, also found in ESE-1 and ESE-3 and 
some other Ets proteins. It is very similar to the SAM domain, 
which is involved in homo- and hetero-dimerisation. It is therefore 
a possibility that the role of the Pointed domain is similar in the ets 
genes. 
The chromosomal location of ESE-2 (1 lp13-15) has been reported 
to frequently undergo Loss of Heterozygosity (LOH) in certain 
cancers (Reeve et al., 1989; Weinberg, 1991; Fong et al., 1994; 
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Shipman et al., 1998). Studies of this region have focused on 
Wilms Tumor patients. The specific region of LOH in Wilms Tumor 
has been mapped to chromosome 1 lp15 loci, and is thought to 
extend to include the Wilms Tumor, aniridia, genitourinary 
malformations and mental retardation (WAGR) locus at 1 lp13 
(Reeve et al., 1989). Indeed a survey of 48 samples of primary non-
small cell lung cancer (NSCLC) allelic deletions on chromosome 11 
were localised to 1 lp13 catalase (CATl) and beta FSH (FSHBJ, and 
the other at band 11 p 15 corresponding to the IGF II locus (Ludwig 
et al., 1991). 
With ESE-2 and ESE-3 both located in close proximity to catalase 
and the region of LOH, it may be that their absence is also 
significant in the cancers resulting from LOH. ESE-3 is a known 
transcription repressor of some Ets/ Ap-1 responsive genes such as 
interstitial collagenase gene (MMP-1) and it is absent from epithelial 
carcinomas of tissues where it is normally expressed (Tugores et 
al., 2001). MMP-1 is a matrix metalloproteinase gene involved in 
the degradation of the extracellular matrix in processes such as 
mammary gland involution. Its abnormal regulation has been 
implicated in tumor formation (Bolon et al., 1995). Therefore, the 
loss of an ets gene such as ESE-2 or ESE-3 may at least partially 
be responsible for the loss of regulation and hence tumor 
formation. 
Also within the syntenic block of genes of chromosome 11 (and 
chromosome 2 of the mouse) is the Paired Box Homeotic Gene-6 
(PAX6). Mutations to this gene have been implicated as the genetic 
cause of aniridia. Some of these mutations also encompass 
chromosome deletions of the WTl locus and increase the risk of 
Wilms Tumor (Gronskov et al., 2001). It appears that many genes 
in this chromosomal region play a role in tumor and disease 
formation through LOH or other mutations. 
The mouse EST alignment analysis revealed an exon skipping 
event that appears to occur in nearly 50% of all the ESTs 
published in this region. ESTs for Ese-2 are seen to often lack exon 
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4. Also, the published Ese-2 sequence is also lacking exon 4 when 
aligned by the UCSC genome browser. 
Alternative transcription is predicted to occur in at least 30-40% of 
human genes. This includes alternative splicing, polyadenylation 
and transcription start sites, based on EST studies (Hide et al., 
2001). Of the features responsible for altering the protein coding 
sequence of a gene, exon skipping is the most frequent (Mironov et 
al., 1999). The use of such alternative transcripts has been 
confirmed in developmental, tissue-specific and disease-specific 
processes (Zacharias et al., 1995; Dufour et al., 1998; Jiang and 
Wu, 1999; Lambert de Rouvroit et al., 1999; Lim et al., 1999; 
Unsworth et al., 1999; Kawahara et al., 2000; Mercatante and 
Kote, 2000; Strehler and Zacharias, 2001). Such diversity in the 
processing of transcripts can enhance the diversity of protein 
products available within the genome. This is particularly 
important as the exon skipping events often have a significant 
impact on the protein. This has been demonstrated for many 
genetic disorders and tumor formations (Birrell et al., 2001; 
Manson and Huxley, 2001; Sironi et al., 2001). 
The functional implications of exon skipping of exon 4 in Ese-2 
have not been studied. However, the loss of exon 4 is predicted to 
result in a frame shift, likely to cause major changes in the protein 
product. 
The mRNA sequence alignment for mouse, human and bovine 
revealed a high degree of similarity. Although the bovine mRNA 
may not be complete, the coding region is of a similar length to 
both human and mouse. The mouse and human differ widely in 
the 3' UTR and the two mouse isoforms also differ widely in this 
region as mentioned earlier. Genomic sequence alignments 
revealed several interesting homologous regions. With respect to 
the human alternate first exons, ESE-2b exon 1 was very similar to 
that of the mouse. ESE-2a first exon showed some homology to 
approximately 40bp of the mouse first intron at 2kb. The 5' region 
of mouse and human had several regions of similarity. In the more 
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distal 5' region, an alignment of 50bp spanned an Elf-1 consensus 
binding site, and a larger alignment of 120bp encompassed 
conserved Ap 1 and C / EBP binding sites. These conserved regions 
may be more important than unconserved regions in the regulation 
of transcription of the gene. 
Of particular note was a homologous region m the proximal 5' 
promoter of the ESE-2b gene. The proximal promoter alignment 
spanned several Ap 1 transcription factor consensus binding sites, 
as well as a potential GATA-1 site, which suggest their importance 
as a result of their conservation. Several short alignments 
throughout the intron of the mouse were also located though these 
didn't appear to contain many potential transcription factor 
binding sites. 
A 5' upstream region of the mouse sequence also showed high 
homology to both the uPA and DAGl genes. As explained earlier, 
the area of homology was to the coding region of DAGl and the 
upstream promoter of uPA. Both these genes, along with ESE-2 
may have some common ancestry, also suggested by their similar 
predicted functions. The possible functional relationship between 
these genes is striking. Plasminogen activators are involved in 
extracellular proteolysis such as tissue remodelling and cell 
migration during processes such as mammary gland involution 
and tumor cell metastasis {Degen et al., 1987). Dystroglycan is 
expressed in cell types directly adjacent to basement membranes 
{including epithelia) and its function is in the formation of 
basement membranes as an attachment between extracellular 
matrix and cytoskeleton (Henry et al., 2001). Abnormalities in both 
structure and function of basement membranes are involved in 
metastatic disease, thus it is likely that DAGl will also play a role 
here. Reduced expression of DAGl has been observed in both 
prostate and breast tumours, suggesting this is a feature of 
epithelial neoplasia, leading to abnormal cell and extracellular 
matrix interactions (Henry et al., 2001). 
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ESE-2 is an epithelial expressed gene, and information to date 
implicates it having a role in the regulation of the extracellular 
matrix degradation. These functional similarities seem to suggest 
that the sequence homology may be of significance. For example, it 
may harbour sequences to direct expression to epithelia, 
extracellular matrix or their regulators. 
Functional analysis of these regions of homology 1s required to 
ascertain their biological significance. The use of deletion 
constructs in cell culture may give valuable evidence to the 
regulation of Ese-2. 
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Chapter 5. Investigation of Ese-2 
sequences for promoter activity in vitro 
5.1 Introduction 
Usually, a promoter is a region of DNA that contains all the 
response elements required for the complete transcriptional 
regulation of a gene. In practice the promoter requires additional, 
non-contiguous regions of DNA, encompassing elements such as 
enhancers for its correct function. 
In the first instance, the promoter 1s often referred to as the 
proximal promoter, which is an arbitrary amount of sequence 
immediately 5' of the first exon, usually extending 300-800bp 5' of 
the transcription initiation site. It is normally able to drive a basal 
level of transcription of the gene, without the need for additional 
elements such as enhancers. 
Theoretical characteristics of the promoter region of Ese-2 have 
already been discussed in Chapter 3 and 4. Multiple programs 
exist that locate the most probable promoter and transcription 
start sites based on algorithms of promoter elements and their 
locations from known sequences (Prestridge, 1995; Reese and 
Eeckman, 1995; Burge and Karlin, 1997; Hyatt et al., 2000). With 
respect to the activity of the promoter, functional predictions based 
on such computer analyses, potential sites of interest or 
comparisons to other related genes are not at all reliable. In order 
to gain insight into the functional regulation of Ese-2, the next step 
was to test the activity in a cell culture system. Ideally, the use of 
an in vivo model such as a mouse with inserted transgene 
constructs would give the best functional representation. However, 
with time restraints and other impracticalities, the in vitro system 
is often the next choice for examining promoter activity. Once some 
initial regions and factors have been pinpointed from such an in 
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vitro analysis, then a mouse model could be used to confirm the 
activity. 
In this study, a model system was set up usmg two cell lines 
derived from the mouse mid-pregnant mammary gland. One of 
these (CommalD) expresses the endogenous Ese-2 gene in vitro, 
while the other (HCl 1) does not (Figure 5.1) (see also Langley, 
1999). The Northern blot shown in Figure 5.1 highlights the 
existence of endogenous Ese-2 mRNA transcripts in the CommalD 
cell line, as well as in mouse mammary gland tissue (17 day 
pregnant). It is notably absent from the HCl 1 cell line (at least at 
this level of sensitivity). Both the 1.5 and 2.5kb bands are detected, 
though the smaller band is much weaker. The discrepancy in size 
between the Comma 1 D and mammary gland band may be due to 
the presence of salt in some samples. There may also be two bands 
present around 2.5kb, which may correspond to 2.4 and 2.6kb as 
seen in the human form of ESE-2 (Oettgen et al., 1999b). This is 
discussed in more detail at the end of the chapter. 
For the purposes of this study, approximately 850bp of DNA 5' to 
the major transcription start site is referred to as the proximal 
promoter and was studied first. This length of sequence is purely 
arbitrary, allowing for a convenient location for deletion constructs 
to be designed based on restriction sites and potential binding sites 
of interest. 
Following the proximal promoter study, enhancer regions were 
searched for. Potential sites for enhancers are often further 5' and 
in some cases in the first intron. Both of these possibilities were 
examined. 
In keeping with the proximal promoter and enhancer theory, Elk-1 
(an Ets transcription factor) was recently identified as having good 
proximal activity in vitro within -43 / +63bp of the major initiation 
site, showing a 10 fold increase in activity over a vector only 
control (Lehmann et al., 1999). This activity increased over 2-fold 
when the promoter construct was extended to 480bp. The addition 
of 700bp of 5' promoter sequence to the first intron (679bp) showed 
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a further 2-fold increase in activity. This represents an overall 
increase of 40 fold above the vector alone. Elements in the Elk- I 
promoter include a TATA box at-25, which corresponds to a region 
of DNase 1 hypersensitive chromatin. A second DNase 1 
hypersensitive region was isolated in the first intron, which may be 
the location of important factors responsible for increasing the Elk-
I in vitro activity. 
Another example is that of ETS-2, another ets transcription factor 
member. Its promoter activity was studied in HeLa cells using a 
series of deletion constructs (Mavrothalassitis et al., 1990). The 5' 
boundary for the proximal promoter and maximal activity was 
found to be 159bp from the major start site. Sequences further 
upstream between 890-1460bp were found to be dispensable for 
ETS-2 promoter activity. Multiple elements exist between 1460-
1599bp, which may play a role in the regulation, seen as a loss in 
activity when this region is removed. 
This chapter describes studies of first, the Ese-2 proximal 
promoter, second, the 5' region, which may harbour enhancers and 
finally the first intron. Many problems were encountered with all 
stages of this analysis, from the cloning to the transfection. Finally 
the analysis of these results will be discussed. 
In addition to these transient assays, a stable transfection was 
performed and results from that experiment are detailed. In an 
attempt to increase or modulate promoter activity in some way, the 
effect of the hormones ~-estradiol and progesterone were 
examined. This was analysed in relation to the expression of 
chloramphenicol acetyltransferase (CAT) by several of the Ese-2 
promoter constructs. These hormones were chosen as they have a 
similar expression pattern to Ese-2 in the developing mouse 
mammary gland. These results are reported, along with a serum 
induction experiment at the end of the chapter. Finally to 
supplement the results given m the chapter, a DNase 
hypersensitive assay is discussed with some preliminary results 
that support an enhancer region in the first intron. 






Figure 5.1 Expression of Ese-2 in HCll and Comma1D cells 
Northern blot analysis of RNA from HCl 1 (HC) and CommalD (CD) 
cells. The 2 .5 and 1.5 kb Ese-2 fragments are marked to the left of 
the diagram. The ethidium bromide stained gel showing the 18 and 
28s rRNA is to the right (in the same order) of the Northern blot 
(not to scale) . 
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5.2 Results 
5.2.1 Ese-2 proximal promoter analysis 
(a) Construct design 
In order to examine whether or not the Ese-2 proximal promoter of 
approximately 850bp contains a functional promoter, constructs of 
the gene were tested in a cell culture system. Five deletion 
constructs of this region were generated to ascertain the minimal 
sequence necessary for transcriptional activity. The promoter 
fragments were inserted upstream of the chloramphenicol 
acetyltransferase-coding region (CAT) 1n a modified pBLCAT2 
(Promega) vector. pBLCAT2 normally contains a minimal thymidine 
kinase (tk) promoter, which was replaced in the construction of the 
deletion plasmids by Ese-2 promoter sequence. The vector also 
contains ampicillin resistance and the SV40 polyadenylation 
sequence. 
Deletion fragments were based on the presence of suitable 
restriction sites as well as the location of potential transcription 
factor binding sites. The 3' end of each fragment was a BssHII site, 
which falls midway through the first untranslated exon, 19bp after 
the major transcription start site. To simplify cloning, the BssHII 
site and another identical site further 5' were cleaved and the 
resulting 2kb fragment cloned into pBluescript II KS (Statagene). 
This allowed an Xhol digest to free the 3' end such that it would 
make a compatible ligation with the pBLCAT2 vector, when also 
cut with Xhol. 
The longest fragment included in this analysis was about 850bp 
with a PvuII restriction site at the 5' end, leaving a blunt end 
(construct 5) (Figure 5.2). It was excised from the pBluescript II KS 
vector using Xhol and PvuII and inserted into a pBLCAT2 vector 
that had been previously digested with XbaJ., Kienow blunt ended 
and Xhol digested. The digestion of the pBLCAT2 vector results in 
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the removal of the minimal tk promoter sequence. Further 
deletions were made with Barn.HI at approximately 500bp 
(construct 4) and EcoRI at 200bp (construct 3). These fragments 
were released in a similar fashion using BamHI-Xhol and EcoRI-
Xhol respectively. They were then cloned into the pBLCAT2 vector 
that had been digested with the same enzyme pairs. Two short 
deletions were also included subsequently to identify a non-active 
promoter. These were made by PCR amplification. Firstly a 76bp 
construct was generated by PCR amplification from a 5' primer 
'Forward + l' (sequence given in Chapter 2) that anneals at -50bp 
in relation to + 1, and 3' sequence primer (5' Seq.) that anneals at 
position + 1. This was subcloned into the pGEM-TEasy (Promega) 
vector and subsequently into the pBLCAT2 expression vector 
(construct 2). Later a 39bp PCR extension product was amplified 
from primers 1.11(1) and 5' sequence (encompassing -22bp to 
+ 17bp) and excluded the first GATA-1 site. Again this PCR 
fragment was cloned into pGEM-TEasy initially and then pBLCAT2 
(construct 1). The constructs are depicted in Figure 5.2. 
Finally, a negative control plasmid was constructed by digesting 
the pBLCAT2 vector with Bglll and Barn.HI, and religating these 
compatible restriction sites. This deleted the minimal tk promoter 
and hence is an empty expression vector containing no promoter 
sequence (construct 0). 
All constructs were confirmed after cloning to be correct by full 
length sequencing across both ligation boundaries. 
The potential transcription factor binding sites were discussed in 
Chapter 3. For the proximal promoter, the longest construct (5) 
encompasses the majority of the sites shown in Figure 3. 7. These 
include YYl, GATA-1, NFKB, STAT, Ets, Ap-1 and others. As the 
constructs are shortened, more sites are lost so that construct (4) 
does not contain the YYl or NFKB sites. For construct (3), the sites 
included in the sequence are Ets, C/EBPP, GATA-1, a single Spl-
GC box, and multiple Ap-1 elements. Construct (2) only contains 
the first Ap-1 and GATA-1 sites. 
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(b) Transfection of the constructs 
To obtain the best in vitro representation of the in vivo system, 
several cell lines were used. First, Comma1D, a mouse mammary 
gland cell line from a mid-pregnant animal was studied (Danielson 
et al., 1984). Comma1D was found to express Ese-2 mRNA, and 
was therefore considered a good model system. Second, a derived 
cell line from Comma1D, called HCl 1 was tested (Ball et al., 1988). 
HCl 1 was isolated from the Comma1D mouse mammary epithelial 
line as a single cell clone that had high transfection efficiency and 
retained the ability to be induced by the lactogenic hormones. 
HCl 1 had the added advantage of growing well and being induced 
on a plastic surface (Ball et al., 1988). Comma1D also appears as a 
mixed population of two cell types when viewed under 
magnification. This was the best cell culture model available, 
though these lines do not produce a full spectra of milk proteins. 
Analysis by Langley ( 1999) and in this study found HC 11 did not 
express endogenous Ese-2 (Figure 5.1). The reason for this is 
unknown, though may be due to the lack of a transcription factor 
or a sequence mutation in the promoter or other critical location, 
or aberrant RNA processing for example. HC 11 cells replicate more 
quickly than Comma1D cells, show higher transfection efficiency 
and appear more robust under cell culture conditions. The 
differences between HCl 1 and Comma1D did not appear to affect 
the major activities of the constructs, though some differences were 
seen and are discussed later. Together, these two lines provided a 
suitable model system for examining the in vitro activity of the Ese-
2 promoter constructs. Cell lines were used with passage number 
below 30 to ensure the characteristics of the cell line were 
unaltered. Further to these lines, a human breast tumor cell line 
was also used, T47D (Keydar et al., 1979). However, transfection of 
this line using either Fugene6 (Roche) or Lipofectamine 2000 
(Invitrogen) failed to give detectable levels of transfection and this 
experiment was curtailed. 
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The deletion constructs were co-transfected with a control reporter 
plasmid pCHl 10 (Promega), which allowed measurement of ~-
galactosidase activity that could be used to normalise differing 
transfection efficiencies, explained further in section 5.2. lc. 
Initially, transient transfections were performed usmg 
Lipofectamine 2000 (LF2000)(1nvitrogen). The exact protocol is 
given in Chapter 2. LF2000 is a mixture of lipids and other 
components that are complexed to the DNA to be transfected. The 
cells are more susceptible to taking DNA up when it is packaged 
into highly condensed particles. Moderate success was achieved 
with this transfection system, though better results were acheived 
using Fugene6 (Roche). LF2000 often resulted in cytotoxicity, 
killing up to 80% of plated cells (data not shown). The method was 
successful in the tansfection of constructs for stable integration, as 
detailed in section 5.2.10. 
Fugene6 is another proprietary blend of lipids and other 
components that also increases transfection efficiency. The 
procedure of transfection is very similar to that of LF2000 as 
described in Chapter 2. DNA and Fugene6 ratios were optimised in 
several preliminary experiments to obtain the consistently highest 
level of transfection. No signs of cytotoxicity were seen with 
Fugene6, however the efficiency of transfection did vary between 
experiments and in some cases single results or whole experiments 
were discarded when variance was great (data not shown). 
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Exon 1 
5' Ese-2 sequence Intron 1 
----------------------111----
-2630bp t BssHII 
PCR-39bp -I (1) 
PCR-76bp -I (2) 
EcoRI-200bp I (3) 
BamHI-SOObp I (4) 




tk CAT SV40 
Negative construct ---~---~I·········· (0) 
Figure 5.2 Diagram of deletion constructs (0),(1),(2),(3),(4) and 
(5) The Ese-2 5' region is represented in the line above the 
constructs. Exon 1 and the BssHII restriction site are marked. The 
constructs extend in the 5' direction and include 30bp of exon 1 
(untranslated), and are not drawn to scale. The pBLCAT2 vector is 
outlined below the constructs, showing the tk promoter, which is 
replaced in the constructs at the XhoI site and the CAT and SV40 
polyadenylation coding sequences. The negative construct (0) is 
shown below, with no tk promoter sequence. 
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(c) Control and CAT assays 
Transiently transfected cells were harvested after 48 hours in a 
lysis buffer compatible with the type of assay to be performed. CAT 
was measured either by the ELISA (Roche) protocol or the 
traditional 14c thin layer chromatography method (TLC). Initially 
the ELISA method was used, but after multiple repeat experiments 
results were characterised as having low activity, and variances 
between duplicates and experiments were seen to be high. To 
ascertain if this was an artefact of the assay system and not a real 
result, the thin layer chromatography method was performed. This 
method allowed the visual detection of activity and was found to 
give more reproducible results between experiments and within 
duplicates. Once this method had been established, it was used for 
the remainder of the experiments. At a later time, the ELISA 
protocol was repeated and found to give similar data to that of TLC, 
suggesting the earlier unreproducible results were an artefact of 
the experimental procedure. 
Once the cells had been extracted into lysis buffer, control assays 
were performed. A BCA protein determination assay (Pierce) 
allowed the protein content per well to be standardised, so that any 
large deviances would be corrected for or with extreme cases 
discarded, and hence each well would represent the same amount 
of protein (and cells). This assay usually resulted in similar protein 
levels indicating consistent cell death or other disturbance in cell 
growth. There were no trends for any construct to have 
consistently higher protein levels. This indicates the results were 
due to CAT differences and not cell numbers. The use of a control 
with no transfected DNA also ensured protein was due to cell 
number alone. 
A P-Galactosidase (P-Gal) assay was also performed, usmg the 
substrate ONPG in a solution of BME and PBS (see Chapter 2 for 
methodology). The yellow end product was quantified by a 
microtiter plate reader at 405nm. This assay was used as a control 
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for transf ection efficiency. In many cases, differences 1n 
transfection efficiency were seen and in cases where differences 
were great, the experiment was discarded. For example, if the 
control without DNA gave a reading equal to or above one of the 
promoter constructs, then this result would be omitted. In some 
cases the whole experiment was discarded if the overall ~-Gal 
transfection efficiency was lower than a non-transfected control 
(data not shown). 
The result from the protein assay was used to standardise the 
amount of extract used in the CAT assay. The ~-Gal transfection 
efficiency control was corrected for after quantification of CAT. 
Both CAT methods are given in Chapter 2, and the principles are 
explained below. The CAT ELI~A protocol is based on pre-bound 
antibodies (to CAT) on a microtiter plate, which bind any CAT 
enzyme from the cell extract. A digoxigenin labelled antibody to 
CAT is then bound, followed by an antibody to this complex, which 
is conjugated with peroxidase. The substrate for peroxidase is 
added, resulting in its cleavage by any bound enzyme and yielding 
a coloured end-product that can be measured by an ELISA plate 
reader at 405nm. The assay is in kit form from Roche Diagnostics, 
with preparation involving the dilution of lyophilised antibodies 
and solutions. 
In comparison to ELISA, the radioactive CAT assay (Promega) 
quantifies CAT m the cell extract by transferring the n-Butyryl 
group from the cofactor (n-Butyryl Coenzyme A) to 14C-
chloramphenicol. This butyrylated radioactive product runs with a 
faster Rf value along a thin layer chromatography plate. The 
converted product can then be quantified by cutting the product 
from the plate and scintillation counting. This method gave an 
accurate quantification unaffected by saturation values often seen 
in overexposed autoradiographs analysed by densitometry. An 
example of an autoradiograph of a completed thin layer 
chromatography plate is shown in Figure 5.3(A). 
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Table 5.1 CAT assays or HCll cells transfected with the 
proximal promoter constructs (experiment H-6), in duplicate 
indicated as a/b. 
Construct BCA 13-Gal I4C Correct Average Fold 
data data count ed 14C I4C(a&b) induction 
Sa 0.244 0.155 219 327 393 3.0 
Sb 0.247 0.149 320 459 
4a 0.252 0.136 352 461 391 3.0 
4b 0.301 0.134 249 321 
3a 0.253 0.156 2160 3240 2946 22.2 
3b 0.238 0.15 1840 2653 
2a 0.306 0.16 127 195 178 1.3 
2b 0.199 0.151 111 161 
1 a 0.269 0.117 156 175 162 1.2 
1 b 0.238 0.116 133 149 
Oa 0.268 0.107 148 152 132 1 
Ob 0.249 0.111 106 113 
No DNA a 0.275 0.088 N/a N/a N/a N/a 
No DNA b 0.298 0.092 N/a N/a 
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From the TLC experimental results depicted in Figure 5.3, the 
highest activity is seen with construct (3), at about 22 times 
greater than the negative background level. This is significantly 
(95% level) different from the negative construct (0) and also from 
all other deletion constructs. Construct (1) is only marginally but 
not statistically significantly above the negative. Also, construct (2) 
shows only a slight increase over construct (1), though again not 
significant compared to the negative. While the lengthened 
proximal sequence of construct (3) gives increased activity, a large 
decrease in activity is seen with the longer constructs (4 and 5). 
Even so, a 5-6 fold level of activity over the negative is seen with 
these two constructs, which is significant at the 95% level. 
(Statistical data given in Appendix 3) 
Differences between the TLC and ELISA methods of detecting CAT 
activity are small. For both the trends were the same, _with 
construct (3) showing a clear increase in activity. A difference 
between methods is seen in the actual level of induction relative to 
the negative control for each construct. For constructs (4) and (5), 
both methods show an approximate three-fold increase in activity 
over the negative construct (0). Similarly for the constructs ( 1) and 
(2), the induction in activity is only 1-2 fold greater than the 
negative control when measured by either ELISA or TLC. The main 
discrepancy was for construct (3), though the result is still a clear 
induction for this construct compared to the other constructs, 
shown by both methods of detection. These discrepancies were not 
evaluated to be significant given the limitations of the methods of 
analysis. 
The results shown for one experiment are representative of the 
accumulated data set of several separate experiments shown in 
Figure 5.4 and are discussed further as accumulated data. The 
accumulated data set is shown as individual experiments 
superimposed on the same graph. This was the chosen method 
rather than calculating an average over all the data, allowing for 
individual variances between experiments to be evaluated. 
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(A) CAT TLC results (H-6) 
Butyrylated 14C 
Un-butyrylated 14C 
5 4 3 2 1 0 Construct No. 
(B) ELISA results (H-6) 
Construct B-Gal ELISA Corrected Averaged Fold 
result CAT a/b induction 
over 
negative 
Sa . 155 0.454 0.66 0 .656 2 .6 
Sb . 149 0.470 0.65 
4a . 136 0 .577 0 .73 0 .724 2 .8 
4b .134 0 .571 0 .72 
3a . 156 1.648 2.4 2.368 9.3 
3b .15 1.665 2.33 
2a .16 0.281 0.42 0.408 1.6 
2b . 151 0 .281 0.40 
la .117 0.255 0 .28 0.283 1.1 
lb .116 0.264 0.29 
Oa .107 0 .257 0.26 0.255 1.0 
Ob .111 0 .244 0 .25 

























Figure 5.3 Analysis of a single HCll experiment (raw data given 
in Table 5.1). (A) Autoradiograph of the thin layer chromatography 
plate showing I4C chloramphenicol results. The un-butyrylated 
chloramphenicol is at the bottom with the butyrylated form 
running faster up the plate. The solvent direction is from bottom to 
top. (B) Tabulated results from the ELISA method of the same 
experiment. (C) Graphical representation of both ELISA and TLC 
results for each construct after corrections have been made and 
duplicates have been averaged. Results are shown as fold 
induction over the negative control (construct 0). 
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In a single experiment (Figure 5.3C for HCl 1) the difference 
between the negative control and the promoter constructs is clear. 
However, over the course of the experimentation, two different 
negative control plasmids (both with the minimal tk promoter 
deleted), were found to give varying results. In initial experiments 
the first negative construct gave a high CAT background activity 
(approximately equal to that of construct 5). Data was not 
reproducible for this construct, although the expression of the 
promoter constructs displayed a similar pattern to that finally 
achieved. This negative vector was sequenced to ensure that the 
promoter sequence had indeed been removed. Later, a new 
negative control construct was made. This negative construct was 
designed by using different restriction sites to remove more of the 
sequence around the minimal tk promoter (construct 0). As seen in 
the results in Figure 5.4, it had a very low background activity. 
Where the negative control gave some activity, the lowest activity of 
any other construct was used as the baseline. (Construct 1 gave 
activity similar to the new negative construct and was therefore a 
suitable negative control). 
The complete set of data from the CommalD line represents six 
experiments, though for construct (1) it is representative of only 
two. This was due to a bacterial infection causing cell death in 
several experiments. A new preparation of DNA was made and 
used for the remainder of the experiments. The trend seen in 
Figure 5.4A indicates that construct (1) was not sufficient for 
proximal promoter activity. However, the addition of 30bp to 
construct (2) gives near maximal activity. The three mid-sized 
constructs (2, 3, 4) all show high activity relative to construct (1) 
and the negative control (0), while a decline is seen in the extended 
construct (5). 
The data set representing the HC 11 cell line shows a similar trend 
for highest activity in construct (3). Two of the six experiments 
show very high activity for this construct compared to construct 
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(C) CommalD experiment C-6 
.__ "C butyrylated 
Construct No. 5 4 3 2 1 0 
(D) HCl 1 experiment H-2 
14C butyrylated 
Construct No. 5 4 3 2 1 0 
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Figure 5.4 Accumulated data from CommalD and HCll cell 
lines transfected with the proximal promoter constructs (A) 
Comma 1 D experimental results from six separate experiments (C 1-
C6), where duplicate samples were averaged. Each experiment is 
graphed as fold induction over the negative construct (0). (B) 
Graphical representation of the results from six experiments 
performed in HCl 1 cells (Hl-H6), transfected with the proximal 
promoter deletion constructs. Duplicate samples were averaged 
and the individual experiments plotted. All results were measured 
by TLC CAT assay. Lines connecting values on the graphs are not 
representative of intermediate values but are an indication of each 
data set. (C) TLC plate result from CommalD experiment C-6. The 
constructs are listed below the plate, and the solvent ran from 
bottom to top. (D) TLC plate result of experiment H-2 in HCl 1 
cells. 
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(0), while the level of activity falls sharply m both shorter and 
longer constructs. 
The overall level of induction between CommalD and HCl 1 cell 
lines differs dramatically. CommalD cells respond slowly to 
transfection, showing very low levels of DNA uptake. This cell line 
also has a longer doubling time, resulting in lower numbers of cells 
expressing the transfected construct. Within the HCl 1 line, the 
condition of the cell population appears to vary between 
experiments. In experiments H-4 and H-5 the induction of 
construct (3) was much greater than seen in other experiments 
(50-80 fold compared to 5-20 fold). Whether or not the high level of 
induction is a gross overestimation of activity is difficult to explain 
as all conditions of the experiment were kept as constant as 
possible. The major difference was most likely a reflection of the 
status of the cells on the day of the experiment. 
The next part of the chapter sets out the findings from studying the 
distal 5' promoter region. Sequences further beyond the proximal 
promoter may contain enhancer elements that may be capable of 
increasing activity to account for the biological levels observed zn 
VlVO. 
5.2.2 Regulation of Ese-2 promoter activity including 
the distal 5' promoter region 
(a) Construct design 
In order to examine sequences outside the proximal promoter, a 
further three deletion constructs were generated. From the original 
clone Sacl4.9kb (see Figure 3.1) a total of 2.6kb of 5' sequence was 
isolated. Again, the new constructs were based on the location of 
suitable restriction sites that divided the sequence into appropriate 
sizes. An Xbal site in the pBluescript II KS vector was used to 
generate the full 2.6kb construct (construct 8, shown in Figure 
5.5). This was cloned into the pBLCAT2 expression vector at sites 
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Xhol-Xbal. Similarly, the next construct of 1.7kb total length 
(construct 7) was excised from another Xbal site within the 
promoter sequence. The third construct was generated from an 
EcoRV digest, which gave a construct size of 1.3kb (construct 6). 
This was cloned into the expression vector that had been digested 
with Xbal, Klenow blunt ended and digested with Xhol. Cloning of 
these constructs was relatively straight- forward and they were 
confirmed to be correct by sequencing from each end across the 
ligation boundaries. Two preparations of each construct were made 
and purified by Qiagen maxiprep column to ensure their purity. 
(b) Transfection of the constructs 
Transient transfections were performed for the distal constructs in 
the same manner as for the proximal constructs. Both HCl 1 and 
Comma 1 D cell lines were transfected with Fugene6 as the 
transfection agent for all experiments. A summary of the results is 
given in Figure 5.6 representing the data from a set of seven 
(CommalD) or six (HCl 1) experiments, with each construct 
transfected in duplicate and the duplicates averaged. 
When averages were calculated from the seven CommalD 
experiments of distal Ese-2 constructs, no significant difference 
(95% level) was detected between any construct and the negative 
construct. For the six HC 11 experiments, averaged results showed 
a significant difference at the 95% level, for construct (6) and (7) 
above the negative construct. 
For HCl 1 experiments, a 7-10 fold average increase was seen for 
all distal constructs over the negative, though the error between 
experiments is high. Again in the HC 11 experiments, two separate 
experiments show much higher levels of activity than other 
experiments. These differences are most likely due to differences in 
the cell culture from day to day. 
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5' Ese-2 sequence Exon 1 Intron 1 
II 
-2630bp t BssHII 
EcoRv-1. 3kb I (6) 
XbaI-l.7kb I (7) 




tk CAT SV40 
Figure 5.5 Deletion constructs of the distal 5' promoter The 
full length of 5' sequence is depicted above the constructs, with 
exon 1 represented by the black box, and the cloning site of BssHII 
indicated by the arrow. The constructs are not drawn to scale. 
Below the constuct representation is an outline of the expression 
vector, the arrow points to the location of the XhoI site used m 
cloning. Each construct is numbered to the right of exon 1. 
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(C) CommalD experiment C-6 
"c un-butyrylated 
Construct No. 8 7 6 0 
(D) HCI 1 experiment H-6 
~ "c un-butyrylated 
Construct No. 0 8 7 6 
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Figure 5.6 5' distal promoter construct results for both HCll 
and CommalD cells (A) A graph of distal promoter results from 
seven CommalD cell experiments (C2-C8), shown with respect to 
the level of induction above the negative control. (B) HCl 1 
experimental results from six separate experiments (Hl-H6), 
represented as level of induction over the negative control. (C) An 
autoradiograph of a thin layer chromatography plate with samples 
from experiment C6. Lanes are marked below the autoradiograph. 
The solvent direction is from bottom to top. The butyrylated and 
un-butyrylated chloramphenicol forms are indicated by arrows on 
the right. (D) Autoradiograph of a thin layer chromatography plate 
of samples from an HCl 1 experiment (H6). 
In summary, the Ese-2 deletion constructs spanning 2.6kb of 
promoter sequence reveal a region of potential regulatory 
importance. This is located between 76bp and 200bp 5' of the 
transcription start site, where the activity of construct (3) was 
found to be significantly different from each of the other constructs 
(for the HCl 1 cell line). This region appears to be the only 
potentially significant location within the 2.6kb analysed in vitro. 
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5.2.3 Regulation within the first intron of Ese-2 
To look for further regulatory elements, the first intron of Ese-2 
was studied. Other studies have shown Intron 1 as a potential site 
of regulation, including for the Ets factor Elk-1 (Lehmann et al., 
1999), the mouse connexin40 gene (Seul et al., 1997) and the a-
fetoprotein gene (Scohy et al., 2000). 
(a) Construct design 
The ninth construct was generated to contain the entire first 
intron, the first exon and 5' promoter sequence as far as 2.6kb, 
where construct (8) finished. It contains a total of 9kb of sequence. 
It also contains a mutation in the ATG start codon in the beginning 
of exon 2, to ensure that translation is initiated from the ATG 
codon present in the pBLCAT2 expression vector. Primers were 
designed at each end of the region for the construct (see Figure 
5.8). The 3' primer contained a mutation at the ATG, changing it to 
TTG (primer exon2ATG*mod.), and an engineered XhoI site for 
cloning. The forward primer (Far 5' Sad) encompassed a Sad 
restriction site for cloning. PCR was performed as described in 
Chapter 2 using the Elongase system (Roche) for amplifying long 
products. This amplification did not initially work even after 
manipulation of conditions including magnesium concentration, 
annealing temperature, extension time and template concentration. 
Seven more primers were generated at the 5' end (Far5' -#30, -#50, 
-#84, -#104, -#146, Far5' SphI mod., Far5' Xbal) to achieve better 
annealing. Moderate success was achieved and a small proportion 
of a 9kb product was excised from an agarose gel from multiple 
PCR reactions that were accumulated. 
Attempts to clone this product were unsuccessful. Cloning directly 
into the CAT expression vector by digesting the PCR product with 
XhoI was limited by the very low concentration of digested DNA 
recovered. Cloning into the pGEM-TEasy vector (Promega) was also 
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limited by the tailing reaction required to generate enough product 
with suitable "A tail" for cloning. Further primers were generated at 
the 3' end to try and increase the yield of product. These were 
exon2ATG*mod.2 and exon2ATG*mod.Bglll. The first contained a 
different location for the Xhol site and the second contained a BgUI 
restriction site, which may digest better at the end of the fragment 
than Xhol. New 5' and 3' primers were set up in multiple reactions 
with combinations of each and the amplification identified several 
combinations of higher efficiency. These were Far5'-#51, -#104 and 
-Sphl mod., with exon2ATG*mod.2 and exon2ATG*mod.Bglll. 
Cloning was not greatly improved due to loss of product in pre-
cloning reactions. The transformation of the ligation was another 
crucial step where the intron fragment may have been lost or 
poorly transformed. Transformation was generally performed into 
chemically competent cells by heat shock. For construct (9), 
electroporation of the DNA was performed to enhance 
transformation efficiency. This resulted 
in many more clones, though still none of those selected and tested 
contained the correct sequence. Finally, using STBL2 cells 
(Invitrogen) transfected by heat shock, success was achieved. Many 
PCR reactions were accumulated with post-amplification 
modification and a very large amount ligated into the pG EM-TEasy 
vector. From pGEM-TEasy, the 9kb product was digested with Sphl 
and BgUI and cloned into the pBLCAT2 expression vector. 
(b) Transfection of the construct 
Several attempts were made to transfect construct (9) into HCl 1 
and Comma 1 D cells in the same way as for the other constructs. 
An equi-molar amount of DNA was co-transfected with pCHl 10 
using an optimised volume of Fugene6. No transfection was 
observed as evidenced by baseline l3Gal levels, and CAT activity in 
these experiments. However, other constructs in the same 
experiment showed high l3Gal and CAT activities (data not shown). 
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Figure 5.7 Intron 1 and negative construct results in HCll and 
Comma1D cells (A) Graphical representation of eight separate 
experiments of Comma1D cells transfected with construct (9) 
(C3,5-1 l). (B) Graphical analysis of six HCl 1 cell line experiments 
(Hl-H6) transfected with construct (9) and (0). All results are 
shown as relative to the negative construct. Coloured lines are 
used as a graphical device purely to differentiate data. 
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The preparation of new plasmids did reduce this problem and it 
appeared that one of these preparations contained some 
contaminant that inhibited both the construct and pCHl 10 
transfection. Using the new preparations, measurable transfection 
efficiency was obtained, though not comparable to that of the 
proximal and distal 5' constructs. Construct (9) was much larger in 
size than other constructs, being 13kb in total, whilst construct (8) 
was only 7kb. This size difference was considered to be a major 
factor contributing to the low transfection of the construct. 
Normalising for the construct (9) CAT activity in reference to the 
transf ection efficiency was not reliable as the pCH 110 transf ection 
may also have been affected. To avoid this, a volume of "junk" DNA 
was added to the shorter constructs to make the total 
concentration of DNA equal between transfections. Figure 5.7 
shows eight CommalD transfected lines and six HCl 1 lines. 
The activity from construct (9) containing the first intron, did not 
show any increased activity over the level seen with other 
constructs. In Comma 1 D cells the activity only marginally 
increased above the proximal promoter constructs. In the HCl 1 
cells the activity of construct (9) ranged between a single and 16 
fold increase over the negative construct. The large difference 
between experiments reflects the poor transfection, and other 
technical difficulties with the system. The size of construct (9) 
(13kb total) may have reduced the apparent activity of the 
construct, based on its low transfection efficiency. This is 
examined in the next section through the use of smaller constructs 
containing part of intron 1. This approach varies the plasmid size, 
intron size and potentially the RNA processing of the transcript. 
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5.2.4 Reduced intron 1 constructs 
(a) Construct design 
To reduce the size of the constructs, but retain some of the intron 
1 and proximal promoter, three constructs were generated. Each of 
these contained 500bp of proximal promoter sequence, equivalent 
to that of construct (4). They also contained between 1.5 and 3kb 
of intron 1 sequence directly attached to the proximal sequence, 
preceding the partial CAT gene in pBLCAT2. The constructs are 
depicted in Figure 5.8. Construct (10) contains the most 5' 
sequence from intron 1, and is continuous genomic sequence. 
Construct (11) was generated from 2.5kb of intron 1 sequence and 
the 500bp of proximal promoter, containing a gap in the genomic 
sequence. Similarly, construct (12) is not continuous, but contains 
the most 3' 2kb of intron 1 and approximately 15bp of exon 2 with 
a mutated ATG codon. Construct (10) was generated by releasing a 
BamHI 3kb fragment from construct (9) and re-ligating into 
pBLCAT2 digested with BamHI and Bglll (to remove the minimal tk 
promoter). The generation of this construct was not straight-
forward, appearing to be hindered by sequence within the 5' region 
of the first intron. Using STBL2 (lnvitrogen) cells and high ratios of 
insert to vector in the ligation, a single clone was correct from 
sampling over one hundred. 
Construct (11) was generated by subcloning the BamHI-Hindlll 
fragment into the pEGFP-Nl vector (CLONTECH) and later 
releasing it from this vector using the restriction enzymes Sall and 
Xhol. This allowed cohesive termini to re-ligate into construct (4) 
that had been linearised with Xhol. The orientation of this clone 
was random, but was later checked by sequence analysis to 
confirm the correct orientation was achieved. The 3' intron 1 
fragment of 2kb was also subcloned into another vector (pGEM-3), 
which allowed for its release at Sad and Xhol sites to be cloned in 
the same manner as construct (11) into the CAT expression vector. 
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(b) Transfection of the constructs 
Constructs (10), (11) and (12) were transfected into HCl 1 and 
CommalD cells as described in Chapter 2. Each cell line was 
transfected four times in duplicate with each construct, including 
the negative (construct 0). The results were corrected for ~Gal 
activity and averaged between duplicates. They are shown 
graphically in Figure 5.9. 
Overall very low levels of activity were observed for these 
constructs. The trend seen for both HCl 1 and CommalD cells 
showed that the activity generated by the complete intron and 
promoter (construct 9) was mostly accounted for by construct (12) 
(3' intron region). Again construct (9) did not transfect well, so that 
activity may be much higher than measured. 
Due to the shortening of the constructs, splice sites have been 
deleted. This may or may not be significant with respect to the DNA 
processing of the transcript. Construct ( 10) in particular has a 
splice donor site but no acceptor, which may cause aberrant 
splicing. Aberrant splicing is less likely to occur in construct (11) 
which has no splice sites, or construct ( 12), which has a splice 
acceptor but no donor. Analysis of the RNA would resolve this, by 
showing the size of the spliced products. The potential for aberrant 
splicing means interpretation of the results must be made with 
caution. 
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Figure 5.8 Deletion constructs (9), (10), (11) and (12) The full 
length genomic sequence is depicted at the top of the diagram by a 
line, with exons 1, 2 and intron 1 marked. Construct (9) 
encompasses the entire 5' region of 2.6kb and the 9kb region of 
intron 1, with a mutation of ATG to TTG at the start codon. 
Constructs (10), (11) and (12) contain 500bp of proximal promoter 
sequence and a segment of the intron. Construct (10) contains a 
splice donor site only, construct (11) contains no splice sites and 
construct (12) contains a splice acceptor site only. The dotted line 
represents deleted sequences. Each construct then has the CAT 
sequence immediately 3' followed by the remainder of the 
expression vector sequence. The size of the exons is not to scale. 
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5.2.5 Hormone supplemented cell culture 
In separate experiments usmg selected promoter and intron 
deletion constructs, transfected cells were treated with 
progesterone or estradiol. The effect of the hormone was studied in 
relation to the activity of the Ese-2 construct. These two hormones 
were chosen for their known role in mammary processes (Mepham, 
1987). Such hormones may play a secondary role in the regulation 
of Ese-2 as it is found at elevated levels in the mammary gland at 
stages of development co-inciding with the hormone levels. 
Cells were transfected as usual then treated with 1 o-7M 
progesterone or estradiol. The treatment was given 24 hours after 
transfection and cells were harvested 48 hours after this. Both 
HCl 1 cells and CommalD cells were included in experiments. 
Each line was transfected at least three times with the constructs 
(0), (4), (8), (9) and (12). These constructs were selected as a 
representative sample from all the constructs. Construct (9) 
contained the complete intron, and construct (12) had shown some 
activity as part of the intron sequence. Construct (4) contained the 
5' sequence used in the intron constructs and construct (8) was 
the largest 5' construct. 
The results of one experiment from HC 11 cells are shown in Figure 
5.10. Results from the CommalD cell line experiments did not 
show any difference in CAT activity for each construct with or 
without hormone. Between the constructs, the differences were the 
same as already observed. 
Results from the progesterone treated cells (Figure 5. lOA) show 
that the addition of progesterone may have had some effect on 
construct (12). All other constructs had a level of activity between 
untreated and treated cells. In a repeat experiment (data not 
shown) the level of activity was higher overall, but there was no 
difference between treated and untreated cells, even for construct 
12. 
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In the estradiol treated cells, no difference was observed between 
treated and control cells. This was verified in a repeat of the 
experiment (not shown). 
The endogenous Ese-2 level was not studied under the conditions 
described here. This may have provided useful information 
regarding the lack of effect of the hormones on the promoter 
constructs, and may be an avenue for future research. 
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Figure 5.9 Deletion constructs (9),(10),(11),(12) and the 
negative (O) (A) Graphical representation of five experiments 
performed in duplicate in CommalD cells (C7-Cl 1), with 
constructs (9),(10),(11) and (12). Each experiment is graphed 
relative to the amount of induction above the negative construct, 
which has been normalised to 1. (B) HCl 1 cell line experiments 
representing six separate experiments (H7 -H 12), where duplicate 
samples have been averaged. The results are calculated as fold 
induction above the negative construct. 
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Figure 5.10 Hormone treatment experiments in HCl 1 cells (A) 
HC 11 cells transfected with constructs (4), (8), (9), (12) and (0) 
followed by treatment of 1Q-7M Progesterone. The graph shows an 
averaged figure for each construct representing 2 duplicate 
experiments. Each construct was also assayed without hormone 
(blue bars). (8) Estradiol (1Q-7M) treated HCl 1 cells. Experimental 
conditions were the same as described for (A). 
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5.2.6 Effect of serum on Ese-2 deletion construct 
activity 
Several deletion constructs were tested in cell culture for their 
ability to respond to serum. As for the hormone treatments, only 
five constructs were tested for simplicity. These were constructs 
(0), (4), (8), (9) and (12). HCl 1 cells were transfected with each 
construct under normal serum conditions (8% FCS) and 16-20 
hours later the media was removed and replaced with a series of 
dilutions of media plus serum. These ranged from 0.1 % to 20% 
serum. The cells were harvested after 48 hours with the serum 
dilutions and assayed. Results from one experiment are shown in 
Figure 5 .11. 
The protein levels of each sample show that cell density is lower in 
those cells treated with lower percentages of serum. This was also 
reflected in transfection efficiency. Where there were fewer cells 
present, the pGal activity was lower. These factors were accounted 
for after the CAT activity was measured. Overall, four sets of stably 
transfected cell lines were analysed and when averaged the data 
showed no response to serum was occurring in the Ese-2 deletion 
constructs as examined in vitro. 
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Figure 5.11 Effect of serum on Ese-2 deletion constructs in 
HCll cells The data shown represents one of four experiments 
where each construct was tested in duplicate and the results 
averaged. Each line indicates the percentage of FCS in the media. 
Constructs tested were negative (0), (4), (8), (9) and (12). 
Chapter 5. Ese-2 promoter and enhancer activity 
176 
5.2. 7 Stable transfection of deletion constructs 
Differences have been previously reported between stable and 
transient transfection on the activity of constructs tested in cell 
culture (Berland and Chasin, 1988). Stably transfected cells give 
rise to clonal cell lines in which the transf ected target gene is 
integrated into chromosomal DNA, from which it directs the 
synthesis of a lesser amount of target protein (relative to 
transiently transfected cells). Stable transfection does result in a 
more natural chromatin configuration at a more normal copy 
number and doesn't overload cellular machinery. Stable 
transfection does have the advantage of removing transfection 
efficiency differences between transiently transfected cells of 
different experiments. This is the main reason for studying stably 
transfected cells. 
To extend the results obtained with the transient system used in 
the previous experiments, a set of stably transfected cells was also 
produced. The method for the transfection is given in Chapter 2. 
Stable transfection was performed for constructs (8-2) and (0) in 
HCI 1 cells. Five sub-lines from each construct were grown. The 
CAT activity results from one duplicate experiment are shown in 
Figure 5.12. 
Results from this experiment are consistent with those from 
transient experiments. High activity was observed in construct (3), 
which was reduced when the sequence was extended to construct 
(5). Due to technical difficulties with construct (4), no data is 
available for that construct in Figure 5.12. 
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5.2.8 DNasel hypersensitive analysis 
As another approach to search for important regulatory regions, 
DNasel hypersensitive analysis (OHS) was performed. DNasel 
hypersensitive sites represent regions where nucleosomes have 
been displaced by the binding of a transcription factor or by DNA 
unwinding proteins. Such regions are more sensitive to 
degradation by the enzyme DNasel, as they are more accessible 
and open to nuclease cleavage. 
DNA was extracted from HCl 1 and CommalD cells and digested 
with various concentrations of DNase 1. Following this the DNA was 
restriction digested (Sad) and separated by electrophoresis through 
an agarose gel. The DNA was transferred to a nylon membrane, 
and subsequently probed with labelled genomic fragments from the 
Ese-2 promoter and first intron regions. 
Difficulties with both the recovery of DNA and degradation of DNA, 
resulting from contaminating DNases limited the quality of the 
results. Figure 5.13 shows one example of DHS on HCl 1 and 
CommalD cells. The probe spanned approximately 850bp of the 
first intron, which hybridised to a 4.8kb Sad fragment. Increasing 
amounts of DNasel revealed the generation of a 1.6kb DNasel 
digestion product. 
The same pattern was seen in both HCl 1 and CommalD cells. The 
size of the product and probe indicate that the DHS region falls in 
the 5' region of the first intron, as explained in Figure 5. l3B. Only 
one fragment was generated even at higher DNase I concentrations, 
suggesting only one hypersensitive site lies in the region of this 
probe. Multiple probes were hybridised to several membranes, 
though most resulted in non-specific binding to regions such as 
the ETS domain or repetitive sequences, and were consequently of 
no use (data not shown). 
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Figure 5.12 Stably transfected HCll cells with Ese-2 deletion 
constructs (A) TLC plate visualised by autoradiography of different 
stably transfected cell lines, numbered below the figure. (B) 
Graphical analysis of the fold induction of each construct above 
the level of the negative construct. An experimental error occurred 
in the recovery of construct (4) hence it is not represented in the 
graph. 
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Figure 5.13 DNase hypersensitive analysis of HCll and 
Comma1D DNA (A) Autoradiograph of DHS showing both 
CommalD (left set of data) and HCl 1 DNA. The lanes are labelled 
above the diagram. M, 1kb marker labelled to the left of the 
autoradiograph; 0-60, DNasel concentration (µg/ml). Each sample 
of DNase treated DNA was digested with Sacl restriction enzyme 
prior to electrophoresis. Sizes of products are shown to the right. 
(B) Schematic diagram showing the position of the identified DHS 
site in the 5' region of the first intron. The position of the probe is 
indicated above the sequence, exon 1 is marked by the black box. 
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5.3 Discussion 
This chapter describes an investigation of the promoter and first 
intron region from the Ese-2 gene, for in vitro transcriptional 
regulatory activity. The proximal promoter (850bp of immediate 5' 
sequence) was predicted to function at a basal level of transcription 
whilst the distal promoter and first intron could harbour enhancer 
type elements. Enhancers and promoters affect transcription 
differently, with enhancers being responsible for increasing the 
probability of forming transcription complexes and hence 
increasing the rate of transcription. The promoter affects the half-
life of the transcription complex and the rate of re-initiation of 
transcription (Yean and Grall, 1997). The biological importance of 
the promoter is therefore dependent on other such elements, 
including enhancers. 
The use of the chloramphenicol acetyltransferase reporter system 
allowed a simple assay (either ELISA or TLC) to determine any in 
vitro promoter activity. The choice of the in vitro model was made 
over an in vivo option (transgenic mouse for example) due to time 
constraints and simplicity. The CAT gene was used as a reporter as 
no endogenous CAT activity is present in eukaryotic cells, and 
several methods have been described for its detection. The use of 
an in vivo model is limited in the time it may take to produce 
suitable animals with the desired transgene. This is reflected in the 
cost and examining larger numbers of constructs in vivo would be 
expensive. Once important elements have been located by an in 
vitro model, they could then be further investigated in vivo to get an 
idea of their biological relevance. As the in vitro system does not 
fully represent the biological situation, the results cannot be as 
accurate and many factors must be considered in such a system. 
The surrounding tissues and factors may play a role that cannot be 
replicated in a cell culture environment. 
The cell system used in this investigation included two lines from 
mouse mid pregnant mammary gland tissue. CommalD cells are 
Chapter 5. Ese-2 promoter and enhancer activity 
183 
responsive to the lactogenic hormones and are therefore considered 
to be a good representation of the murine mammary gland 
situation (Danielson et al., 1984). HC 11 cell line is derived from the 
Comma1D cell line, also expressing the endogenous ~-casein gene 
when induced in vitro (Ball et al., 1988). The HCl 1 line has the 
advantage of growing well on plastic culture dishes, while the 
Comma1D line requires a support. Interestingly, endogenous Ese-2 
mRNA transcripts can be detected by Northen blot analysis of total 
RNA in the Comma1D line, but not in the HCl 1 line. This may 
reflect a much lower level of expression in the HCl 1 line, as no 
expression was detected in other tissues such as the kidney or 
lung where Ese-2 expression has previously been seen (Zhou et al., 
1998). It may also reflect aberrant RNA processing, where the 
transcribed RNA is incorrectly processed. As seen in Figure 5.1, the 
Comma1D RNA expresses two transcripts of approximately 2.5kb. 
This is of interest as the human ESE-2 transcript is also detected 
as two bands (2.6 and 2.4kb) (Oettgen et al., 1999b). These were 
determined to have alternate promoter usage resulting in different 
first exons, causing the discrepancy in size. Such a possibility may 
also exist in Comma 1 D cells, though this was not further 
investigated. Neither has it been reported in mouse tissues. The 
possibility also exists for alternate promoter usage for the Ese-2 
gene in the mouse, as transcripts may be present in low levels and 
in tissues not yet examined. 
Within the proximal promoter deletion constructs there was a 
difference in activity of approximately 3.5-fold for the mid-sized 
proximal constructs (1-5) in Comma1D cells over the negative 
construct. The average difference for construct (3) compared to the 
negative construct (0) was calculated to be statistically significant 
to the 95% confidence level. The definite increase in activity in both 
HCl 1 and Comma1D cells indicates the presence of possible 
regulatory elements of importance existing within this region. As 
seen in Chapter 3, (Figure 2.7) a GATA-1, an AP-1 element and the 
putative TATA box are all located in this region and could account 
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for the increase in activity. Similarly, the decrease in activity seen 
between construct (3) and (5) may be the result of negative 
elements acting here. The decline in activity between these two 
constructs 1s statistically significant and many potential 
transcription factor elements are possible candidates here. 
The average of data from the proximal constructs from HC 11 
(Figure 5.48) experiments shows a significant change in activity 
within the proximal promoter region. Construct (3) showed a 20-
fold activity increase over the negative. In this context, a strong 
positively acting element appears to be located between construct 
(2) and (3). Several candidates for this element were identified by 
computer analysis including Ap-1, Ap-2, Sp-i/GC-box, C/EBPP 
and Ets as shown in Figure 3.7. No activity was seen for constructs 
(1) and (2) compared to the negative. Following the sharp increase 
in activity of construct (3), activity appeared to drop again with the 
extended constructs (4) and (5). The decline in activity when the 
sequence was extended 200bp upstream from construct 3 would 
suggest the presence of a strong negatively acting element located 
in this region. 
Analysis of each cell line here has shown some differences. Overall 
the scale of difference is marked, with HC 11 cells line showing up 
to an 80 fold increase over the negative control, but only a 6 fold 
increase for CommalD cell experiments. This difference in the level 
of activity is reflected in the remainder of the results. The 
difference between individual experiments may be due to the varied 
status of the cells on each experimental day. 
Most other proximal construct results are consistent between 
CommalD and HCl 1. Construct (2) indicates some discrepancy 
between HCl 1 and CommalD, where it is has a higher relative 
activity in CommalD. That is, construct (2) shows near equal 
activity to construct (3) in CommalD cells. In this case, the level of 
activity is then increased further 5' at construct (3). 
Overall, the results of the proximal promoter constructs expressed 
in vitro show a significant level of activity was seen over the 
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negative control. Whilst it is difficult to compare this level of 
activity to the in vivo biological level it may partially account for the 
increase seen in the biological mRNA expression as seen during 
pregnancy and lactation of the mouse (unpublished observations). 
The promoter constructs were extended further 5' to encompass a 
maximum of 2.6kb 5' of the + 1 transcription start site. These were 
divided into three separate constructs. Activity in CommalD and 
HC 11 cells was found to remain constant between these three 
constructs, with some small changes in activity seen. CommalD 
cell experiments showed an approximate 2-fold increase in activity 
over the negative. This was above the level of construct (5), but 
below the high activity of construct (3). In HCl 1 cells, the overall 
induction of the distal constructs ranged between experiments but 
averaged around a 10-20 fold induction. The level of activity 
between the three distal constructs did not vary greatly on average. 
This suggests there are no important regulatory elements in the 
regions between them. However, the level of activity is increased 
significantly from 0.85kb (construct 5) to 1.3kb (construct 6) which 
indicates some factor(s) is acting to overcome the repression seen 
following construct 3 at 200bp. The level of induction is significant 
only for HCl 1 cells and not CommalD. HCl 1 experiments H4 and 
H5 showed much higher levels of induction in most distal and 
some proximal constructs. This may be a feature of the cell 
condition on the day of experimentation, though the trend of 
results is retained. 
It is known that a large first intron can harbour sites capable of 
influencing regulation of transcription. Elk-1 is another ets 
transcription factor that has been shown to have strong positive 
regulatory sequences in the first intron (Lehmann et al., 1999). A 
similar approach was used in the current investigation to study the 
promoter activity, which, for Elk-1, was found to be increased 2-
fold when the first intron was included, over that of the proximal 
promoter activity. In the Elk-1 study, the intron was only 700bp 
and the longest construct a total of 1400bp. This may have been a 
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factor in the difference in results. The cell line analysed (RK-13) 
may also have been a more authentic replica of the tn vzvo 
situation, having strong Elk- I endogenous activity. 
Ese-2 contains a large first intron, which was examined firstly as a 
complete sequence including 2.6kb of 5' sequence and the entire 
intron of 6kb. This analysis resulted in only a small induction in 
transcription within the CommalD system. In HCl 1 cell culture 
the induction was seen to range between 1 and 16 fold. This range 
appeared to be due to a lack of transfection efficiency. Several 
different preparations were generated with little improvement in 
cell uptake. A likely reason for this may be the large size of the 
construct. Size limitations in transfection efficiency have been 
reported previously (Smith and Morris, 1991) (Hofman et al., 2000), 
where an inverse relationship was found between transfection and 
size of construct. 
One possible complication m the experiments, that was not fully 
appreciated at the time, concerned aberrant splicing due to 
inadvertent removal of donor and/ or acceptor sites in constructs. 
Clearly, the best way of checking for such complications would be 
to measure the size of the RNA transcripts produced from the 
transf ected construct. Moreover, given the large size of some 
constructs it is possible that various cryptic splice signals could 
complicate in vitro experiments of this nature, even in the 
presence of authentic splice sites. 
To determine if size was a limiting factor in the transfection and 
hence activity of the intron, three smaller constructs were made to 
span 500bp of proximal promoter and 2-3kb each of the intron. 
Transfection was not found to increase as expected with the 
reduction in size of the constructs. Sequences within the intron 
could possible interfere with transfection; anecdotal reports 
suggest that cloning problems can be experienced with some 
sequences. Sequence analysis_ of this region did not reveal repeat 
or secondary structure that may be responsible for such 
difficulties. The activity was measured and found to be low overall, 
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with a 1-2 fold induction over the negative. Construct (12) (3' 
intron region) appeared to have activity approximately equal to that 
of the total intron (construct 9) in these experiments and may 
therefore contain regulatory elements. The analysis has not 
eliminated the intron from containing important regions as 
technical difficulties could not be fully overcome. 
In the mammary gland, hormone levels fluctuate with the state of 
development. Specifically, progesterone is strongly expressed from 
the beginning of pregnancy and abruptly declines at parturition. 
Estrogen has a role linked to progesterone, though its expression 
mcreases gradually following pregnancy (Mepham, 1987; 
Hennighausen and Robinson, 1998;). 
The influence of progesterone on female mammalian physiology is 
well known (Clarke and Sutherland, 1990). Both progesterone and 
estrogen steroid hormones are found to control growth, 
differentiation and function of reproductive tissues and others via 
the control of gene expression. They also are known to influence 
the growth of tumours, especially of the breast and uterine tissues. 
As Ese-2 is highly up-regulated in the mammary gland at the start 
of pregnancy the effect of these two hormones was examined in 
vitro on the Ese-2 constructs. The concentration of progesterone 
and estradiol was experimented with to achieve a level suitable for 
the number of cells, without causing cell death. After several 
experiments it was clear that the in vitro system using a range of 
constructs was not responding to either hormone. A possible in 
vivo relationship between the hormone and Ese-2 not detected in 
vitro may still be possible. 
Following this analysis, the Ese-2 deletion constructs were 
examined in cell culture for a response to serum stimulation. 
Serum is important during cellular activities including tissue 
remodelling, by stimulating collagens and other proteins (Ihn et al., 
2001). A response to serum was observed for Ets-1 in HeLa cells 
(Majerus et al., 1992) and increases collagen gene expression via 
Spl phosphorylation (Ihn et al., 2001). The method for this 
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analysis was similar to that described by lhn et al., (2001), but did 
not result in any significant change in activity other than 
increasing general cell growth. 
The transfer and activity of foreign genes into cells is dependent on 
a number of parameters of the system. These include the type of 
promoter/ enhancer sequence, the level of expression and the type 
of expression (transient or stable). Transient expression in cells is a 
simpler procedure for obtaining a brief period of high expression. 
Stable expression is more laborious and results in an overall lower 
detectable level per cell transfected. The two types of expression 
have also been reported to differ in the regulation or expression of 
a transfected foreign gene (Berland and Chasin, 1988). 
All transfections performed in this study were by the transient 
method. To ensure the accuracy of the transient method, a set of 
stably transfected cells was generated. The harvested and assayed 
cells from these lines showed a similar pattern of activity for the 
tested constructs, confirming the transient method was a suitable 
substitute in this study. 
Overall, the use of the in vitro cell culture system may have limited 
the expression of the CAT reporter by the constructs compared to 
an in vivo model. Factors influencing the activity may include the 
transcription factors available within the cell system, signals 
lacking from neighbouring tissues or signalling pathways. 
Generally the cellular context plays an important role in the overall 
expression of a gene. 
Many studies have been carried out where an in vitro system was 
used to gain information. Results of such studies vary greatly, 
between no expression being observed, as in the Fli-1 ets gene, 
where 600bp of 5' proximal promoter did not increase activity in 
erythroid cell lines (Barbeau et al., 1996). Moderate levels of 
expression have also been observed. The 13-casein gene promoter 
contains positive and negative elements between -221 and -170bp. 
A deletion of -344 to -183 results in a 50 fold increase in basal 
activity of the reporter gene by the rat 13-casein promoter construct. 
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This is probably due to the disruption of an activator element 
(Groner and Gouilleux, 1995). Levels of expression several hundred 
fold greater than a negative control were seen with promoter 
constructs of the GABRB3 gene, associated with imprinted genetic 
disorders of the brain (Kirkness and Fraser, 1993). 
As an alternative method for defining important regulatory regions 
within the Ese-2 gene, DNase-1 hypersensitive analysis was 
performed. DNase-1 cleaves at exposed regions on the chromatin in 
a higher frequency than at other locations. As transcriptionally 
active regions are usually more exposed during transcription 
processes, DHS can identify regions of importance. 
Several problems were experienced with this technique, including 
low yield of DNA, degradation by DNases and non-specific binding 
of probes. Only one probe was successfully used to detect products 
of DHS (PstI-DraI 850bp). This probe was hybridised to reveal 
different preparations of DNA, digested with different restrictions 
enzymes and confirmed the location of a single DHS site. Due to 
the technical problems, other DHS sites cannot be ruled out. The 
presence of the DHS site in the 5' region of the intron does not 
correlate with the deletion construct results. Construct (10) (5' 
intron) did not show high activity, though this may not be 
representative of the in vivo situation. 
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Chapter 6. Final Discussion 
6.1 Introduction 
Gene expression 1s regulated by a complex combination of 
transcription factors binding to cis-regulatory elements in target 
genes. Elucidation of the underlying molecular mechanisms is 
necessary to better understand the complexities of transcriptional 
regulation. 
Ets proteins make up a transcription factor family which is known 
to be important in the regulation of transcription events involved in 
cell proliferation, differentiation, development, transformation and 
apoptosis. Determination of the regulatory mechanisms that 
control these factors would assist an understanding of the 
regulation pattern of their downstream targets. 
Neither the function nor the mode of regulation of the Ese-2 
transcription factor is known. 
This study was aimed at determining the important regulatory 
regions of the Ese-2 gene, in particular, the elements responsible 
for the specific temporal and spatial features of the gene. 
Expression of Ese-2 is restricted to epithelial tissues (Oettgen et al., 
1999b) and it displays an interesting pattern of temporal 
expression during the development of the mammary gland through 
pregnancy and lactation (unpublished observations by L 'Huillier et 
al.). This temporal and spatial pattern of expression implies that an 
important Ese-2 function may be in mammary gland tissue 
remodelling. It follows that knowledge of the regulation of Ese-2 
may help determine its role in such processes. 
Gene expression is most often controlled at the level of 
transcriptional regulation (de la Brousse and McKnight, 1993) but 
post-transcriptional and translational levels may also contribute. 
However, clues to temporal and spatial control are more likely to be 
found at the level of gene transcription, through cis-acting DNA 
binding elements. To date, studies of members of the ets 
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transcription factor family have focussed on transcriptional control 
and indicate that a complex array of factors operate at this level. 
In the twenty years since the v-ets gene was identified, over 30 
other ETS domain genes have been isolated. The extent of 
homology varies greatly in regions outside the ETS domain, making 
comparisons between important regulatory regions of multiple ets 
genes difficult. Individually, only a few ets genes have been 
analysed with the aim of identifying important regulatory elements. 
Of particular relevance to the current study was the 
characterisation of the human Elk-1 promoter by Lehmann et al., 
in 1999. In vitro cell culture assays in RK13 cells showed that 
approximately 1kb of 5' UTR sequence had a 10-fold greater 
activity over an empty expression vector. This reached a maximum 
of a 23-fold increase with 480bp of 5' sequence. Interestingly, when 
700bp of 5' sequence was combined with the complete first intron 
(another 679bp), activity was increased a further 2-fold. This data 
was supported by DNase hypersensitivity analyses that revealed 
two hypersensitive sites in this region. One spanned the TATA box 
in the proximal 5'UTR and the other, a site in the first intron 
contained binding elements for factors Egr-1 and SRF /TCF. Little 
is known of the function of Elk-1 although, as it is a ternary 
complex factor, it is likely to play a role in effecting a response to a 
certain stimulus, such as in differentiating monocytes (Lehmann et 
al., 1999). Thus, the potential for a modest degree of regulation 
within the first intron is shown by the Elk-1 study. In contrast to 
the Elk-1 study, the current investigation did not show a similar 
enhancement for Ese-2. Technical problems were encountered 
during analysis of Ese-2, and these may account for the overall 
lack of induction of the CAT activity by the promoter constructs. 
Conversely, the lack of activity may be a true reflection of the in 
vivo situation, with the main areas of regulation sited outside of 
those studied. 
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6.2 Preliminary Ese-2 promoter analysis 
Initial studies into the regulatory mechanisms of gene expression 
must first begin with the localisation and characterisation of the 
promoter DNA sequence. Thus, the first step in the current study 
was to isolate genomic DNA spanning the first exon and intron, 
and 2.6kb of 5' sequence. Analysis of the nucleotide sequence did 
not reveal consensus TATA or CAAT boxes. However, these 
elements are not necessary for, and do not necessarily define, a 
promoter. Indeed, several other elements have been implicated as 
having a transcription initiating role in TATA-less promoters, 
including YYl (Seto et al., 1991; Usheva and Shenk, 1994) Spl, 
Apl, ATF or TEFl (Gilinger and Alwine, 1993). Promoters without 
any such elements also exist, and are thought to initiate from as 
yet unidentified upstream elements (Novina and Roy, 1996). 
In the current study, the confirmation of the location of the Ese-2 
gene promoter came from primer extension analysis that identified 
multiple transcription start sites. The core promoter (approximately 
50bp), sited adjacent to the transcription start site is usually 
involved in temporal regulation, as in the Drosophila Alcohol 
dehydrogenase gene (Adh). Adh is transcribed from two different 
promoters (proximal and distal) controlled by discrete initiator (Inr) 
elements. Promoter usage represents different stages of 
development (Hansen and Tjian, 1995). Interestingly, the human 
ESE-2 gene is transcribed from two core promoters to produce 
slightly different transcripts. This may or may not have some 
relationship to its temporal (or spatial) regulation. Alternate 
promoters have not been identified for murine Ese-2, though they 
may be active at low levels in some tissues. 
The core promoter is not necessarily the only point of control for 
temporal or spatial expression, though these factors are most often 
independent of enhancer type activity. 
Crawford et al. (1999) examined a population of TATA-less 
promoters of Ldh-B genes and concluded that these regions did 
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bind transcription factors in vivo, which effected a change in 
transcription rates. Sequence variation in the population was 
found to be due to directional selection. The variation effected a 
phenotypic change, resulting from a transcription rate change from 
the proximal promoter. They concluded, on the basis of this 
combined molecular and evolutionary analysis, that the biological 
importance of the proximal promoter is relevant in the context of 
the whole genome. 
Sp-1 like sequences have previously been reported to affect 
transcription of proximal promoters by altering interactions among 
different transcription factors (Bigger et al., 1997). Specifically, in 
TATA-less promoters, Sp-1 binding has a critical role in 
transcription initiation (Zenzie-Gregory et al., 1993; Zhang et al., 
1994; Colgan and Manley, 1995; Block et al., 1996; Chen et al., 
1997a). The interactions between transcription factor IID (TFIID), 
Sp-1 proteins and other transcription factors usually effect subtle 
changes in expression (Wiley et al., 1992; Azizkhan et al., 1993; Al-
Asadi et al., 1995; Yean and Grall, 1997). Much larger variations in 
expression (around 10 fold or complete on/off control) are caused 
by upstream enhancers or tissue-specific regulatory elements, and 
these are important in determining patterns of temporal and 
spatial gene express10n (Guarente and Bermingham-McDonogh, 
1992; Patel, 1994; Ernst and Smale, 1995a; Ernst and Smale, 
1995b). 
In the context of the Ese-2 proximal promoter, the lack of a TATA 
box may be compensated for by the presence of Sp-1 and other 
sites. Indeed, studies have shown that the -25bp region 1s 
important for the initiation of transcription via binding of TFIID-
whether it be a TATA-less or TATA-box containing promoter (Wiley 
et al., 1992). The major difference is the affinity of the -25bp region 
for TFIID, and in TATA-less cases, the support of nearby sequence 
elements is necessary for the functional binding of TFIID. 
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The most proximal Sp-1/GC-box element in Ese-2 occurs at 
approximately -120bp, with two other Sp-1 sites found within the 
first 1kb of the 5' upstream region. 
As for other ets genes, Fli-l lacks typical TATA and CCAAT boxes, 
but contains sequences for elements such as Ap-1, Ap-2, EBS, 
GATA and GC-rich stretches (Barbeau et al., 1996). Transcription 
of Fli-l is initiated at multiple sites, as is predicted for a TATA-less 
promoter. Like Fli-l, ETS-l lacks TATA and CCAAT elements whilst 
containing many Ap-1, Ap-4 and Sp-1 sites (Jorcyk et al., 1991). 
On the other hand, human ELF-3 contains consensus sequences 
for TATA and CCAAT, and sites for Ap-1, EBS and NFKB (Oettgen et 
al., 1999a). Interestingly, the mouse Elf-3 sequence shows neither 
the TATA nor Ap-1 sites, in contrast to human ELF-3. 
In some cases the function of a TATA box may be replaced by a 
GATA motif. Originally, the GATA element was identified as an 
upstream cis-regulatory site in erythroid specific promoters (Evans 
et al., 1988). To date, four GATA factors have been isolated, with 
distinct patterns of expression (Ho et al., 1991; Lee et al., 1991; 
Arceci et al., 1993). The presence of a GATA element in the core 
promoter appears to play an inhibitory role in the interaction of 
both the basal transcription machinery and the promoter, and 
inhibits the initiation of transcription from the PF4 promoter (Aird 
et al., 1994). However, upstream GATA elements are capable of 
functioning as transcriptional activators, and several cases of a 
dual interaction, dependent on the distance between the GATA 
motif and TATA-binding-protein (TBP) binding site, have been 
reported (Ohkuma et al., 1990; Dostatni et al., 1991; Kaufman and 
Rio, 1991). Aird et al. (1994) suggest that a GATA motif must be 
"sufficiently upstream of the TBP binding site to preclude steric 
interference of pre-initiation complex formation". 
Interestingly, a GATA core motif is present m the antisense 
direction at approximately -30bp upstream from the major 
transcription start site of Ese-2. Whether this element (or others 
further upstream) are functional remains to be determined. In a 
Chapter 6. Discussion 
195 
study of the ets gene Fli-1, a GATA/EBS dual element was 
identified m exon 1, shown to bind GATA-1 and Spi-1, and had 
enhancer activity (Barbeau et al., 1999). 
The presence of multiple c/EBPP (CCAAT / enhancer binding 
protein) sites may prove important, as this factor has been reported 
to play a role in the development and differentiation of epithelial 
cells in the mammary gland. Ese-2 contains at least five c/EBPP 
consensus sequences in the first 1kb of 5' upstream sequence, 
with more further upstream. 
The c / EBP proteins are known to have broad regulatory functions 
and the isoforms (a, p, o, 1::) are expressed in overlapping patterns 
(Cao et al., 1991; Williams et al., 1991). Cell culture studies reveal 
that both a and p are strong regulators of cell proliferation and 
differentiation (Johnson and Williams, 1994). Of particular note is 
the developmentally regulated pattern of expression of a and p in 
the mammary gland. C / EB Pa is most highly expressed in virgin 
mouse mammary gland and at a slightly lower level during 
pregnancy. On the other hand, c/EBPP levels are lowest in the 
virgin state and increase throughout pregnancy (Robinson et al., 
1998). C / EB Po mRNA expression is normally low but increases 
dramatically at involution (Gigliotti and DeWille, 1998) and 
correlates with the growth arrest of mammary epithelial cells in 
culture (O'Rourke et al., 1997). Use of a mouse model deficient in 
the transcription factor c/EBPP has indicated a critical role for 
c/EBPP in both the proliferation and morphogenesis of epithelial 
cells in the mammary gland, and also for the differentiation of 
these cells to secretory cells during pregnancy (Robinson et al., 
1998). The Ese-2 mRNA temporal expression pattern is most 
dramatically regulated at involution with a sudden decrease in 
levels. As Ese-2 is known to be epithelial specific, with a possible 
role in tissue remodelling, the potential exists that one or more of 
the c/EBP isoforms may play a role in the regulation of Ese-2. 
Robinson et al. ( 1998) also hypothesise that c / EBPP is required for 
epithelial cell recognition of hormonal signals, and the appropriate 
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responses to extracellular signals (Robinson et al., 1998). This 
observation would support a role for c/EBP~ in the regulation of 
Ese-2. 
A recent publication on the transcription factor NFKB and its role 
in mammary epithelial apoptosis supports a relationship with Ese-
2 (Clarkson et al., 2000). In the mouse mammary gland a major re-
organisation of gene expression occurs during the transition from 
lactation to involution. This dramatic example of developmentally 
regulated epithelial apoptosis is correlated with changes in the 
expression of a number of transcription factors including Ap-1, 
STATs, Ets isoforms, c/EBP isoforms, NF-1 and c-myc (Strange et 
al., 1992; Feng et al., 1995; Furlong et al., 1996; Li et al., 1997; 
Gigliotti and DeWille, 1998; Neve et al., 1998; Chapman et al., 
1999). Involution is characterised by an increase in apoptotic 
events in the luminal epithelial layer of the lobulo-alveolar 
compartment following weaning (Strange et al., 1992; Lund et al., 
1996). This proceeds with the supporting basement membrane 
being proteolytically degraded and the gland remodelled to 
resemble its pre-pregnant state (Strange et al., 1992; Lund et al., 
1996). Such maintenance and survival of the secretory epithelia is 
dependent on extracellular signals from the basement membrane, 
cell adhesion molecules, lactogenic hormones and other factors 
(Feng et al., 1995; Boudreau et al., 1996; Lund et al., 1996; Li et 
al., 1997; Streuli and Gilmore, 1999). Mammary gland involution is 
divided into two stages. First, local stimuli result in activation of 
STAT3 (Liu et al., 1996; Philp et al., 1996), Bel-XL and Bax 
(Heermeier et al., 1996), down-regulation of milk protein genes and 
STATS (Liu et al., 1996; Philp et al., 1996), and an increase in cells 
undergoing apoptosis (Strange et al., 1992; Lund et al., 1996; Li et 
al., 1997). Second, in the following 48 hours, increases in 
metalloproteinase gene expression together with the degradation of 
basement membrane and remodelling of the gland are observed 
(Strange et al., 1992; Lund et al., 1996). 
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NFKB up-regulation is coincident with the increase in apoptotic 
cells in the mammary gland and the decrease of lactogenic 
hormones {Strange et al., 1992; Quarrie et al., 1996; Travers et al., 
1996; Li et al., 1997). Its expression is effectively zero during 
lactation, becomes evident 1 hour after suckling ceases, and 
reaches a maximum level at 3 days of involution. At 3 days of 
involution an increase in DNA-protein mobile complexes 1s 
observed, correlating to the increase in metalloproteinase activity 
and gland remodelling. 
NFKB subunits have been found in breast tumour and transformed 
mammary cell lines. Due to its role in negative regulation of 
apoptosis, its aberrant expression may contribute to mammary 
epithelial carcinogenesis through incorrect regulation of apoptosis 
in both developing and regressing mammary gland {Dejardin et al., 
1995; Nakshatri et al., 1997; Sovak et al., 1997). 
Ese-2 expression correlates negatively with both NFKB expression 
and the metalloproteinases involved in the degradation of 
mammary epithelia. Theoretically, there may be a relationship 
between the two transcription factors. Specifically, negative 
regulation of the Ese-2 gene by NFKB at involution may play a role. 
Sequence analysis has revealed the presence of two consensus 
NFKB sites within the proximal promoter region of Ese-2 and 
further sites within the first intron. 
The combined effects of factors working cooperatively also play an 
important role in the regulation of gene expression. Ap-1 and Ets 
are assumed to interact in the regulation of gene expression, as 
binding sites are often juxtaposed in promoter sequence. Also, 
proteins are able to act synergistically at a multimerised viral 
enhancer site {Wasylyk et al., 1990) and do so to regulate the TIMP-
l gene {Logan et al., 1996). The Transglutaminase-3 (TGM3) gene is 
regulated by Ets-1 and Sp-1 proteins in cooperation {Lee et al., 
1996). Since the identification of sites for Ets-1 in proximity to 
sites for Sp-1 and Ap-1 in the extracellular matrix protein- l gene 
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(Ecml), it has been hypothesised that these factors are important 
for its control (Smits et al., 1999). 
Another example of this cooperative function of factors is 
documented for the 92-kDa type IV collagenase gene (MMF9), 
which is important for extracellular matrix degradation. A 
PEA3/Ets site is located 7bp upstream of an AP-1 consensus 
sequence and mutation of either results in near complete loss of 
stimulation of this promoter by ras (Gum et al., 1996). These sites 
are not predicted to be sufficient for optimal expression of the gene 
with other identified sites such as Sp-1, GT-box, Ap-1 and NF1eB 
being implicated. When any of these sites throughout the promoter 
(600bp) were individually mutated, they all caused loss of gene 
expression. 
Futher, the urokinase promoter, which is also stimulated by ras, 
required the closely spaced PEA3/Ets and Ap-1 motifs for 
induction by the GTP binding protein (Lengyel et al., 1995). 
Ese-2 contains closely spaced sites for Ets and Sp-1, Ap-2, GATA, 
c/EBP and Ap-1. Given the wealth of data on cooperative 
interactions between such factors, it is likely that similar 
interactions are important for Ese-2, and function may relate to 
the matrix metalloproteinases or tissue inhibitors of matrix 
metalloproteinases. 
6.3 Human and mouse genome and EST analysis 
The publication of the draft human (and mouse) genome has given 
researchers another tool for studying gene structure, and provides 
vast quantities of information for use in the various branches of 
molecular biology. Not only does it pertain to the human, but it 
also combines information from other species. This is particularly 
useful in comparison studies of the genomic structure of 
orthologues. The release of the completed mouse genome draft 
sequence has further increased the depth of knowledge that can be 
gained. 
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Prior to the human genome sequence release, only the cDNA 
sequences of the human and mouse Ese-2 genes were known. The 
present study has provided several kilobases of mouse genomic 
sequence, and, in Chapter 4, comparisons have been made with 
that of the human. This comparison identifies several small regions 
of strong homology between the mouse and human, while the 
majority of genomic DNA is highly divergent. It was hypothesised 
that the regions of close homology (>80%) might be important 
regulatory locations. However, the deletion constructs analysed in 
the present investigation did not reveal this to be the case. The 
regions of homology spanned by the constructs did not show 
marked levels of enhanced or depressed CAT expression. Again, 
this may reflect a technical failing of the system and not be 
representative of the in vivo situation. 
The chromosomal location of human ESE-2 shows a group of 
adjacent genes that are similar to the syntenic block of the mouse 
chromosome 2 surrounding Ese-2. 
Alternative splicing of the human ESE-2 gene has been reported in 
the form of two isoforms produced by alternative promoter usage. 
The ESE-2a isoform contains 10 more amino acids at the N-
terminus than ESE-2b. This is thought to be species specific, as in 
the homologous gene of the mouse, the two transcripts that have 
been identified to date, contain C-terminal but not N-terminal 
differences. Alignment of the first untranslated exon of each 
human isoform with the first mouse exon (which 1s also 
untranslated), reveals sequence homology between the mouse and 
the 2b isoform. Interestingly, the 2a human isoform has a striking 
similarity to the bovine 5' UTR, suggesting an evolutionary pathway 
for the two isoforms. The two known isoforms of the mouse Ese-2 
gene represent alternative polyadenylation products (Langley, 
1999). Northern analysis of total RNA from the CommalD cell line 
revealed two possible isoforms around the 2.5kb size that may 
correspond to the human isoforms and implicate alternative 
promoter usage. 
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Alternative splicing is an important mechanism involved in 
generating functionally distinct products from the same gene 
(Maniatis, 1991; Smith et al., 1989). It adds another level of 
regulation to the expression and function of genes and is thought 
to be important in a number of cellular processes. Alternative 
splicing actually encompasses a wide range of events such as 
alternate polyadenylation, pre-mRNA splicing, promoter usage, 
transcription start site usage, exon skipping and other events. A 
study of alternative splicing in the human genome (using the TIGR 
human gene index) showed 35% of genes had some form of 
alternative splicing (Mironov et al., 1999). This is likely to be an 
underestimation limited by the incompleteness of current data. The 
role of the two isoforms of Ese-2 in the human and mouse are not 
yet known, though differences in expression patterns suggest they 
will have functionally distinct roles (Zhou et al., 1998; Oettgen et 
al., 1999b). 
One key feature discovered during the analysis of the murine EST 
database sequences was the apparent exon skipping of exon 4. 
Such an event could be functionally significant, resulting in a 
separate protein domain present or absent in certain instances. 
Indeed, the removal of exon 4 from the cDNA sequence would 
result in a frame shift, causing a quite different protein to be 
translated. 
The skipping of munne Ese-2 exon 4 has not previously been 
reported which implies it is a rare event, or occurs in temporal or 
spatial regulatory patterns that have not yet been studied. 
However, the event occurred in almost 50% of the deposited EST 
sequences, suggesting that it may indeed have an important role. 
This has potential as a future avenue of research, with regard to 
the regulation of splicing and its functional significance. 
Loss of heterozygosity (LOH) and other chromosomal events, such 
as translocations and inversions, are key factors involved in the 
development of many tumors and diseases. With respect to the ets 
transcription factor family, Ewings sarcoma deserves special 
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mention (discussed in Chapter 1). LOH is a frequent event at the 
locus of ESE-2 (chromosome 1 lp13-15), which spans the WTl 
(Wilms tumor) gene at 1 lpl5. Many tumors are known to involve 
rearrangements in this region of chromosome 11. ESE-2 is flanked 
by EHF, another ets factor. As ets genes are known proto-
oncogenes, frequent LOH in this region is consistent with them 
having a role in tumorigenesis. 
The significance of alternative splicing, especially the apparent 
exon skipping in Ese-2, may provide useful information on the 
gene's regulation and spatio-temporal expression. Knowledge of the 
involvement of Ese-2 in tumorigenesis and an understanding of its 
transformation to an oncogene may prove useful in future gene 
modulation therapies that focus on this chromosomal location. 
6.4 Regulation of Ese-2 
The in vitro cell culture experiments performed in this study 
resulted in a modest enhancement of activity above the negative 
control, showing that the promoter sequence of 200bp was active. 
The level of activity varied greatly between experiments, from a 
minimal 5-fold induction of construct (3) above the shortest 
promoter construct (1), to a maximum of an 80-fold induction, on a 
different experimental day (HCl 1 cells). Such discrepancies 
between results may be due to variations in culture conditions and 
epithelial cell properties on different days. When the data was 
averaged, it gave an approximate 20-fold induction of construct (3) 
above construct ( 1) and the negative construct (0). While the level 
of induction was much lower in CommalD cells (around 5-fold), 
construct (3) still showed a significant level of induction above 
constructs ( 1) and (0). 
Enhancement levels of distal promoter constructs also varied 
between experimental days, fluctuating between 5 and 50-fold 
levels of activity (for constructs (6) and (7)), above the negative 
construct in HC 11 cells. Again the level of enhancement was 
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greatly reduced in Comma1D cells. It was hard to interpret the 
data due to the fluctuations between experiments, but it does 
appear that the Ese-2 promoter constructs are active and regulated 
in this system. 
The constructs encompassing the intron and proximal 500bp of 
promoter sequence showed similar fluctuations between 
experimental days. The overall level of activity of the complete 
intron and promoter sequence (construct (9)) was low compared to 
construct (3). This may indeed be a true reflection of the regulation 
by the intron, though technical problems (as discussed later) were 
more prevalent in these experiments. 
The promoter region of a gene is an arbitrary length of DNA 
sequence that is critical for the initiation and correct temporal and 
spatial expression of that gene. It usually consists of 200-lOOObp 
5' of the transcription initiation site, though it does vary greatly 
amongst genes, so as to encompass distant enhancer elements. In 
higher eukaryotes, genes are transcribed by a polymerase II 
dependent promoter, characterised by many regulatory elements 
where the order and spacing is critical. Intervening sequences 
between these elements are not necessarily conserved and appear 
to have no obvious function. The identification of regulatory 
elements based on consensus sequence alignment does not provide 
information as to their biological importance. To this end 
experimental evidence must be gained. 
Confirmation of a functional promoter is most often provided by an 
in vitro system using a reporter gene driven by a segment of 
potential promoter sequence, transfected into an appropriate cell 
line. The in vitro system, while not ideal usually provides a rough 
parallel to the in vivo situation such that an approximate 
delineation of important regions can be gained. A vast number of 
technical factors need to be considered when designing transfer 
and expression experiments for studying a gene in eukaryotic cells. 
Many approaches have been developed, though optimisation for 
each study is usually necessary. The level of gene expression will 
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depend on the number of copies per cell and the number of cells 
containing the transferred gene. Other factors influencing levels of 
gene expression include the rate of transcription and the stability 
of the mRNA. 
The cell culture system used in the analysis of the Ese-2 gene was 
a mouse mammary cell line derived from a mid-pregnant mouse. 
This line (CommalD) expresses the beta-casein milk protein when 
induced by the lactogenic hormones and grown on matrigel 
(Danielson et al., 1984). A derivative of this line (H C 11), which 
expresses beta-casein under the same hormonal influence but has 
the advantage of good growth on plastic, was previously generated 
(Ball et al., 1988). Interestingly, CommalD was found to 
constitutively express endogenous Ese-2 mRNA while HC 11 did 
not. 
Based on the Ese-2 endogenous expression data, it was expected 
that only transfected CommalD cells would express the construct 
while HCl 1 cells would act as a negative control. In the current 
experiments, this was not found to be the case, as the HCl 1 line 
actually showed higher expression of the reporter gene under the 
control of the Ese-2 promoter. The lack of endogenous expression 
in the HCl 1 line possibly could be the result of a mutated 
regulatory element, aberrant RNA, interference in the transcript 
processmg or some such phenomenon. However, it is more likely 
that the enhanced expression of the reporter in HCl 1 was due to 
greater transfection efficiency, with a higher percentage of cells 
taking up the foreign DNA. It has not been investigated whether 
other non-mammary cell lines express endogenous Ese-2. Such 
cell lines may be of future use. Indeed, a cell line that was more 
receptive to transfection regardless of endogenous Ese-2 
expression would be of great value in future research. 
Other factors that limit the transfection efficiency would also 
influence the reporter express10n. One of the most well 
documented factors is the size of the transfected plasmid, with 
small DNA molecules showing higher transfection efficiency than 
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those more than a few kb in sequence (Labat-Moleur et al., 1996; 
Xu and Szoka, 1996; Darquet et al., 1997; Kreiss et al., 1999). 
Baker et al., ( 1997) suggest that the ultimate expression of larger 
molecules 1s not the problem, rather, some intracellular 
phenomenon interferes with the efficiency of actual uptake of 
larger molecules. In keeping with this intracellular phenomenon, 
Kreiss et al., ( 1999) suggest that a large DNA size may affect the 
mechanism of DNA release from cationic lipids or may retard the 
intracellular migration of DNA from the cytoplasm to the nucleus. 
There may also be a sieving effect on the DNA molecules during 
migration into the nucleus. Kreiss et al., (1999) also report an 
effect due to the topology of the transfected DNA molecules. 
There does appear to be a size effect on the uptake of the largest 
construct used in this study, as evidenced by a reduction in the co-
transfected reporter gene activity. The smallest plasmid constructs 
(up to 1.5kb of inserted sequence) gave the highest transfection 
efficiency. The largest construct (construct (10)) showed very low 
levels of transfection efficiency, though an attempt to reduce the 
size of this construct (by generating three smaller constructs each 
spanning part of the intron), did not appear to lessen the effect of 
plasmid size on transfection efficiency. However, the size of the 
truncated constructs still remained at 7.5kb, much larger than the 
proximal constructs (largest of those was construct (5) at 5kb). 
There may be other factors involved, though the true activity of the 
intron region must first be proven. 
There is much literature on the effect of construct size, and all 
shows that similar problems occur when larger constructs are 
used. For example, decreased expression of the mouse renin gene 
(total of 8.5kb) was observed in comparison to a promoter-less 
control (Ekker et al., 1989). It was hypothesised that the reason for 
this was that non-specific initiation of transcription at upstream 
locations result in decreased CAT protein expression, simply due to 
the length of inserted sequences. Thus, the longer constructs 
resulted in more non-specific initiation. This may also be the case 
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for Ese-2, though for promoter lengths of less than 1.5kb this was 
not observed. 
Interference has also been observed between co-transfected control 
plasmids (used for measuring transf ection efficiency), and the test 
plasmid (Hofman et al., 2000). Inhibition of the test plasmid 
appears to be inversely related to the length of the insert construct 
in the control plasmid, with maximal inhibition occuring with an 
empty expression vector. Conversely, the use of the empty 
expression vector for standardising transfected DNA can also be 
misleading, as it may result in apparent co-activation for co-
transfected control constructs (Hofman et al., 2000). These 
interference problems are thought to be due, at least in part, to the 
total amount of DNA transfected exceeding the transcription 
capacity of the cellular machinery, which results in competition 
between the co-tranfected plasmid and the promoter plasmid. 
Again, this explanation may have some importance for the system 
used to study Ese-2, which included an empty expression vector 
and a co-transfected control plasmid. Indeed, the pCHl 10 vector 
(and others) have been reported to have a bias when used to 
standardise transfection efficiency (Farr and Roman, 1992; 
Bergeron et al., 1995). In a series of experiments performed by 
Bergeron et al., ( 1995) constructs of the Fli-1 gene were co-
transfected with different control reporter plasmids. Significant 
variations were found in the control reporter expression that did 
not reflect differences in transfection efficiency. The mechanism 
involved was not studied, but was suggested to involve differences 
between DNA sequences within the co-transfected plasmid 
(Bergeron et al., 1995). 
The method of transfection also plays an important role in the 
overall expression of the promoter construct. The current study 
has been based on the use of two liposome reagents. Alternative 
methods for transfection have been developed and are constantly 
being researched, especially for gene therapy purposes. Alternative 
methods employ, amongst others, CaP04, cationic polymers, 
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electroporation and liposomal transfection. Another agent, 
chloroquine, acts by interfering with lysosomal degradation, and 
allows DNA to be released from an endosome into the cytoplasm 
(Hasan et al., 1991 ; Wolfert and Seymour, 1998). Peptides have 
also been successfully used, and a variety of groups are utilised to 
link the DNA to the peptide, including lysine residues, 
endosomolytic peptides, or RGD peptides (Gottschalk et al., 1995; 
Wilke et al., 1996; Zanta et al., 1999). The use of adenoviruses is 
one of the most efficient methods of gene delivery, particularly for 
long constructs. This method has also been used in conjunction 
with peptide delivery (Campeau et al., 2001). 
Limitations of the cell culture system were not the only hurdle to 
overcome in the present investigation. Difficulties in cloning the 
first intron region hindered the analysis. PCR amplification of the 
desired fragment was achieved after much time was spent in the 
optimisation of conditions. The subsequent cloning of this 
fragment was also difficult. Deletions and translocations of 
sequences often occurred and resulted in plasmid constructs that 
had to be discarded. The problematic sequence was narrowed 
down to a specific region that was repeatedly deleted, though no 
features known to cause this such as repeat sequences or 
secondary structure were identified. 
From the in vitro cell culture analysis of the promoter deletion and 
the first intron constructs of Ese-2, several conclusions can be 
drawn regarding important regulatory regions. The most significant 
was the increased activity between the 70 and 200bp upstream 
region. A 20-30 fold enhancement was detected in this region, 
though the element(s) responsible was not determined. This would 
fit with the theory of the proximal promoter being responsible for 
initiation of the transcription complex and its longevity. The 
increase in activity was somewhat lower than hypothesised when 
compared with the biological activity seen in the pregnant mouse 
mammary gland. The identification of a region containing 
important regulatory sequences capable of such temporal and 
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spatial activity was not found in this study. The reasons for this 
may be the insensitivity and fluctuations in the in vitro system, 
which made it impossible to consistently pick up small increases 
(2-fold or less) in activity. 
The possibility of alternate promoter involvement in the mouse 
mammary gland regulation of Ese-2 has been discussed. However, 
if a promoter did exist in the first intron of the mouse Ese-2 gene, 
equivalent to the human ESE-2a promoter, then transcription of 
the constructs in the cell system would be altered. In this case, the 
construct (9) CAT activity could well be interrupted by the use of 
an out of frame start site. Transcripts could code for an early 
termination codon, or simply exhaust the cellular machinery. Such 
a phenomenon would result in low CAT expression. 
The level of activity seen here may possibly only reflect the 
promoter responding to the basal cell machinery and not the 
enhancing effects of mammary specific factors. Although both 
CommalD and HCl 1 are mammary derived cells it is possible, as 
discussed earlier, that they respond no better to Ese-2 constructs 
than would a range of other cultured cell types. Moreover, cellular 
interactions with other cells, tissues, or the extracellular 
environment are likely to play an important role in the expression 
of Ese-2. Such factors have not been studied in this investigation, 
as a somewhat more sophisticated in vitro system, for example 
involving an extracellular matrix such as Matrigel, would be 
required. This limitation may prove critical in the determination of 
important regulatory mechanisms for Ese-2. The use of an in vivo 
model would provide useful information regarding the role of the 
cellular environment. 
The in vitro regulatory activity of Ese-2 was only studied at the 
transcriptional level in this investigation. As yet, the regulation 
occurring at other levels is undetermined and should be 
investigated in future research. Nuclear run-on assays, for 
example, could be performed to determine if mRNA accumulation 
in the mammary gland during pregnancy is a direct result of high 
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transcription rates, or reflects a high level of mRNA stability. 
Multiple levels of regulation may be important to provide the 
necessary spatial and temporal control of Ese-2. 
In the current study, the constructs were tested for a response to 
progesterone, estradiol and serum but showed no change in 
activity. However, in reporting these results, it must be noted that 
endogenous Ese-2 activity was not studied under these conditions. 
Serum is an important factor influencing the growth of cells during 
processes such as injury, wound repair and tissue-remodelling. It 
stimulates collagen production and other such proteins important 
in these processes (Narayanan and Page, 1987). As previously 
discussed, collagen, other MMPs and their inhibitors (TIMPS) may 
be downstream targets of ets genes. Indeed in vitro, serum has 
been shown to stimulate the human ETS-1 promoter, potentially 
mediated by AP-1 (Majerus et al., 1992). 
Indeed, a study by Lyer et al., (1999) of pnmary fibroblasts in 
culture under serum starvation and stimulatory conditions, 
revealed serum dependent expression of many genes known to be 
involved with the extracellular matrix and wound repair (Lyer et al., 
1999). The transcriptional response to serum stimulation by genes 
involved in processes such as proliferation, angiogenesis, tissue 
remodelling and other processes was striking. Although ets genes 
were not studied by Lyer et al., it may be reasonable to expect that 
their expression would also be increased in a similar manner, due 
to their known involvement in the processes described above. 
Based on those reports, the serum responsiveness of the Ese-2 
promoter elements was tested. No response was observed, though 
serum responsive elements may not have been present in the 
region studied. A study of the endogenous mRNA Ese-2 level under 
conditions of serum starvation and activation may be useful in the 
future. 
The basis for examining the responsiveness of Ese-2 constructs to 
progesterone and estradiol was the observation that similar 
temporal patterns of elevated expression of these hormones and 
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Ese-2 occurred in the mammary gland. Additionally, the hormones 
are known to effect epithelial development of the mammary gland, 
a role that may also involve Ese-2 (Dulbecco, 1986). 
The pattern of expression of Ese-2 does not appear to correlate 
with other known mammary gland factors such as STATS or 
lactogenic hormones though this does not preclude them from 
having some role in regulating Ese-2. 
Stable, rather than transient, expression of a reporter gene in cell 
culture is known to influence the level of expression (Berland and 
Chasin, 1988). To this end, a set of stably transfected cell lines 
with various Ese-2 constructs was produced for assay in parallel 
with transiently transfected constructs. In the constructs studied 
over a set of repeated experiments no significant difference in 
expression was observed between stable and transient transfection. 
Several researchers have investigated similar deletion constructs of 
promoters of other ets genes in cell culture. Elk-1 in particular 
shows a modest (2-fold), but significant, intronic regulatory activity 
above that of the proximal promoter alone (Lehmann et al., 1999). 
Oettgen et al., ( 1999) showed that Elf-3 / Ese-1, which is closely 
related to Ese-2, has a strong promoter activity in two epithelial 
lines using 1.5kb of promoter. The main promoter activity gave, 
depending on the cell line, 200 or 700-fold stimulation of 
transcription above an empty expression vector control (Oettgen et 
al., 1999a). The elements responsible for this activity were not 
determined. In contrast to Elf-3, the Fli-1 promoter gave no 
detectable activity with 600bp of the mouse 5' flanking region, 
exon 1 or the 5' end of intron 1. Similarly, 1.5kb of the human Fli-1 
5' flanking region was also inactive in transfected cells. These 
examples demonstrate that there must be several modes of 
regulation for ets genes. 
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6.5 Future Work 
An important step in future Ese-2 research would be in situ 
analysis. Such studies would provide information on the exact 
location of expression within specific tissues and throughout 
development and other processes. Further, immunohistochemistry 
would show the distribution of the Ese-2 protein product. 
Similarly, the use of Western blots could provide a useful tool for 
protein analysis. The use of antibodies has been limited in such 
investigations by cross-reactivity amongst multiple ETS proteins 
(unpublished observations, L 'Huillier et al.), and a specific 
monoclonal, rather than polyclonal, reagent would need to be 
produced. 
Further research into the transcriptional regulation of the Ese-2 
promoter could be undertaken using a different approach. The in 
vitro cell culture system using Comma1D and HCl 1 cells has been 
exhausted as a possibility, though other cell lines expressing high 
endogenous levels of Ese-2 may represent the in vivo situation 
more closely. The research should not be limited to such lines only, 
as Ese-2 mRNA expression has been detected in other tissues 
(Zhou et al., 1998; Oettgen et al., 1999). Further, a cell line that is 
easily transfected may be equally as informative as using a poorly 
transf ecting cell line that, theoretically, is expected to express Ese-
2 at high levels. The use of a cell line with an invasive phenotype 
might also be an avenue for future study, as Ese-2 expression is 
likely to be increased under such conditions. Alternatives to the 
cell culture in vitro system include the use of an animal model 
such as mouse. Indeed, considering the time spent in obtaining the 
cell culture in vitro data, it would have been reasonable to utilise a 
mouse model! The use of deletion constructs in a transgenic mouse 
would potentially provide more representative results on the region 
of regulation. The use of a mouse model would allow different 
stages of development to be studied as well as multiple tissues. As 
Ese-2 is expressed in many tissues containing epithelial cells, 
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information could be obtained regarding its regulation m 
potentially different cellular processes involved in the function of 
the kidney, lung and mammary gland for example. The mammary 
gland model system studied in this investigation, represented by 
cell lines derived from this tissue, could be analysed at the various 
stages of development at which Ese-2 expression is known to be 
elevated rather than depressed. These include early pregnancy 
where it is up-regulated and early involution where it is down-
regulated. 
An alternative and promising method of analysis involves DNase 1 
hypersensitive (DHS) mapping. Preliminary analysis identified a 
possible site of interest within the first intron. More intensive 
investigations usmg alternative probes to detect other 
hypersensitive regions in the gene would be worth pursuing. DHS 
has successfully been used in many other studies as an approach 
to identify important regulatory regions (Luo et al., 1999; McArthur 
et al., 2001; Li et al., 2002). It is often followed by protein binding 
studies to identify the specific factors involved. 
Of particular advance to the current study is the fact that DHS 
sites were discovered in the cystic fibrosis transmembrane 
conductance regulator gene (CFTR), which also has a tight temporal 
and spatial pattern of expression. The hypersensitive sites of 
importance were found to be in extreme and diverse locations, 
including intrans 1, 20 and 21, all of which had enhancer activity 
(Phylactides et al., 2002). Another study, that of the mouse 
monocyte chemoattractant protein-l (MCP-1) by DHS, identified 
sites between -24kb and +13kb (Wagner et al., 2001). A 
comprehensive chromatin analysis of Ese-2 would also likely reveal 
regulatory sites at greater distances. 
6.6 Potential function of Ese-2 
This investigation has focussed on the regulation of Ese-2 in 
mammary epithelial cells in culture. Observations show that Ese-2 
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mRNA expression 1s up-regulated from early pregnancy and 
throughout lactation and then declines in involution, though this 
was not conclusively demonstrated to be a result of transcriptional 
regulation (L 'Huillier et al., unpublished observation). As tissue 
remodelling of the mammary gland is an important process for the 
correct development of the gland through these stages, it seems 
likely that Ese-2 may have a role in this. 
Ets genes are known to play roles in many diverse cellular 
processes, including cell proliferation, differentiation, apoptosis, 
development, hematopoiesis, tissue remodelling and angiogenesis 
(Sementchenko and Watson, 2000). The variety of functions 
performed by this group of transcription factors suggests that Ese-
2 functions will not be restricted to the mammary gland. Its 
expression has been detected in many epithelial containing tissues 
and, as such, is likely to play a role in other processes. Knockout 
studies of ets genes such as PU.1, Ets-1, Spi-B, Fli-1, and Tel all 
show phenotypes related to defective hematopoiesis (Bories et al., 
1995; Muthusamy et al., 1995; lwama et al., 1998; Scott et al., 
1997; Su et al., 1997; Wang et al., 1997; Hart et al., 2000; 
Spyropoulos et al., 2000). Many ets genes also have a role in 
angiogenesis, in particular Tel-1, in which a null mutation in mice 
resulted in embryonic lethality with the histology revealing 
vascular defects (Wang et al., 1997). Other studies have also shown 
ets genes to be involved in development, including an Ets-2 mutant 
mouse with defects in embryonic trophectoderm and a knockout 
Ets-2 mouse that is embryonic lethal at day 8.5 (Yamamoto et al., 
1998). Distinct from other mouse ets knockouts, the Er81 mouse 
has a phenotype which indicates neurogenesis defects (Arber et al., 
2000). A large number of the ets genes that have been studied by 
gene disruption, appear to have distinct roles in the regulation of 
hematopoiesis. PU.1 for example, has a strong effect on the 
development of multiple hematopoietic lineages, Fli-1 has most 
impact on the development of specialised compartments within 
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myeloid lineages, Ets-l within lymphoid lineages and Spi-B 
appears only to affect mature B cell function (Bartel et al., 2000). 
In the case of Ese-2, if it has a role early in development, as seen 
with most other ets genes studied thus far, the potential roles in 
epithelial tissues in later processes including the remodelling of the 
mammary gland might only be analysable using conditional tissue 
specific knockouts. 
Ets genes are widely involved in tissue remodelling, whether it be 
in wound repair, bone and cartilage formation or mammary gland 
development. Crucial to this process is the extracellular matrix 
(ECM), which creates a physical barrier that must be penetrated 
for terminal end bud formation and lateral branching (Williams 
and Daniel, 1983). The ECM is maintained by the interaction of 
matrix metalloproteinases (MMPs) and tissue inhibitors of matrix 
metalloproteinases (TIMPS)(Gomez et al., 1997). TIMPS are involved 
in the regulation of MMPs and thus are implicated in regulating the 
development of the mammary gland and the ECM. Fata et al., 
( 1999) propose that TI MPs may control the rapid physical 
expansion of mammary ducts by limiting matrix degradation. 
TIMPS may limit cellular proliferation, which may be the basis for 
their ability to suppress tumor growth (Khokha, 1994; Montgomery 
et al., 1994; Kruger et al., 1997). MMPs are often found up-
regulated in epithelial cancers and are considered to be essential in 
tumor angiogenesis, invasion and metastasis as they can efficiently 
degrade the ECM, which is a barrier to tumor growth (Coussens 
and Werb, 1996). 
Some MMP and TIMP genes have been shown to be Ets responsive. 
Thus, MMP- l (interstitial collagenase) gene expression is up-
regulated in vitro by ETS-1 (Westermarck et al., 1997; Behrens et 
al., 2001) and MMP-1, -3, and -9 are activated by ElA-F (Kaya et 
al., 1996), ETS-1, ETS-2 and PEA3 (Buttice et al., 1996; Gum et 
al., 1996; Westermarck et al., 1997). Urokinase type plasminogen 
activator is another MMP also transactivated by ETS-1, and is 
linked to lung cancer invasion (Bolon et al., 1995). The TIMP-l gene 
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contains transcriptionally responsive elements in both its promoter 
and first intron regions that bind Sp-1, Sp-3 and an Ets-related 
factor (Dean et al., 2000). PEA3 also has a role in basal expression 
of TIMP-1 (Clark et al., 1997). 
All TIMP genes (1-4) are expressed predominantly in luminal 
epithelial cells (Fata et al., 1999). The pattern of expression of Ese-
2 fits well with TIMP-1, which has expression limited to high 
epithelial cell proliferation. Indeed, the yet un-identified Ets factor 
that is involved in TIMP-1 regulation may be Ese-2 or a closely 
related family member. Thus, a very profitable area for future 
research could be the interaction between Ese-2 proteins and 
matrix metalloproteinase genes. 
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Statistical analysis of cell culture results 
Formula for determining the least significant difference (LSD) 
I µ1 - µ2 I ~ t o./2, d.f X "MSE X 2/N 
Use a one-way AN OVA table to determine the MSE and d.f. N is 
the number of replicates for each factor. Use 't' tables to determine 
the 't' value at the desired level of confidence i.e 0.05 (95%). 
Comma 1 D Proximal constructs 
Construct No. No. Expts (n) Mean Std Dev. 
0 6 39.39 17.26 
1 4 30.92 9.07 
2 6 89.25 52.99 
3 6 117.5 37.68 
4 6 92.84 29.69 
5 6 47.36 28.23 
LSD= 39.52 
Constructs (2), (3) and (4) are significantly different from the 
negative construct (0) at the 5% level. 
Comma 1 D Distal constructs 
Construct No. No. Expts (nl Mean Std Dev. 
0 7 62.10 62.97 
6 7 90.00 60.04 
7 7 93.90 58.27 
8 7 107.19 98.26 
LSD= 79.2 
No construct is significantly different from the negative construct. 
CommalD Intron construct 
Construct No. No. Expts (n) Mean Std Dev. 
0 8 17.54 13.14 
9 8 25.63 20.64 
LSD= 18.55 
The Intron construct (9) is not significantly different to the negative 
construct (0). 
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C omma 10 I t f t t t n ron ragmen cons rue s 
Construct No. No. Expts (n) Mean Std Dev. 
0 5 8.60 1.54 
9 5 11.93 3.67 
10 5 8.80 1.13 
11 5 9.80 2.40 
12 5 11.68 2.80 
LSD= 3.27 
Construct (9) is significantly different from the negative construct 
(0). 
HC 11 Proximal and Distal constructs 
Construct No. No. Expts (n) Mean Std Dev. 
0 6 58.9 37.9 
1 6 63.0 49.7 
2 6 125.2 67.0 
3 6 1718.5 1211.1 
4 6 404.8 104.9 
5 6 238.5 132.1 
6 6 924.5 857.7 
7 6 850.8 777.5 
8 6 433.1 363.2 
9 6 363.5 233.0 
LSD= 638.8 
Constructs (3), (6) and (7) are significantly different from the 
negative control at the 5'% level. All constructs are significantly 
different from construct (3) at the 5% level. 
HCl 1 I t f n ron ra t t t .i;men cons rue s 
Construct No. No. Expts (n) Mean Std Dev. 
0 6 7.95 1.75 
9 6 12.96 5.43 
10 6 6.78 2.51 
11 6 7.73 2.57 
12 6 13.00 3.81 
LSD= 3.27 
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